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MicroRNAs (miRNAs) are a recently identified class of small non-coding RNAs 
that have been implicated in multiple developmental processes and disease 
states. While their biogenesis is relatively well understood, their transcriptional 
regulation is less well characterized and we therefore sought to elucidate the 
role of the transcription factor p53 in control of miRNAs. Through its function 
as a transcription factor, p53 regulates hundreds of genes involved in control 
over proliferation, apoptosis and senescence and mutation in the p53 pathway 
is identified in almost all human tumors, including epithelial ovarian cancer 
(EOC) which is thought to originate from the ovarian surface epithelium (OSE).  
 
OSE cells were chosen as a model to identify p53-regulated microRNAs. 
Using a microarray approach, the miR-34 family of miRNAs was found to be 
downregulated 12-fold after Cre/loxP-mediated conditional p53 inactivation in 
OSE in cell culture. Computational analysis identified evolutionarily conserved 
p53 recognition elements in the mir-34b/c promoter, which were deemed to be 
functional based upon DNA damage-induced increased miR-34b/c expression 
only in p53 wild type cells. Functionally, miR-34b and miR-34c cooperated in 
reducing proliferation and adhesion-independent growth in soft agar when 
transfected into p53-null neoplastic OSE cells.  
 
 As a next step in characterization of miR-34 family, their potential involvement 
in human cancer was investigated. Expression analysis demonstrated that all 
three members of the miR-34 family are downregulated in human EOC and 
their reduced expression was correlated with p53 mutation, promoter 
methylation and copy number variation. Importantly, reduced miR-34b/c 
expression was correlated with more advanced tumor stage. Consistent with 
reconstitution experiments in mouse cells, proliferation of human EOC cell line 
SKOV-3 was reduced after miR-34 reconstitution. Furthermore, cell invasion 
and motility in Matrigel chambers was also significantly reduced.  
 
To gain a more complete understanding of the role of miR-34 family members 
in vivo, and to test the hypothesis that they function as tumor suppressors, 
conditional mir-34b/c knockout mice were generated. Characterization of these 
mice will elucidate the role of these miRNAs in development and in cancer 
initiation and progression. 
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CHAPTER 1 
 
INTRODUCTION* 
 
1.1 Ovarian cancer etiology, pathogenesis and classification 
 
It is predicted that over 21,000 women will be diagnosed with ovarian cancer 
and over 15,000 will die from the disease in the US during 2009 (Jemal et al., 
2009). Like cancers at many other sites, 5-year survival is good if diagnosed at 
an early stage when the cancer is confined to the ovary. However, almost 70% 
of women are diagnosed at an advanced stage, at which point 5-year survival 
is 30%. Clearly, improved screening programs to detect epithelial ovarian 
cancer (EOC) at an early stage and better therapeutics to treat advanced 
disease are urgently required. Unfortunately, asymptomatic development in 
humans, combined with a scarcity of accurate animal models, has resulted in 
a marked lack of knowledge of the pathogenesis of ovarian cancer. However, 
risk factors include persistent ovulation, age and family history, the latter being 
largely attributed to carriers of hereditary BRCA1 mutations, which may 
account for up to 10% of EOC (Risch et al., 2001).  
 EOC is the most prevalent type of ovarian cancer, far outnumbering the 
sex cord-stromal tumors and germ cell tumors. Based upon morphological 
criteria, EOCs are classified as serous, mucinous, endometrioid, clear cell, 
transitional cell, squamous cell, and mixed epithelial neoplasms, with serous 
being the most common subtype (Scully and Sobin, 1999). The etiology of 
EOC is poorly understood and although several risk factors have been 
                                                 
* Modified from Corney et al. (2008). Histology & Histopathology. 23 (9): 1161-1169 
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identified, their direct involvement remains largely unaddressed. The risk 
factor receiving widest attention is ovulation. Persistent ovulation was 
hypothesized to increase ovarian cancer incidence (Fathalla, 1971; Fathalla, 
1972). Multiple studies have demonstrated that a reduction in ovulatory events 
by pregnancy and/or oral contraceptive decreases EOC risk (Riman et al., 
2002; Risch et al., 1994; Risch et al., 1983; Titus-Ernstoff et al., 2001; 
Whittemore et al., 1992). The presumed origin of EOC is the ovarian surface 
epithelium (OSE), a single layer of cuboidal cells coating the ovary (Auersperg 
et al., 2001; Nikitin et al., 2004). Early in life, the OSE is generally smooth but 
with age becomes increasingly convoluted, resulting in an increase in number 
of inclusion cysts. Such cysts, which may form by pinching off of invaginations 
or by trapping of epithelial cells during postovulatory wound healing, may be a 
precursor lesion for progression to carcinoma. Advocates of the so-called 
incessant ovulation hypothesis argue that postovulatory wound healing by 
OSE proliferation may increase the frequency at which cysts and mutations 
arise. Yet, this hypothesis is relatively simplistic since the potentially 
mutagenic effects of reproductive hormones and acute inflammation are not 
taken into account (Bose, 2005; Bukulmez and Arici, 2000; Cramer and 
Welch, 1983; Fleming et al., 2006; Konishi, 2006; Mohle et al., 1985; Ness and 
Cottreau, 1999; Nikitin and Hamilton, 2005). 
 A recent study by Horiuchi et al. demonstrated that while almost 50% of 
tumors developed from pre-existing lesions, in the remaining patients no such 
pre-existing lesions had been present 12 months prior to diagnosis. 
Furthermore, cancers arising from pre-existing cysts were categorized as low-
grade by pathological analysis, while those with no evidence of a precursor 
lesion were mostly of a high-grade serous carcinoma (Horiuchi et al., 2003). 
  
3 
 
This study gives significant weight to the hypothesis that high-grade serous 
carcinomas are not derived step-wise from low-grade tumors but instead arise 
de novo from the OSE (Shih Ie and Kurman, 2004). 
 
1.2 Mutations in the p53 Pathway in Ovarian Cancer 
 
Germline mutations in BRCA1 and BRCA2 tumor suppressor genes are the 
most common genetic alterations in hereditary ovarian carcinomas and can 
account for 10-15% of ovarian cancers (Risch et al., 2006; Risch et al., 2001), 
yet by far the most frequent inactivating mutation in sporadic serous EOC are 
in the p53 pathway. Defects in the p53 tumor suppressor pathway are present 
in over eighty percent of human cancers (Hahn and Weinberg, 2002; Sherr 
and McCormick, 2002) and have been associated with poor prognosis in 
ovarian carcinomas (Bali et al., 2004; Fujita et al., 1994; Hashiguchi et al., 
2001; Salani et al., 2008; Tachibana et al., 2003) 
 Mutation of the p53 gene at the locus 17p13.1 is the most common 
single genetic alteration in sporadic human serous EOC. The p53 protein 
contains four functional domains – a transcriptional activation domain, a 
tetramerization domain and two DNA binding domains. p53 protein binds a 
p53 recognition element (p53RE) commonly found in either promoter regions 
or first introns of its target genes to activate transcription (el-Deiry et al., 1992). 
However, in addition to transactivation properties, transcriptional repression 
has been described, although binding sites are less well characterized (Curtin 
and Spinella, 2005; D'Souza et al., 2001; Hammond and Giaccia, 2005; 
Hoffman et al., 2002; Imbriano et al., 2005).  
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 Loss of wild type p53 function by inactivating or dominant-negative 
mutations, or gain of oncogenic mutant p53 function, severely compromises 
the capacity of cells for controlled proliferation. Multiple types of cellular stress, 
such as DNA damage as a result of UV or γ irradiation, ribosomal stress, 
inappropriate oncogene activation and hypoxia activate p53 by post-
translational modifications, such as acetylation and phosphorylation (Toledo 
and Wahl, 2006; Vousden and Ryan, 2009). Depending on the cell type, 
severity and type of stress, p53 implements one of several responses, such as 
cell cycle arrest, senescence, differentiation or, if damage is severe, induction 
of the apoptotic cascade. p53 executes the desired response by directly 
binding p53REs of target genes. Over 4,000 putative target genes were 
identified by computational methods (Wang et al., 2001), while chromatin 
immunoprecipitation combined with paired-end ditag (ChIP-PET) experiments 
have identified over 500 genes with promoter-bound p53 protein with high 
confidence (Wei et al., 2006). Validated p53 targets include the Cdk inhibitor 
p21, members of the Bcl-2 family, the death receptor Fas and p53 repressor 
MDM2 (el-Deiry et al., 1993; Miyashita and Reed, 1995; Oda et al., 2000; 
Owen-Schaub et al., 1995).   
 While most post-translational modifications occur in residues in the C-
terminal and transactivation domains, the majority of p53 mutations are found 
in the DNA binding domain (Sigal and Rotter, 2000; Toledo and Wahl, 2006). 
Mutant p53 protein is able to act as a dominant negative by binding to and 
tetramerizing with wild type p53 to repress normal physiological processes of 
p53, possibly by inducing an inactive conformation of the DNA binding domain 
and reducing the ability to transactivate/repress target genes (Chene, 1998; 
Kern et al., 1992; Shaulian et al., 1992; Unger et al., 1993). Normally, p53 
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exists in a negative feedback loop with MDM2, which tightly controls both p53 
and MDM2 levels in the cell. However, loss of p53 transcriptional activity as a 
result of dominant negative mutation may result in decreased MDM2, with the 
consequence of mutant p53 stabilization and increased amount of non-
functional/gain-of-function mutant p53 protein (Blagosklonny, 2000).  
Although p53 mutations have been detected in all histological types of 
EOC, mutations in serous EOC are much more commonly observed (Table 
1.1). Interestingly, p53 mutation frequency differs between serous tumors of 
low and high-grade, with p53 mutations strongly associated with high-grade 
serous carcinomas and rare in low-grade/borderline serous carcinomas 
(Kupryjanczyk et al., 1995; Kupryjanczyk et al., 1993; Skomedal et al., 1997; 
Zheng et al., 1995). In contrast, low-grade/borderline tumors frequently harbor 
mutations in K-ras, which are very rare in high-grade serous adenocarcinomas 
(Cuatrecasas et al., 1997; Diebold et al., 2003; Singer et al., 2002; Singer et 
al., 2003a; Singer et al., 2003b; Zheng et al., 1995). These observations have 
given strong support to the hypothesis that high-grade and low-grade serous 
carcinomas arise via discrete pathways (Shih Ie and Kurman, 2004; Singer et 
al., 2003a; Singer et al., 2003b; Singer et al., 2005). Lending further support to 
this hypothesis is the observation that p53 is mutated in early stage high-grade 
carcinomas as well as adjacent dysplastic epithelium in prophylactically 
removed ovaries from BRCA1 heterozygotes (Pothuir, 2001; Werness et al., 
2000). This supports a model in which p53 mutation is not only required for 
carcinogenesis, but is an early event in the pathogenesis of high-grade serous 
carcinoma. 
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Table 1.1 Frequency of p53 mutations in histological subtypes of EOC. 
Type of EOC (average %) 
Defective/Total 
cases (%) 
Reference 
Serous 
Low-grade (14%) 
4/22 (18) (O'Neill et al., 2005) 
1/12 (8) (Singer et al., 2005) 
33/190 (17) (Lassus et al., 2003) 
5/27 (19) (Chan et al., 2000) 
1/13 (8) (Salani et al., 2008) 
High-grade (68%) 
30/47 (64) (O'Neill et al., 2005) 
30/59 (51) (Singer et al., 2005) 
167/180 (93) (Lassus et al., 2003) 
25/46 (54) (Chan et al., 2000) 
57/71 (80) (Salani et al., 2008) 
Clear cell (8%) 
6/38 (17) (Ho et al., 2001) 
0/4 (0) (Otis et al., 2000) 
1/12 (8) (Caduff et al., 1999) 
Endometrioid 
(45%) 
 5/15 (33) (Dogan et al., 2005) 
7/13 (54) (Henriksen et al., 1994) 
13/27 (48) (Caduff et al., 1999) 
Mucinous (19%) 
 1/12 (8) (Dogan et al., 2005) 
3/12 (25) (Renninson et al., 1994) 
3/11 (27) (Henriksen et al., 1994) 
3/21 (14) (Caduff et al., 1999) 
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1.3 MicroRNAs 
 
It had been known for many years that the Caenorhabditis elegans 
heterochronic gene lin-4 is required for correct developmental timing and that 
its loss of function results in reiterations of early fates at inappropriate 
developmental stages (Chalfie et al., 1981). Conversely, mutation of lin-14 
results in an opposite phenotype and is completely epistatic to lin-4 loss of 
function, suggesting that lin-4 may negatively regulate lin-14. Despite much 
effort, however, no LIN-4 protein could be identified and it was not until 1993, 
when lin-4 was cloned in the Ambros lab, that it was realized that the gene is 
non-coding (Lee et al., 1993). Rather, two transcripts of 61 nt and 22 nt in 
length, the later which is partially antisense complementary to the 3’ 
untranslated region (UTR) of lin-14 (Wightman et al., 1993), were the only 
detectable products – the first miRNA. However, not until the identification of a 
second small RNA, let-7 (Reinhart et al., 2000), and the observation that it is 
widely conserved (Pasquinelli et al., 2000), did miRNAs receive attention by 
the wider scientific community.  
 Biogenesis of miRNAs starts with transcription of their primary transcript 
(pri-miRNA), largely by RNA polymerase II, but polymerase III for some 
miRNAs within Alu repeats (Borchert et al., 2006; Lee et al., 2004). The pri-
miRNA, which may be several kilobases in length, is then subjected to step-
wise processing by two RNase III endonucleases. Firstly, in the nucleus, 
Drosha together with DGCR8/Pasha processes the pri-miRNA to a ~70 nt 
double stranded precursor miRNA (pre-miRNA) (Landthaler et al., 2004; Lee 
et al., 2003). After Exportin-5 mediated export to the cytoplasm (Lund et al., 
2004; Yi et al., 2003), pre-miRNA molecules are subjected to processing by 
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Dicer resulting in a ~22 nt RNA duplex: one stand being the mature miRNA 
and the other being the passenger strand (denoted in the literature as 
miRNA*). The miRNA duplex is unwound with the miRNA*, generally the 
strand with the highest stability at the 5’ end, being degraded, while the mature 
miRNA is loaded into the RNA induced silencing complex (RISC) (Khvorova et 
al., 2003; Schwarz et al., 2003). Although the mechanism of miRNA unwinding 
is unclear, the unwinding of let-7 can be attributed to the P68 RNA helicase 
(Salzman et al., 2007). In addition to Drosha-mediated processing to generate 
pre-miRNAs, a Drosha-independent biogenesis pathway has recently been 
reported (Berezikov et al., 2007; Okamura et al., 2007; Ruby et al., 2007). 
Mirtrons, short introns that, after splicing and de-branching, form pre-miRNA-
like molecules, are a second source of pre-miRNA molecules. Once exported 
to the cytoplasm by Exportin-5, they are processed by Dicer to mature 
miRNAs and seem to function identically to canonically synthesized miRNAs. 
The number of identified mirtrons is far lower than that of miRNAs, however, 
and it would appear that Drosha-dependent miRNAs are far more common. 
 There are 2 possible outcomes upon binding of the miRNA-loaded 
RISC to a target 3’ UTR (Figure 1.1). The first possibility is target cleavage, 
which occurs if perfect base pairing is achieved between the entire miRNA and 
target. The mechanism for this is target cleavage between nucleotides 10 and 
11 by Ago2-containing RISC. However, while this outcome is common in 
plants, it is less so in animals. The second potential outcome in animals is 
translational repression. For this to occur perfect base pairing between 
miRNA/mRNA is not required and mismatches and bulges are tolerated so 
long as perfect base pairing is achieved at the seed region of the miRNA,  
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Figure 1.1 Flow diagram outlining miRNA biogenesis and function. 
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which encompasses nucleotides 2-8. While the outcomes of miRNA-mediated 
translational repression are well agreed upon, the first step in bringing this 
about is controversial. Experimental data currently falls into one of two groups: 
evidence for repression at initiation stage of translation, and evidence for 
repression post-initiation. Supporting the hypothesis that a post-initiation stage 
is repressed, reporter genes with internal ribosomal entry site (IRES)-directed 
expression are still repressed, which suggests that binding of the full 
complement of initiation factors is not required (Lytle et al., 2007; Petersen et 
al., 2006). Additionally, miRNA-targeted mRNAs are found to be associated 
with polysomes (Lytle et al., 2007; Maroney et al., 2006; Petersen et al., 
2006). To the contrary, other groups have shown that during sedimentation 
gradient experiments, repressed mRNAs are shifted towards the top, 
suggesting reduced ribosome loading, and that mRNAs with IRES or a 
nonfunctional 5’ cap are no longer repressed (Bhattacharyya et al., 2006; 
Humphreys et al., 2005; Pillai et al., 2007). The cause of these conflicting 
results has been suggested to be a result of the differing systems used by 
each group. For example, different transfection protocols were shown to affect 
the outcome of miRNA repression (Lytle et al., 2007). Recent in vitro, cell-free 
extract experiments have provided more evidence for a role at translation 
initiation. Using different cell extracts and protocols, several groups showed 
that the m7GpppN 5’ cap is required for repression, and this requirement 
cannot be resolved by substitution with a nonfunctional ApppN cap or IRES, 
while a poly [A] tail is also indispensable (Mathonnet et al., 2007; Thermann 
and Hentze, 2007; Wakiyama et al., 2007; Wang et al., 2006). It was shown by 
Mathonnet et al. that an increase in the cap binding protein eIF4e attenuates 
miRNA-mediated repression in a cell-free system (Mathonnet et al., 2007). 
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These data are consistent with the presence of a cap binding domain within 
RISC component Ago2 (Kiriakidou et al., 2007), suggesting that repression 
occurs by Ago2 competitively inhibiting eIF4e binding to the cap structure 
which might lead to decapping and deadenylation of the mRNA target. 
However, an alternative explanation of this observation was made by Eulalio 
et al., who showed that the domain binds GW182, not Ago2, which functions 
downstream in the miRNA repression pathway (Eulalio et al., 2008). In closing, 
it is important to bear in mind that data obtained from miRNA/mRNA reporter 
assays and cell-free systems is not necessarily compatible with the in vivo 
situation. It is possible that a combination of both initiation and post-initiation 
stages are repressed. Underlining this, Kong et al. recently showed that in 
addition to different transfection methods affecting mechanism of repression, 
the promoter used to drive mRNA expression is critical. While mRNA 
transcribed from SV40 promoter are repressed at initiation stage, TK promoter 
results in post-initiation repression (Kong et al., 2008). Regarding the identity 
of mRNA targeted by miRNAs, computational predictions were first used 
based solely upon evolutionarily conserved perfect base pairing at the seed 
region (John et al., 2004; Krek et al., 2005; Lewis et al., 2005). In recent years, 
advances in computational prediction have resulted in consideration of 
location of target site within 3’ UTR, free energy and localization near AU-rich 
sequence (Grimson et al., 2007; Kertesz et al., 2007). Methods to identify 
authentic mRNA targets of individual miRNAs by proteomic approaches are 
currently under development by multiple groups (Baek et al., 2008; Selbach et 
al., 2008). 
 In a highly intriguing twist, it appears that in certain contexts and 
circumstances, RISC can be “converted” into a translation activating complex. 
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Firstly, Vasudevan and Steitz demonstrated that tethering AGO2 and fragile-X-
mental-retardation-related protein 1 (FXR1) to an AU-rich element (ARE) 
present in the 3’ UTR of TNFα was sufficient to increase translation 
(Vasudevan and Steitz, 2007). In a separate paper, they went on to show the 
requirement of miR-369-3 in directing the AGO/FXR1 complex to the mRNA, 
resulting in increased translation (Vasudevan et al., 2007). Mutating the seed 
sequence for the miRNA binding site in the ARE prevents translation 
upregulation, yet mutating miR-369-3 to match the mutated binding site 
restores upregulation. This effect is not a peculiarity of miR-369-3, either, 
since the authors also demonstrate similar effects with the artificial miRNA 
cxcr4 system and the endogenous miRNA let-7 on its target HMGA2. 
However, whether activation over repression is observed depends on the 
stage of the cell cycle – only when cells have been serum-starved and have 
undergone cell cycle arrest is activation observed, whereas in proliferating 
cells, repression is seen. While clearly an exciting observation, further work 
will be required to elucidate the responsible mechanisms and to establish the 
consequences of miRNA-mediated translation upregulation in vivo in a non-
synchronized cell pool. 
 
1.4 MicroRNAs in cancer 
 
Given the large number of mRNAs predicted to be directly regulated by 
miRNAs, it would be expected that a large number of processes be controlled 
by miRNAs, and indeed this is the case. Processes under miRNA control 
include hematopoiesis (Chen et al., 2004; Felli et al., 2005), cardiogenesis 
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(Zhao et al., 2007), blastocyst implantation (Chakrabarty et al., 2007) and 
neuronal development (Schratt et al., 2006). Yet the majority of research has 
been focused on the possible roles that miRNAs may play in disease, and 
specifically in cancer. 
 The first indications of a role for miRNAs in cancer came from the 
laboratory of Carlo Croce. A bicistronic miRNA cluster containing mir-15a and 
mir-16-1 at chromosome 13q14 was observed to be mutated, deleted or have 
reduced expression in chronic lymphocytic leukemia (CLL) (Calin et al., 2002; 
Calin et al., 2005). Later, germline mutations in mir-15a/-16-1 were observed, 
and it was shown that these two miRNAs target anti-apoptotic BCL-2 mRNA 
(Calin et al., 2005; Cimmino et al., 2005). While these reports suggested that 
miR-15a/-16 act as tumor suppressors, a tumor suppressor role in B cells was 
confirmed by deletion of mir-15a/16-1 in vivo resulting in CLL (Klein et al., 
2010). However, conventional knockout of this cluster resulted in no 
developmental defect or tumor development other than the aforementioned 
CLL, suggesting that either the main effect of miR-15a/-16-1 is in B cells, or 
miR-15a/-16-1 loss is compensated by other members of the miR-15 family in 
non-B cells, such as by the second copy of the miR-15 and miR-16 cluster on 
chromosome 3 and/or the related miR-195 on chromosome 17. This 
hypothesis fits well with the observation that miRNAs appear to have cell type 
specific roles, since while miR-15a/-16 induces apoptosis by targeting BCL-2 
in megakaryoblastic cell line MEG-01, no such induction of apoptosis or 
change in BCL-2 protein is observed in non-hematopoietic cells (Cimmino et 
al., 2005; Linsley et al., 2007). 
 In addition to possessing growth inhibitory activities, some miRNAs, 
such as those in the miR-17-92 cluster, have been implicated as oncogenes. 
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mir-17-92 is found in the c13orf25 locus on human chromosome 13q31, a 
region that is commonly amplified in multiple cancer types (Knuutila et al., 
1998). Tumors arising from hematopoietic stem cells expressing both c-myc 
and a subset of miRNAs from miR-17-92 demonstrate an absence of 
apoptosis observed in c-Myc-only tumors (He et al., 2005), while 
overexpression of this miRNA cluster also results in greater angiogenesis in 
tumors (Dews et al., 2006). Subsequent experiments in mice have shown that 
overexpression of all members of the miR-17-92 cluster is not required for 
Myc-induced B-cell lymphomagenesis. Rather, overexpression of miR-19a/b 
recapitulates overexpression of the entire cluster (Mu et al., 2009; Olive et al., 
2009). Underlying the importance of Myc in cooperating with miR-17-92, Myc 
directly binds canonical E-box sequences in the mir-17-92 promoter and 
members of the miR-17-92 cluster target E2F1. This suggests an interesting 
signaling pathway, since Myc and E2F1 are known to induce each other’s 
expression, while at the same time Myc represses E2F1 translation through 
miRNAs (O'Donnell et al., 2005). Complicating the issue further still are 
reports demonstrating that E2F proteins also bind the mir-17-92 locus, 
resulting in a negative feedback loop (Sylvestre et al., 2007; Woods et al., 
2007).  
 The genomic location of miRNAs is not evenly distributed throughout 
the human genome. Instead, there are some chromosomes, for example 
chromosome 4, with a lower than expected number, and some with greater 
than expected miRNAs, for example chromosomes 17 and 19 (Calin et al., 
2004). More importantly, however, taking a computational approach, Calin et 
al. demonstrate that miRNA genes are frequently found at fragile sites, regions 
commonly amplified or lost, common breakpoint regions and are close to 
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human papilloma virus integration sites (together abbreviated to CAGRs; 
cancer-associated genomic regions). Of 186 miRNAs studied, 98 (52.5%) 
were located in CAGRs and a significant number of miRNAs are located either 
in, or close to, homeobox clusters. Homeobox genes are transcription factors 
playing important roles in both normal development and carcinogenesis in a 
variety of cancers, including ovarian cancer (Hennessy and Mills, 2006).  
 
1.5 MicroRNA alterations in ovarian cancer 
 
As outlined previously, Calin et al. provided evidence that miRNA expression 
may be altered by changes in gene copy number by proximity to CAGRs. To 
gain a more detailed view of miRNA copy number alterations in cancer, Zhang 
et al. used array comparative genomic hybridization (aCGH) to identify miRNA 
loci gained/lost in ovarian cancer, breast cancer and melanoma (Zhang et al., 
2006). Towards ovarian cancer, 93 primary tumors and 16 cell lines were 
compared to wild type DNA. A tumor-to-reference ratio less than 0.8 was 
considered as a copy number loss, while a value greater than 1.2 was 
considered as a copy gain. Of 283 miRNA loci analyzed, 105 (37.1%) were 
significantly altered in their copy number. Similarly, significant copy changes 
were observed in 206 of 283 (72.8%) miRNAs in breast cancer and 243 of 283 
(85.9%) in melanomas. Quantitative RT-PCR demonstrated that expression of 
miRNAs was consistent with DNA copy number status for 73.1% of miRNAs, 
demonstrating that DNA copy number alterations may have an important effect 
on miRNA expression. Consistent with reports of tissue-specific expression of 
many miRNAs, the aCGH profile for each ovarian cancer type were not the 
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same, as revealed by cluster analysis. However, there are a number of copy 
number gains and losses shared between all three tumor types such as loss of 
the mir-17-92 locus in all tumor types. In addition, the mir-15a/16-1 locus is 
lost in 23.9% of ovarian and 24.7% of breast cancers. Consistent with reduced 
copy number, reduced miR-15a and miR-16 expression is observed in a panel 
of 38 high grade serous tumors (Bhattacharya et al., 2009). Interestingly, 
Bhattacharya et al. identify the Polycomb gene Bmi-1 as a direct target of 
these two miRNAs and show that Bmi-1 expression is inversely correlated with 
miR-15a and miR-16 in ovarian cancer. Functionally, and similar to roles in 
other cancers, miR-15a or miR-16 reconstitution experiments reduces 
proliferation and clonal growth, the latter of which can be rescued by a miR-
15a/miR-16-independent Bmi-1 transgene. 
Interestingly, Zhang et al. observed that 24.8% and 51.5% of ovarian 
tumors exhibited gains in copy number of the Dicer and Ago2 loci. As outlined 
previously, Dicer and Ago2 proteins are required for efficient miRNA 
processing and function. Most recently it has been shown that short-hairpin 
RNA (shRNA)-mediated knockdown of Dicer and Ago2 increases colony 
formation in soft agar and tumor formation in vivo (Kumar et al., 2007) and is a 
haploinsufficient tumor suppressor (Kumar et al., 2009). Consistent with this, 
Drosha and Dicer are associated with favorable prognosis in ovarian cancer 
(Merritt et al., 2008).  
 Given the relatively large number of ovarian cancer samples analyzed 
by Zhang et al., it is disappointing that no data was presented regarding the 
histological characteristics of each sample, since particular alterations may be 
correlated with particular EOC subtypes. However, this issue has been 
addressed, to some extent, at the transcriptional level by microarray profiling 
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experiments and a follow-up study by Zhang et al. (Iorio et al., 2007; Zhang et 
al., 2008). Iorio et al. analyzed a total of 69 primary EOC tissues, including 31 
serous, 8 endometroid and 4 clear cell tumors and compared to total normal 
ovarian tissue. The miR-200 family, which comprises 3 members (miR-200a, -
200b and -200c) was among those miRNAs significantly overexpressed, while 
those downregulated included miR-199a, miR-140 and miR-145. Only 2 
miRNAs were downregulated in serous, endometrioid and clear cell 
carcinomas, miR-200a and miR-200c, while 19 were overexpressed in all 
three tumor types, including miR-140 and let-7d. Notably, the expression of 
the miR-200 family, miR-140 and let-7d is concordant with DNA copy number 
previously reported (Zhang et al., 2006) (Table 1.2). Functionally, the miR-200 
family of miRNAs regulate ZEB1 and ZEB2 transcription factors and their 
reconstitution results in increased E-cadherin expression and mesenchymal-
to-epithelial transition in culture (Bendoraite et al., 2010; Park et al., 2008). 
In addition to miRNAs conserved between EOC histological subtypes, 
Iorio et al. also identified pools of miRNAs that are specifically downregulated 
in just one subtype, an observation that may have some implications for 
differential diagnosis in the future. However, while this report may be useful for 
diagnosis, the authors’ choice of total normal ovarian tissue, rather than OSE, 
as normal control, limits what information can be used towards our basic 
understanding of miRNAome alterations in the OSE. For this reason, a follow-
up study by Zhang et al. used qRT-PCR transcriptional profiling of EOC 
specimens and used immortalized OSE cells for comparison to identify a 
similar pool of dysregulated miRNAs as reported by others (Zhang et al., 
2008). Importantly, and consistent with studies in other cell types, the authors 
identified miRNAs that were subject to epigenetic regulation and by copy  
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Table 1.2 MicroRNAs altered in ovarian cancer. 
miRNA Reference 
miR-105 
miR-143 
miR-203 
miR-373 
(Iorio et al., 2007) 
let-7 
miR-9 
miR-34 
miR-140 
(Iorio et al., 2007; 
Zhang et al., 2006) 
miR-15a/-16 
miR-29a/b 
miR-30b/d 
miR-181b 
(Zhang et al., 2006) 
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number variation. DNA copy deletions at mir-15a and mir-140 loci were found 
in over 20% of EOC specimens. Meanwhile, hemizygous deletion at the mir-
34a locus (chromosome 1p36) were identified in 58% (7/12) of low-grade 
serous EOC, but not in high-grade serous tumors (Kuo et al., 2009). 
 
1.6 Use of microRNAs as diagnostic and therapeutic tools 
 
1.6.1 Potential diagnostic uses of microRNAs 
 
The let-7 miRNA family is known to repress expression of the RAS and 
HMGA2 oncogenes and its decreased expression is associated with poorer 
prognosis in non-small cell lung cancer (NSCLC) (Johnson et al., 2005; Mayr 
et al., 2007; Takamizawa et al., 2004). Shell et al. performed miRNA profiling 
of the NCI60 panel of human tumor cell lines (Shell et al., 2007). Members of 
the NCI60 panel can be grouped into 1 of 2 superclusters (SC) based upon 
their gene expression, with SC1 cell lines having mesenchymal and SC2 cell 
lines having epithelial properties. Interestingly, expression of 5 of 7 let-7 family 
members was reduced in SC1, whereas SC2 expressed high let-7 levels. 
Noticing that the mesenchymal-like SC1 cell lines share similarities with EOC, 
which commonly expresses mesenchymal markers (Rosano et al., 2005), the 
authors looked at the expression of let-7 and HMGA2 in 6 ovarian cancer cell 
lines. The expression of let-7 and HMGA2 was inversely correlated, as one 
might expect given that let-7 represses HMGA2 expression via 7 binding sites 
in the HMGA2 3’ UTR. The authors then went on to analyze HMGA2 
expression by performing immunohistochemistry on a tissue microarray 
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containing 100 EOC samples. While no difference in HMGA2 staining intensity 
was observed between primary tumor sites and metastatic tumors, high 
HMGA2 expression significantly correlated with poor overall survival. In clinical 
samples, the let-7/HMGA2 relationship was conserved and importantly, let-7 
and HMGA2 expression was sufficient to group patients into one of two 
groups. The first group, with a high HMGA2/let-7 ratio, has poor prognosis and 
estimated 5-year progression-free survival under 10%. In contrast, the second 
group, with a lower HMGA2/let-7 ratio, has a higher 5-year progression 
survival of about 40%.  
 Similarly, miR-31 has been shown to have diagnostic potential in EOC. 
To identify miRNAs with decreased expression in EOC, massively parallel 
small RNA sequencing was performed in primary OSE cultures, serous tumors 
and EOC cell lines (Creighton et al., 2010). miR-31 was found to be the most 
downregulated miRNA in tumor samples compared to primary OSE cultures 
and, through data mining of CGH data, found to be located at chromosome 
9p21.3 which is deleted in >60% tumors. Further bioinformatic analysis 
revealed possible interaction with the p53 pathway. Overexpression of miR-31 
in p53-null EOC cell lines results in apoptosis and proliferative arrest. 
Meanwhile, in p53 wild type EOC cell lines, such as HEY and OVSAYO, 
proliferation is unchanged in miR-31-treated cells compared to negative 
control. Importantly, a miR-31-inactive gene expression signature was 
significantly correlated with poorer prognosis. Furthermore, miR-31 has 
recently been shown to inhibit metastasis of breast cancer in part through 
targeting of pro-metastatic genes RhoA, integrin-α5 and radixin (Valastyan et 
al., 2009a; Valastyan et al., 2009b). 
 In addition to utility in prognostication, miRNA profiles were shown to 
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classify human cancers of uncertain cellular origin with greater accuracy than 
a mRNA profile (Lu et al., 2005). The significance of the work performed by Lu 
et al. is that a miRNA expression profile was able to classify human cancers 
by their origin, which could be useful given that 2-4% of cases are unable to 
be diagnosed with any certainty by histopathological means (Pavlidis et al., 
2003).  
 While clearly demonstrating diagnostic potential, profiling of miRNAs 
from tumors requires undesirable invasive procedures to obtain necessary 
biopsy tissue. A better alternative might be to use biomarkers present in 
circulating blood, and towards this, several groups have examined the 
presence of miRNAs in serum. Serum-derived miRNAs have been shown to 
be remarkably stable, resistant to RNase, extreme pH and temperature and 
repeated freeze-thaw cycles (Chen et al., 2008; Mitchell et al., 2008). 
Interestingly, resistance to RNase treatment is not due to miRNA structure, 
since naked miRNA spiked in to plasma samples is rapidly degraded (Mitchell 
et al., 2008). It remains to be understood how miRNAs are released by cells 
into the circulation. One possibility, however, is that the circulating miRNAs are 
contained within exosomes, since their existence in these small (50-90 nm) 
vesicles has been recently reported (Skog et al., 2008; Valadi et al., 2007).  
 
1.6.2 Therapeutic potential of microRNAs 
 
Given the potential of miRNAs to function either as tumor suppressors or 
oncogenes, a number of groups have used different approaches to increase or 
decrease expression of different miRNAs in the hope of inducing a therapeutic 
effect. Several methods to reduce, or knock down, miRNA expression have 
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been devised, which may be useful in the case of oncogenic miRNAs. Firstly, 
2’-O-methyl modified oligoribonucleotides complementary to the mature 
miRNA transfected into mammalian cells rapidly and irreversibly bind the 
miRNA, preventing it from binding its target (Hutvagner et al., 2004; Meister et 
al., 2004). For in vivo knockdown “antagomirs”, cholesterol–conjugated 2’-O-
methyl-modified oligo-ribonucleotides antisense to a miRNA of interest, can be 
injected directly into the mouse (Krutzfeldt et al., 2005). At a dose of 240 mg 
per kg body weight, an antagomir directed against miR-122 results in 
undetectable levels of the mature miRNA for up to 23 days. Due to the 
relatively high doses required and the short lived response, however, Ebert et 
al. designed an alternative strategy based upon sequestering miRNAs by 
binding an artificial target expressed at high levels in the cell (Ebert et al., 
2007). In this approach, a target is designed that is perfectly complementary to 
the miRNA with the exception of a bulge at nucleotides 9 to 12 which prevent 
target cleavage by Ago2. Multiple copies of the target are placed in the 3’ UTR 
of a gene such as green fluorescent protein (GFP) and transfected into cells, 
generating a “miRNA sponge” transgene. The strong expression of the sponge 
releases miRNA-mediated repression of endogenous targets. Importantly, in 
principle at least, this technique could be directed to generating transgenic 
animals with constitutive or conditional knockdown of miRNAs. 
 As mentioned, some miRNAs have been described as having tumor 
suppressor properties and ectopic expression of these miRNAs in neoplastic 
tissues may have therapeutic potential. Numerous groups, including 
ourselves, have overexpressed miRNAs through infection of retrovirus or 
lentivirus expressing the miRNA of interest. This approach has the advantage 
of using inducible and/or cell-type specific promoters although, as with mRNA 
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overexpression, there are many safety concerns if this technology is to be 
used in humans. A second approach is delivery of mature miRNAs to a cell. 
These molecules are commercially available, can result in increased silencing 
of a miRNA target and can be delivered to cells through non-viral means 
(Johnson et al., 2005). Currently, however, their use has largely been 
restricted to transfection of cells in cell culture and while they have worked well 
in our hands (Corney et al., 2007; Corney et al., 2010), their usefulness in 
vivo, like siRNAs, will depend on efficient delivery to cancerous cells (reviewed 
by Kota et al., 2009; Whitehead et al., 2009).  
 
1.7 Concluding remarks and project overview 
 
Due to asymptomatic development, the initiating events of ovarian cancer 
remain obscure and much of our current understanding is based upon 
circumstantial and correlative evidences. To this end, the development of 
accurate mouse models of ovarian cancer is of utmost importance in 
expanding our knowledge of ovarian carcinogenesis. The emergence of the 
miRNA field has been rapid yet also widespread, given that miRNAs are 
present in multiple species and are predicted to regulate thousands of human 
mRNAs. It is plain to see, however, that we are at an early stage in our 
understanding of these molecules and much remains to be learnt. Yet it is 
equally clear that miRNAs possess a large potential to play a role in the clinic, 
both as diagnostic and therapeutic tools. Such potential is critically required for 
many cancers, but especially for ovarian cancer given late diagnosis and 
inadequate treatment options currently available.  
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Given the poor state of understanding of control of miRNAs in normal 
and pathological physiology, I initiated studies to gain a better understanding 
of the role of miRNAs in EOC. The central hypothesis of these studies is that 
1) there is a direct pathway between p53 and individual and/or all miRNAs and 
that 2) p53-regulated miRNAs fulfill a critical role in the p53 pathway. Towards 
this, in Chapter 2, miRNA microarray profiling experiments were performed to 
identify altered miRNA expression after p53 inactivation in primary mouse 
OSE cells. The most downregulated miRNAs, the miR-34 family, was shown 
to contain evolutionarily conserved p53 recognition elements in the mir-34 
promoters. Functionally, miR-34 reconstitution experiments reveal a role in 
reducing proliferation and adhesion-independent growth in neoplastic ovarian 
cancer cell lines, suggesting a role in tumor suppression. To gain a fuller 
understanding of miR-34 function and determine its clinical relevance two 
approaches were taken. In Chapter 3, the frequency, and mode, of miR-34 
downregulation was determined in a panel of EOC clinical specimens. While 
decreased miR-34 expression was most correlated with p53 mutation, 
promoter methylation and copy number variation were also frequently 
observed. Further demonstrating potential for therapeutic applications of miR-
34, and of miRNAs in general, miR-34 reconstitution in a human ovarian 
cancer cell line resulted in decreased proliferation, motility and invasion. 
Finally, in Chapter 4, mir-34b/c conditional knockout mice were generated to 
allow direct testing of the hypothesis that they are tumor suppressors in vivo. 
 
 
 
  
25 
 
REFERENCES 
 
Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K., and Leung, P. C. (2001). 
Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr 
Rev 22, 255-288. 
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., and Bartel, D. P. 
(2008). The impact of microRNAs on protein output. Nature 455, 64-71. 
Bali, A., O'Brien, P. M., Edwards, L. S., Sutherland, R. L., Hacker, N. F., and 
Henshall, S. M. (2004). Cyclin D1, p53, and p21Waf1/Cip1 expression is 
predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin 
Cancer Res 10, 5168-5177. 
Bendoraite, A., Knouf, E. C., Garg, K. S., Parkin, R. K., Kroh, E. M., O'Briant, 
K. C., Ventura, A. P., Godwin, A. K., Karlan, B. Y., Drescher, C. W., et al. 
(2010). Regulation of miR-200 family microRNAs and ZEB transcription factors 
in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. 
Gynecol Oncol 116, 117-125. 
Berezikov, E., Chung, W. J., Willis, J., Cuppen, E., and Lai, E. C. (2007). 
Mammalian mirtron genes. Mol Cell 28, 328-336. 
Bhattacharya, R., Nicoloso, M., Arvizo, R., Wang, E., Cortez, A., Rossi, S., 
Calin, G. A., and Mukherjee, P. (2009). MiR-15a and MiR-16 control Bmi-1 
expression in ovarian cancer. Cancer Res 69, 9090-9095. 
Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I., and 
Filipowicz, W. (2006). Relief of microRNA-mediated translational repression in 
human cells Subjected to Stress. Cell 125, 1111-1124. 
Blagosklonny, M. V. (2000). p53 from complexity to simplicity: mutant p53 
stabilization, gain-of-function, and dominant-negative effect. Faseb J 14, 1901-
1907. 
Borchert, G. M., Lanier, W., and Davidson, B. L. (2006). RNA polymerase III 
transcribes human microRNAs. Nat Struct Mol Biol 13, 1097-1101. 
Bose, C. K. (2005). Does hormone replacement therapy prevent epithelial 
ovarian cancer? Reprod Biomed Online 11, 86-92. 
Bukulmez, O., and Arici, A. (2000). Leukocytes in ovarian function. Hum 
Reprod Update 6, 1-15. 
Caduff, R. F., Svoboda-Newman, S. M., Ferguson, A. W., Johnston, C. M., 
  
26 
 
and Frank, T. S. (1999). Comparison of mutations of Ki-RAS and p53 
immunoreactivity in borderline and malignant epithelial ovarian tumors. 
American Journal of Surgical Pathology 23, 323-328. 
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, 
H., Rattan, S., Keating, M., Rai, K., et al. (2002). Frequent deletions and 
down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic 
lymphocytic leukemia. Proc Natl Acad Sci USA 99, 15524-15529. 
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, 
S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., and Croce, C. M. (2004). 
Human microRNA genes are frequently located at fragile sites and genomic 
regions involved in cancers. Proc Natl Acad Sci USA 101, 2999-3004. 
Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. 
E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., et al. (2005). A MicroRNA 
signature associated with prognosis and progression in chronic lymphocytic 
leukemia. New Engl J Med 353, 1793-1801. 
Chakrabarty, A., Tranguch, S., Daikoku, T., Jensen, K., Furneaux, H., and 
Dey, S. K. (2007). MicroRNA regulation of cyclooxygenase-2 during embryo 
implantation. Proc Natl Acad Sci USA 104, 15144-15149. 
Chalfie, M., Horvitz, H. R., and Sulston, J. E. (1981). Mutations that lead to 
reiterations in the cell lineages of C. elegans. Cell 24, 59-69. 
Chan, W. Y., Cheung, K. K., Schorge, J. O., Huang, L. W., Welch, W. R., Bell, 
D. A., Berkowitz, R. S., and Mok, S. C. (2000). Bcl-2 and p53 protein 
expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. 
Am J Pathol 156, 409-417. 
Chen, C. Z., Li, L., Lodish, H. F., and Bartel, D. P. (2004). MicroRNAs 
modulate hematopoietic lineage differentiation. Science 303, 83-86. 
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, 
J., Guo, X., et al. (2008). Characterization of microRNAs in serum: a novel 
class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 
997-1006. 
Chene, P. (1998). In vitro analysis of the dominant negative effect of p53 
mutants. J Mol Biol 281, 205-209. 
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., 
Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005). miR-15 and 
miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102, 
13944-13949. 
  
27 
 
Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W., and Nikitin, A. Y. 
(2007). MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in 
control of cell proliferation and adhesion-independent growth. Cancer Res 67, 
8433-8438. 
Corney, D. C., Hwang, C. I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, 
A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., and Nikitin, A. 
Y. (2010). Frequent downregulation of miR-34 family in human ovarian 
cancers. Clin Cancer Res 16, 1119-1128. 
Cramer, D. W., and Welch, W. R. (1983). Determinants of ovarian cancer risk. 
II. Inferences regarding pathogenesis. J Natl Cancer Inst 71, 717-721. 
Creighton, C. J., Fountain, M. D., Yu, Z., Nagaraja, A. K., Zhu, H., Khan, M., 
Olokpa, E., Zariff, A., Gunaratne, P. H., Matzuk, M. M., and Anderson, M. L. 
(2010). Molecular profiling uncovers a p53-associated role for microRNA-31 in 
inhibiting the proliferation of serous ovarian carcinomas and other cancers. 
Cancer Res 70, 1906-1915. 
Cuatrecasas, M., Villanueva, A., Matias-Guiu, X., and Prat, J. (1997). K-ras 
mutations in mucinous ovarian tumors: a clinicopathologic and molecular study 
of 95 cases. Cancer 79, 1581-1586. 
Curtin, J. C., and Spinella, M. J. (2005). p53 in human embryonal carcinoma: 
identification of a transferable, transcriptional repression domain in the N-
terminal region of p53. Oncogene 24, 1481-1490. 
D'Souza, S., Xin, H., Walter, S., and Choubey, D. (2001). The gene encoding 
p202, an interferon-inducible negative regulator of the p53 tumor suppressor, 
is a target of p53-mediated transcriptional repression. J Biol Chem 276, 298-
305. 
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., 
Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., and Thomas-
Tikhonenko, A. (2006). Augmentation of tumor angiogenesis by a Myc-
activated microRNA cluster. Nat Genet 38, 1060-1065. 
Diebold, J., Seemuller, F., and Lohrs, U. (2003). K-RAS mutations in ovarian 
and extraovarian lesions of serous tumors of borderline malignancy. Lab 
Invest 83, 251-258. 
Dogan, E., Saygili, U., Tuna, B., Gol, M., Gurel, D., Acar, B., and 
Koyuncuoglu, M. (2005). p53 and mdm2 as prognostic indicators in patients 
with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 97, 46-
52. 
Ebert, M. S., Neilson, J. R., and Sharp, P. A. (2007). MicroRNA sponges: 
  
28 
 
competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4, 721-
726. 
el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. 
(1992). Definition of a consensus binding site for p53. Nat Genet 1, 45-49. 
el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, 
J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993). WAF1, 
a potential mediator of p53 tumor suppression. Cell 75, 817-825. 
Eulalio, A., Huntzinger, E., and Izaurralde, E. (2008). GW182 interaction with 
Argonaute is essential for miRNA-mediated translational repression and 
mRNA decay. Nat Struct Mol Biol 15, 346-353. 
Fathalla, M. F. (1971). Incessant ovulation--a factor in ovarian neoplasia? 
Lancet 2, 163. 
Fathalla, M. F. (1972). Factors in the causation and incidence of ovarian 
cancer. Obstetrical & Gynecological Survey 27, 751-768. 
Felli, N., Fontana, L., Pelosi, E., Botta, R., Bonci, D., Facchiano, F., Liuzzi, F., 
Lulli, V., Morsilli, O., Santoro, S., et al. (2005). MicroRNAs 221 and 222 inhibit 
normal erythropoiesis and erythroleukemic cell growth via kit receptor down-
modulation. Proc Natl Acad Sci USA 102, 18081-18086. 
Fleming, J. S., Beaugie, C. R., Haviv, I., Chenevix-Trench, G., and Tan, O. L. 
(2006). Incessant ovulation, inflammation and epithelial ovarian 
carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247, 4-21. 
Fujita, M., Enomoto, T., Inoue, M., Tanizawa, O., Ozaki, M., Rice, J. M., and 
Nomura, T. (1994). Alteration of the p53 tumor suppressor gene occurs 
independently of K-ras activation and more frequently in serous 
adenocarcinomas than in other common epithelial tumors of the human ovary. 
Jap J Cancer Res 85, 1247-1256. 
Grimson, A., Farh, K. K., Johnston, W. K., Garrett-Engele, P., Lim, L. P., and 
Bartel, D. P. (2007). MicroRNA targeting specificity in mammals: determinants 
beyond seed pairing. Mol Cell 27, 91-105. 
Hahn, W. C., and Weinberg, R. A. (2002). Modelling the molecular circuitry of 
cancer. Nat Rev Cancer 2, 331-341. 
Hammond, E. M., and Giaccia, A. J. (2005). The role of p53 in hypoxia-
induced apoptosis. Biochem Biophys Res Commun 331, 718-725. 
Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., and Ogita, S. 
(2001). Combined analysis of p53 and RB pathways in epithelial ovarian 
  
29 
 
cancer. Human Pathology 32, 988-996. 
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., 
Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., and 
Hammond, S. M. (2005). A microRNA polycistron as a potential human 
oncogene. Nature 435, 828-833. 
Hennessy, B. T., and Mills, G. B. (2006). Ovarian cancer: homeobox genes, 
autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol 38, 
1450-1456. 
Henriksen, R., Strang, P., Wilander, E., Backstrom, T., Tribukait, B., and 
Oberg, K. (1994). p53 expression in epithelial ovarian neoplasms: relationship 
to clinical and pathological parameters, Ki-67 expression and flow cytometry. 
Gynecol Oncol 53, 301-306. 
Ho, E. S., Lai, C. R., Hsieh, Y. T., Chen, J. T., Lin, A. J., Hung, M. H., and Liu, 
F. S. (2001). p53 mutation is infrequent in clear cell carcinoma of the ovary. 
Gynecol Oncol 80, 189-193. 
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., and Murphy, M. (2002). 
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. 
J Biol Chem 277, 3247-3257. 
Horiuchi, A., Itoh, K., Shimizu, M., Nakai, I., Yamazaki, T., Kimura, K., Suzuki, 
A., Shiozawa, I., Ueda, N., and Konishi, I. (2003). Toward understanding the 
natural history of ovarian carcinoma development: a clinicopathological 
approach. Gynecol Oncol 88, 309-317. 
Humphreys, D. T., Westman, B. J., Martin, D. I., and Preiss, T. (2005). 
MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 
4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A 102, 16961-16966. 
Hutvagner, G., Simard, M. J., Mello, C. C., and Zamore, P. D. (2004). 
Sequence-specific inhibition of small RNA function. PLoS Biol 2, E98. 
Imbriano, C., Gurtner, A., Cocchiarella, F., Di Agostino, S., Basile, V., 
Gostissa, M., Dobbelstein, M., Del Sal, G., Piaggio, G., and Mantovani, R. 
(2005). Direct p53 transcriptional repression: in vivo analysis of CCAAT-
containing G2/M promoters. Mol Cell Biol 25, 3737-3751. 
Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., 
Taccioli, C., Volinia, S., Liu, C. G., Alder, H., et al. (2007). MicroRNA 
signatures in human ovarian cancer. Cancer Res 67, 8699-8707. 
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009). 
Cancer statistics, 2009. CA Cancer J Clin 59, 225-249. 
  
30 
 
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., and Marks, D. S. 
(2004). Human microRNA targets. PLoS Biol 2, e363. 
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., 
Labourier, E., Reinert, K. L., Brown, D., and Slack, F. J. (2005). RAS is 
regulated by the let-7 microRNA family. Cell 120, 635-647. 
Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., 
and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene 
expression. Science 256, 827-830. 
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role 
of site accessibility in microRNA target recognition. Nat Genet 39, 1278-1284. 
Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003). Functional siRNAs 
and miRNAs exhibit strand bias. Cell 115, 209-216. 
Kiriakidou, M., Tan, G. S., Lamprinaki, S., De Planell-Saguer, M., Nelson, P. 
T., and Mourelatos, Z. (2007). An mRNA m7G cap binding-like motif within 
human Ago2 represses translation. Cell 129, 1141-1151. 
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., Ambesi-
Impiombato, A., Califano, A., Migliazza, A., Bhagat, G., and Dalla-Favera, R. 
(2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and Its 
deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40. 
Knuutila, S., Bjorkqvist, A. M., Autio, K., Tarkkanen, M., Wolf, M., Monni, O., 
Szymanska, J., Larramendy, M. L., Tapper, J., Pere, H., et al. (1998). DNA 
copy number amplifications in human neoplasms: review of comparative 
genomic hybridization studies. Am J Pathol 152, 1107-1123. 
Kong, Y. W., Cannell, I. G., de Moor, C. H., Hill, K., Garside, P. G., Hamilton, 
T. L., Meijer, H. A., Dobbyn, H. C., Stoneley, M., Spriggs, K. A., et al. (2008). 
The mechanism of micro-RNA-mediated translation repression is determined 
by the promoter of the target gene. Proc Natl Acad Sci U S A 105, 8866-8871. 
Konishi, I. (2006). Gonadotropins and ovarian carcinogenesis: a new era of 
basic research and its clinical implications. International Journal of 
Gynecological Cancer 16, 16-22. 
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., 
Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R., 
et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a 
murine liver cancer model. Cell 137, 1005-1017. 
Krek, A., Grun, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., 
MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., and Rajewsky, 
  
31 
 
N. (2005). Combinatorial microRNA target predictions. Nat Genet 37, 495-500. 
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, 
M., and Stoffel, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. 
Nature 438, 685-689. 
Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., and Jacks, T. (2007). 
Impaired microRNA processing enhances cellular transformation and 
tumorigenesis. Nat Genet 39, 673-677. 
Kumar, M. S., Pester, R. E., Chen, C. Y., Lane, K., Chin, C., Lu, J., Kirsch, D. 
G., Golub, T. R., and Jacks, T. (2009). Dicer1 functions as a haploinsufficient 
tumor suppressor. Genes Dev 23, 2700-2704. 
Kuo, K. T., Guan, B., Feng, Y., Mao, T. L., Chen, X., Jinawath, N., Wang, Y., 
Kurman, R. J., Shih Ie, M., and Wang, T. L. (2009). Analysis of DNA copy 
number alterations in ovarian serous tumors identifies new molecular genetic 
changes in low-grade and high-grade carcinomas. Cancer Res 69, 4036-4042. 
Kupryjanczyk, J., Bell, D. A., Dimeo, D., Beauchamp, R., Thor, A. D., and 
Yandell, D. W. (1995). p53 gene analysis of ovarian borderline tumors and 
stage I carcinomas. Human Pathology 26, 387-392. 
Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., 
Bell, D. A., and Yandell, D. W. (1993). p53 gene mutations and protein 
accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90, 4961-
4965. 
Landthaler, M., Yalcin, A., and Tuschl, T. (2004). The human DiGeorge 
syndrome critical region gene 8 and Its D. melanogaster homolog are required 
for miRNA biogenesis. Curr Biol 14, 2162-2167. 
Lassus, H., Leminen, A., Lundin, J., Lehtovirta, P., and Butzow, R. (2003). 
Distinct subtypes of serous ovarian carcinoma identified by p53 determination. 
Gynecol Oncol 91, 504-512. 
Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The C. elegans 
heterochronic gene lin-4 encodes small RNAs with antisense complementarity 
to lin-14. Cell 75, 843-854. 
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., 
Radmark, O., Kim, S., and Kim, V. N. (2003). The nuclear RNase III Drosha 
initiates microRNA processing. Nature 425, 415-419. 
Lee, Y., Kim, M., Han, J., Yeom, K. H., Lee, S., Baek, S. H., and Kim, V. N. 
(2004). MicroRNA genes are transcribed by RNA polymerase II. Embo J 23, 
4051-4060. 
  
32 
 
Lewis, B. P., Burge, C. B., and Bartel, D. P. (2005). Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of human genes are 
microRNA targets. Cell 120, 15-20. 
Linsley, P. S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M. M., Bartz, S. 
R., Johnson, J. M., Cummins, J. M., Raymond, C. K., Dai, H., et al. (2007). 
Transcripts targeted by the microRNA-16 family cooperatively regulate cell 
cycle progression. Mol Cell Biol 27, 2240-2252. 
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., 
Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005). 
MicroRNA expression profiles classify human cancers. Nature 435, 834-838. 
Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., and Kutay, U. (2004). 
Nuclear export of microRNA precursors. Science 303, 95-98. 
Lytle, J. R., Yario, T. A., and Steitz, J. A. (2007). Target mRNAs are repressed 
as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc 
Natl Acad Sci U S A 104, 9667-9672. 
Maroney, P. A., Yu, Y., Fisher, J., and Nilsen, T. W. (2006). Evidence that 
microRNAs are associated with translating messenger RNAs in human cells. 
Nat Struct Mol Biol 13, 1102-1107. 
Mathonnet, G., Fabian, M. R., Svitkin, Y. V., Parsyan, A., Huck, L., Murata, T., 
Biffo, S., Merrick, W. C., Darzynkiewicz, E., Pillai, R. S., et al. (2007). 
MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding 
complex eIF4F. Science 317, 1764-1767. 
Mayr, C., Hemann, M. T., and Bartel, D. P. (2007). Disrupting the pairing 
between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 
1576-1579. 
Meister, G., Landthaler, M., Dorsett, Y., and Tuschl, T. (2004). Sequence-
specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10, 
544-550. 
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., 
Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J. F., Nick, A. M., et al. 
(2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J 
Med 359, 2641-2650. 
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., 
Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., 
Allen, A., et al. (2008). Circulating microRNAs as stable blood-based markers 
for cancer detection. Proc Natl Acad Sci U S A 105, 10513-10518. 
  
33 
 
Miyashita, T., and Reed, J. C. (1995). Tumor suppressor p53 is a direct 
transcriptional activator of the human bax gene. Cell 80, 293-299. 
Mohle, J., Whittemore, A., Pike, M., and Darby, S. (1985). Gonadotrophins 
and ovarian cancer risk. J Natl Cancer Inst 75, 178-180. 
Mu, P., Han, Y. C., Betel, D., Yao, E., Squatrito, M., Ogrodowski, P., de 
Stanchina, E., D'Andrea, A., Sander, C., and Ventura, A. (2009). Genetic 
dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell 
lymphomas. Genes Dev 23, 2806-2811. 
Ness, R. B., and Cottreau, C. (1999). Possible role of ovarian epithelial 
inflammation in ovarian cancer. J Natl Cancer Inst 91, 1459-1467. 
Nikitin, A. Y., Connolly, D. C., and Hamilton, T. C. (2004). Pathology of ovarian 
neoplasms in genetically Modified Mice. Comp Medicine 54, 26-28. 
Nikitin, A. Y., and Hamilton, T. C. (2005). Modeling ovarian cancer in the 
mouse, In Research Advances in Cancer, R. M. Mohan, ed. (Kerala: Global 
Research Network), pp. 49-59. 
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. 
(2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 
839-843. 
O'Neill, C. J., Deavers, M. T., Malpica, A., Foster, H., and McCluggage, W. G. 
(2005). An immunohistochemical comparison between low-grade and high-
grade ovarian serous carcinomas: significantly higher expression of p53, 
MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg 
Pathol 29, 1034-1041. 
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., 
Tokino, T., Taniguchi, T., and Tanaka, N. (2000). Noxa, a BH3-only member of 
the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 
288, 1053-1058. 
Okamura, K., Hagen, J. W., Duan, H., Tyler, D. M., and Lai, E. C. (2007). The 
mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. 
Cell 130, 89-100. 
Olive, V., Bennett, M. J., Walker, J. C., Ma, C., Jiang, I., Cordon-Cardo, C., Li, 
Q. J., Lowe, S. W., Hannon, G. J., and He, L. (2009). miR-19 is a key 
oncogenic component of mir-17-92. Genes Dev 23, 2839-2849. 
Otis, C. N., Krebs, P. A., Quezado, M. M., Albuquerque, A., Bryant, B., San 
Juan, X., Kleiner, D., Sobel, M. E., and Merino, M. J. (2000). Loss of 
heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to 
  
34 
 
expression of p53 protein in ovarian epithelial tumors of different cell types and 
biological behavior. Human Pathology 31, 233-238. 
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., 
Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and et al. 
(1995). Wild-type human p53 and a temperature-sensitive mutant induce 
Fas/APO-1 expression. Mol Cell Biol 15, 3032-3040. 
Park, S. M., Gaur, A. B., Lengyel, E., and Peter, M. E. (2008). The miR-200 
family determines the epithelial phenotype of cancer cells by targeting the E-
cadherin repressors ZEB1 and ZEB2. Genes Dev 22, 894-907. 
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., 
Maller, B., Hayward, D. C., Ball, E. E., Degnan, B., Muller, P., et al. (2000). 
Conservation of the sequence and temporal expression of let-7 heterochronic 
regulatory RNA. Nature 408, 86-89. 
Pavlidis, N., Briasoulis, E., Hainsworth, J., and Greco, F. A. (2003). Diagnostic 
and therapeutic management of cancer of an unknown primary. Eur J Cancer 
39, 1990-2005. 
Petersen, C. P., Bordeleau, M. E., Pelletier, J., and Sharp, P. A. (2006). Short 
RNAs repress translation after initiation in mammalian cells. Mol Cell 21, 533-
542. 
Pillai, R. S., Bhattacharyya, S. N., and Filipowicz, W. (2007). Repression of 
protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17, 
118-126. 
Pothuir, B., Leitao, M., Barakat, R., Akram, M., Bogomolniy, F., Olvera, N. and 
Lin, O. (2001). Genetic analysis of ovarian carcinoma histogenesis, In Society 
of Gynecologic Oncologists 32nd Annual Meeting. 
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., 
Rougvie, A. E., Horvitz, H. R., and Ruvkun, G. (2000). The 21-nucleotide let-7 
RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 
901-906. 
Renninson, J., Baker, B. W., McGown, A. T., Murphy, D., Norton, J. D., Fox, B. 
W., and Crowther, D. (1994). Immunohistochemical detection of mutant p53 
protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation 
with histopathology and clinical features. Br J Cancer 69, 609-612. 
Riman, T., Dickman, P. W., Nilsson, S., Correia, N., Nordlinder, H., 
Magnusson, C. M., and Persson, I. R. (2002). Risk factors for invasive 
epithelial ovarian cancer: results from a Swedish case-control study. Am J 
Epidemiol 156, 363-373. 
  
35 
 
Risch, H. A., Marrett, L. D., and Howe, G. R. (1994). Parity, contraception, 
infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140, 585-
597. 
Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Fan, I., 
Tang, J., Li, S., Zhang, S., Shaw, P. A., and Narod, S. A. (2006). Population 
BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-
cohort study in Ontario, Canada. J Natl Cancer Inst 98, 1694-1706. 
Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E., 
Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L., et al. (2001). 
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a 
population series of 649 women with ovarian cancer. Am J Hum Genet 68, 
700-710. 
Risch, H. A., Weiss, N. S., Lyon, J. L., Daling, J. R., and Liff, J. M. (1983). 
Events of reproductive life and the incidence of epithelial ovarian cancer. Am J 
Epidemiol 117, 128-139. 
Rosano, L., Spinella, F., Di Castro, V., Nicotra, M. R., Dedhar, S., de Herreros, 
A. G., Natali, P. G., and Bagnato, A. (2005). Endothelin-1 promotes epithelial-
to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65, 
11649-11657. 
Ruby, J. G., Jan, C. H., and Bartel, D. P. (2007). Intronic microRNA precursors 
that bypass Drosha processing. Nature 448, 83-86. 
Salani, R., Kurman, R. J., Giuntoli, R., 2nd, Gardner, G., Bristow, R., Wang, T. 
L., and Shih, I. M. (2008). Assessment of TP53 mutation using purified tissue 
samples of ovarian serous carcinomas reveals a higher mutation rate than 
previously reported and does not correlate with drug resistance. Int J Gynecol 
Cancer 18, 487-491. 
Salzman, D. W., Shubert-Coleman, J., and Furneaux, H. (2007). P68 RNA 
helicase unwinds the human let-7 microRNA precursor duplex and is required 
for let-7-directed silencing of gene expression. J Biol Chem 282, 32773-32779. 
Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, 
M., and Greenberg, M. E. (2006). A brain-specific microRNA regulates 
dendritic spine development. Nature 439, 283-289. 
Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P. D. 
(2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 
199-208. 
Scully, R. E., and Sobin, L.H. (1999). Histological typing of ovarian tumours, 
Vol 9 (New York: Springer Berlin). 
  
36 
 
Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., and 
Rajewsky, N. (2008). Widespread changes in protein synthesis induced by 
microRNAs. Nature 455, 58-63. 
Shaulian, E., Zauberman, A., Ginsberg, D., and Oren, M. (1992). Identification 
of a minimal transforming domain of p53: negative dominance through 
abrogation of sequence-specific DNA binding. Mol Cell Biol 12, 5581-5592. 
Shell, S., Park, S. M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., 
Feig, C., Lengyel, E., and Peter, M. E. (2007). Let-7 expression defines two 
differentiation stages of cancer. Proc Natl Acad Sci USA 104, 11400-11405. 
Sherr, C. J., and McCormick, F. (2002). The RB and p53 pathways in cancer. 
Cancer Cell 2, 103-112. 
Shih Ie, M., and Kurman, R. J. (2004). Ovarian tumorigenesis: a proposed 
model based on morphological and molecular genetic analysis. Am J Pathol 
164, 1511-1518. 
Sigal, A., and Rotter, V. (2000). Oncogenic mutations of the p53 tumor 
suppressor: the demons of the guardian of the genome. Cancer Res 60, 6788-
6793. 
Singer, G., Kurman, R. J., Chang, H. W., Cho, S. K., and Shih Ie, M. (2002). 
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160, 
1223-1228. 
Singer, G., Oldt, R., 3rd, Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. 
J., and Shih Ie, M. (2003a). Mutations in BRAF and KRAS characterize the 
development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 
484-486. 
Singer, G., Shih Ie, M., Truskinovsky, A., Umudum, H., and Kurman, R. J. 
(2003b). Mutational analysis of K-ras segregates ovarian serous carcinomas 
into two types: invasive MPSC (low-grade tumor) and conventional serous 
carcinoma (high-grade tumor). International Journal of Gynecological 
Pathology 22, 37-41. 
Singer, G., Stohr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D. F., Wang, T. 
L., Kurman, R. J., and Shih Ie, M. (2005). Patterns of p53 mutations separate 
ovarian serous borderline tumors and low- and high-grade carcinomas and 
provide support for a new model of ovarian carcinogenesis: a mutational 
analysis with immunohistochemical correlation. Am J Surg Pathol 29, 218-224. 
Skog, J., Wurdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Sena-Esteves, 
M., Curry, W. T., Jr., Carter, B. S., Krichevsky, A. M., and Breakefield, X. O. 
(2008). Glioblastoma microvesicles transport RNA and proteins that promote 
  
37 
 
tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10, 1470-
1476. 
Skomedal, H., Kristensen, G. B., Abeler, V. M., Borresen-Dale, A. L., Trope, 
C., and Holm, R. (1997). TP53 protein accumulation and gene mutation in 
relation to overexpression of MDM2 protein in ovarian borderline tumours and 
stage I carcinomas. J Pathol 181, 158-165. 
Sylvestre, Y., De Guire, V., Querido, E., Mukhopadhyay, U. K., Bourdeau, V., 
Major, F., Ferbeyre, G., and Chartrand, P. (2007). An E2F/miR-20a 
autoregulatory feedback loop. J Biol Chem 282, 2135-2143. 
Tachibana, M., Watanabe, J., Matsushima, Y., Nishida, K., Kobayashi, Y., 
Fujimura, M., and Shiromizu, K. (2003). Independence of the prognostic value 
of tumor suppressor protein expression in ovarian adenocarcinomas: A 
multivariate analysis of expression of p53, retinoblastoma, and related 
proteins. International Journal of Gynecological Cancer 13, 598-606. 
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, 
H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004). Reduced 
expression of the let-7 microRNAs in human lung cancers in association with 
shortened postoperative survival. Cancer Res 64, 3753-3756. 
Thermann, R., and Hentze, M. W. (2007). Drosophila miR2 induces pseudo-
polysomes and inhibits translation initiation. Nature 447, 875-878. 
Titus-Ernstoff, L., Perez, K., Cramer, D. W., Harlow, B. L., Baron, J. A., and 
Greenberg, E. R. (2001). Menstrual and reproductive factors in relation to 
ovarian cancer risk. Br J Cancer 84, 714-721. 
Toledo, F., and Wahl, G. M. (2006). Regulating the p53 pathway: in vitro 
hypotheses, in vivo veritas. Nat Rev Cancer 6, 909-923. 
Unger, T., Mietz, J. A., Scheffner, M., Yee, C. L., and Howley, P. M. (1993). 
Functional domains of wild-type and mutant p53 proteins involved in 
transcriptional regulation, transdominant inhibition, and transformation 
suppression. Mol Cell Biol 13, 5186-5194. 
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lotvall, J. O. 
(2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat Cell Biol 9, 654-659. 
Valastyan, S., Benaich, N., Chang, A., Reinhardt, F., and Weinberg, R. A. 
(2009a). Concomitant suppression of three target genes can explain the 
impact of a microRNA on metastasis. Genes Dev 23, 2592-2597. 
Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A. M., Wang, 
  
38 
 
Z. C., Brock, J. E., Richardson, A. L., and Weinberg, R. A. (2009b). A 
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. 
Cell 137, 1032-1046. 
Vasudevan, S., and Steitz, J. A. (2007). AU-rich-element-mediated 
upregulation of translation by FXR1 and Argonaute 2. Cell 128, 1105-1118. 
Vasudevan, S., Tong, Y., and Steitz, J. A. (2007). Switching from repression to 
activation: microRNAs can up-regulate translation. Science 318, 1931-1934. 
Vousden, K. H., and Ryan, K. M. (2009). p53 and metabolism. Nat Rev 
Cancer 9, 691-700. 
Wakiyama, M., Takimoto, K., Ohara, O., and Yokoyama, S. (2007). Let-7 
microRNA-mediated mRNA deadenylation and translational repression in a 
mammalian cell-free system. Genes Dev 21, 1857-1862. 
Wang, B., Love, T. M., Call, M. E., Doench, J. G., and Novina, C. D. (2006). 
Recapitulation of short RNA-directed translational gene silencing in vitro. Mol 
Cell 22, 553-560. 
Wang, L., Wu, Q., Qiu, P., Mirza, A., McGuirk, M., Kirschmeier, P., Greene, J. 
R., Wang, Y., Pickett, C. B., and Liu, S. (2001). Analyses of p53 target genes 
in the human genome by bioinformatic and microarray approaches. J Biol 
Chem 276, 43604-43610. 
Wei, C. L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., 
Yong, H. C., Fu, Y., Weng, Z., et al. (2006). A global map of p53 transcription-
factor binding sites in the human genome. Cell 124, 207-219. 
Werness, B. A., Parvatiyar, P., Ramus, S. J., Whittemore, A. S., Garlinghouse-
Jones, K., Oakley-Girvan, I., DiCioccio, R. A., Wiest, J., Tsukada, Y., Ponder, 
B. A., and Piver, M. S. (2000). Ovarian carcinoma in situ with germline BRCA1 
mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst 
92, 1088-1091. 
Whitehead, K. A., Langer, R., and Anderson, D. G. (2009). Knocking down 
barriers: advances in siRNA delivery. Nat Rev Drug Discov 8, 129-138. 
Whittemore, A. S., Harris, R., and Itnyre, J. (1992). Characteristics relating to 
ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. 
The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer 
Group. Am J Epidemiol 136, 1212-1220. 
Wightman, B., Ha, I., and Ruvkun, G. (1993). Posttranscriptional regulation of 
the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in 
C. elegans. Cell 75, 855-862. 
  
39 
 
Woods, K., Thomson, J. M., and Hammond, S. M. (2007). Direct regulation of 
an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 
282, 2130-2134. 
Yi, R., Qin, Y., Macara, I. G., and Cullen, B. R. (2003). Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17, 
3011-3016. 
Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., 
Liang, S., Naylor, T. L., Barchetti, A., Ward, M. R., et al. (2006). microRNAs 
exhibit high frequency genomic alterations in human cancer. Proc Natl Acad 
Sci USA 103, 9136-9141. 
Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., Liu, C. 
G., Giannakakis, A., Alexiou, P., Hasegawa, K., et al. (2008). Genomic and 
epigenetic alterations deregulate microRNA expression in human epithelial 
ovarian cancer. Proc Natl Acad Sci U S A 105, 7004-7009. 
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., 
Tsuchihashi, T., McManus, M. T., Schwartz, R. J., and Srivastava, D. (2007). 
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice 
lacking miRNA-1-2. Cell 129, 303-317. 
Zheng, J., Benedict, W. F., Xu, H. J., Hu, S. X., Kim, T. M., Velicescu, M., 
Wan, M., Cofer, K. F., and Dubeau, L. (1995). Genetic disparity between 
morphologically benign cysts contiguous to ovarian carcinomas and solitary 
cystadenomas. J Natl Cancer Inst 87, 1146-1153. 
 
 
 
 
 
 
 
 
 
 
 
 
  
40 
 
CHAPTER 2 
 
MICRORNA-34B AND -34C ARE TARGETS OF P53 AND COOPERATE IN 
CONTROL OF CELL PROLIFERATION AND ADHESION-INDEPENDENT 
GROWTH* 
 
2.1 Abstract 
 
MicroRNAs (miRNAs) are a recently discovered class of non-coding RNAs 
that negatively regulate gene expression. Recent evidences indicate that 
miRNAs may play an important role in cancer. However, the mechanism of 
their deregulation in neoplastic transformation has only begun to be 
understood. In order to elucidate the role of tumor suppressor p53 in 
regulation of miRNAs we have analyzed changes in miRNA microarray 
expression profile immediately after conditional inactivation of p53 in primary 
mouse ovarian surface epithelium cells. Among the most significantly affected 
miRNAs were miR-34b and miR-34c, which were downregulated 12-fold 
according to quantitative RT-PCR analysis. Computational promoter analysis 
of the mir-34b/c locus identified the presence of evolutionarily conserved p53 
binding sites about 3 kb upstream of the miRNA coding sequence. Consistent 
with evolutionary conservation, miR-34b/c were also downregulated in p53-null 
human ovarian carcinoma cells. Furthermore, as expected from p53 binding to 
the mir-34b/c promoter, doxorubicin treatment of wild-type but not p53 
deficient cells resulted in an increase of miR-34b/c expression. Importantly, 
miR-34b and miR-34c cooperate in suppressing proliferation and soft agar 
                                                 
*
 Previously published as Corney et al., (2007). Cancer Research. 67 (18): 8433-8438. 
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colony formation of neoplastic epithelial ovarian cells, in agreement with the 
partially overlapping spectrum of their predicted targets. Taken together, these 
results demonstrate the existence of a novel mechanism by which p53 
suppresses such critical components of neoplastic growth as cell proliferation 
and adhesion-independent colony formation.  
 
2.2 Introduction 
 
MicroRNAs (miRNAs) are a recently discovered class of non-coding RNAs 
which control gene expression either by degradation of target mRNAs or, more 
commonly for animal miRNAs, by post-transcriptional repression in a 
mechanism similar to siRNA-mediated gene silencing. Numerous evidences 
point to a role for miRNAs in the etiology and pathogenesis cancer by 
targeting oncogenes or tumor suppressors (Esquela-Kerscher and Slack, 
2006). For example, miR-15a and -16 target antiapoptotic gene BCL-2 
(Cimmino et al., 2005), while the LATS32 tumor suppressor is targeted by 
miR-372 and -373 (Voorhoeve et al., 2006). Dysregulated miRNA expression 
may occur via a number of mechanisms, such as gene copy gain or loss 
(Zhang et al., 2006), germline mutation of precursor miRNA molecules (Calin 
et al., 2005), promoter methylation (Saito et al., 2006) or aberrant miRNA 
processing due to altered expression of miRNA biogenesis machinery 
(Thomson et al., 2006). However, the role of transcription factors in miRNA 
expression has received little attention. Most, if not all, miRNAs are 
transcribed by RNA polymerase II (Lee et al., 2004) suggesting that 
transcription factors involved in mRNA transcription may also regulate miRNA 
transcription. Supporting this hypothesis, the proto-oncogene and transcription 
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factor Myc has been demonstrated to bind canonical E-box sequences found 
upstream of the mir-17-92 miRNA locus (O'Donnell et al., 2005).  
 Given the above observations, we decided to elucidate the involvement 
of p53 in the regulation of miRNAs. The p53 protein is a transcription factor 
that is frequently mutated in many types of human cancer. Cellular stress, 
such as DNA damage, hypoxia or inappropriate oncogene activation, activates 
and stabilizes p53, resulting in an anti-proliferative response, such as cell 
cycle arrest, apoptosis or senescence. p53 orchestrates such responses by 
directly activating key genes via binding two repeats of the DNA sequence 5’-
PuPuPuC(A/T)(T/A)GPyPyPy-3’ (el-Deiry et al., 1992). Genes known to be 
activated by p53 include p21, Gadd45, Bax and its negative regulator Mdm2 
(Levine et al., 2006).  
 p53 mutations are thought to be the initiating or earliest events in 
formation of a number of cancers, including ovarian cancer. Approximately 
90% of ovarian cancers are carcinomas, which are assumed to originate from 
the ovarian surface epithelium (OSE), a single layer of cells coating the ovary. 
Due to near symptomless progression, the majority of cases are diagnosed at 
a late stage, at which stage prognosis is extremely poor (Nikitin and Hamilton, 
2005). Based on the previously described mouse model of epithelial ovarian 
cancer (EOC) (Flesken-Nikitin et al., 2003), we have established a system to 
evaluate immediate effects of p53 inactivation on miRNAome of the OSE 
within the first few passages after explantation. We report that miRNAs miR-
34b and miR-34c are transcriptional targets of p53 and represent novel 
effectors mediating its suppression of such critical components of neoplastic 
growth as cell proliferation and adhesion-independent colony formation. 
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2.3 Materials and methods 
 
Cell Culture. For preparation of primary cell cultures, mouse OSE cells 
from either p53loxP/loxP (Jonkers et al., 2001) or wild-type age-matched mice of 
the same FVB/N background were isolated as previously described (Flesken-
Nikitin et al., 2003). All mice used for cell preparations were maintained 
identically, following recommendations of the Institutional Laboratory Animal 
Use and Care Committee. Neoplastic cell lines OSN1 and OSN 2 were 
generated by Cre-loxP mediated inactivation of p53 and Rb, or p53 
individually, respectively, after 3 passages in culture. These cell lines were 
continually passaged upon reaching confluence using standard techniques 
and late passage OSN1/OSN2 cells were used in this study. Primary cultures 
and established mouse cell lines were maintained in DMEM/F12 (50:50 mix) 
supplemented with 5% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 
ng/ml EGF, 500 ng/ml hydrocortisone, 5 µg/ml each of insulin and transferrin 
and 5 ng/ml sodium selenite. Human SKOV-3 cell line was obtained from 
ATCC and maintained according to supplier's directions.  
 
 miRNA isolation and profiling. At passage three after explantation, 
subconfluent OSE cell cultures were treated with either AdCre or blank 
adenovirus in serum-free medium for two hours at 37°C/5% CO2, cultured for 
a further 2 passages and processed for miRNA isolation. Total RNA was 
isolated using a mirVana miRNA Isolation Kit (Ambion, Austin, TX) and was 
highly enriched for mature miRNA species using a FlashPAGE Fractionator 
(Ambion, Austin, TX). 110 ng miRNA-enriched material was labeled with Cy5 
using Label IT miRNA Labeling kit (Mirus Bio Corporation, Madison, WI) 
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according to the manufacturer’s instructions and subsequently hybridized to 
CombiMatrix MicroRNA 4X2K Microarrays (CombiMatrix, Mukilteo, WA) 
containing probes against mouse miRNAs in Release 8.1 of the Sanger 
database.  
 Each slide harbored 4 microarrays, each containing 2240 probes. 400 
miRNA sequences were represented by a native probe corresponding to wild 
type miRNA sequence (Nat) and a 2 point mutation mutant probe (Mut) to 
maximally disturb the binding between probe and intended target miRNA.  
Each probe was replicated 3 to 5 times on the array. The hybridized arrays 
were scanned by GenePix 4000B scanner (Molecular Devices, Sunnyvale, 
CA) to generate raw fluorescence intensity file. The intensities of replicate 
spots for the same probe sequence were averaged to represent the probe 
signal. Six wild-type samples and six mutant samples were analyzed. Three 
samples with obvious hybridization artifacts were excluded from further 
analysis. True signal for the intended miRNA target was obtained by 
subtracting Mut probe intensity from the corresponding Nat probe intensity. 
Some of these Nat-Mut signals were very small so data flooring was applied to 
raise any value below 2 to be equal to 2 and were log-transformed. To 
minimize slide to slide variation, biological replicate samples on each slide 
were averaged and the difference between sample types taken for subsequent 
analysis. The log-ratio values of each array were centered to have a median of 
0. One-sample t test against mean of 0 was applied on the normalized p53-
mutant/wildtype values of each gene across 3 slide hybridizations. At cutoff 
value of 0.1, a total of 84 genes were selected. 
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Quantitative RT-PCR. Stem-loop quantitative RT-PCR for mature 
miRNAs was performed as described (Chen et al., 2005) on an Applied 
Biosystems AB 7500 Real Time PCR system (Foster City, CA). All PCR 
reactions were run in quadruplicate and gene expression, relative to RNU6B, 
calculated using the 2-∆∆Ct method (Livak and Schmittgen, 2001). 
 
 Bioinformatics. To identify p53 response elements in miRNA promoter 
regions, 5 kb 5’ and 3’ of each miRNA genomic sequence from Build 36 of the 
Mus musculus genome and Build 36.1 of the Homo sapiens genome were 
retrieved from UCSC Genome Browser. Retrieved sequences were analyzed 
by the p53MH algorithm, which searches for two copies of the p53 DNA-
binding motif separated by 0-14 bp (Hoh et al., 2002).  
 
 Molecular cloning of mir-34b and mir-34c. Genomic DNA encoding mir-
34b and/or mir-34c was cloned using standard molecular biology techniques. 
Briefly, a 347 bp, 258 bp or 795 bp fragment of mouse DNA containing mir-
34b, mir-34c or both sequences, respectively, was PCR amplified with 
Herculase II Fusion DNA Polymerase (Stratagene, La Jolla, CA). Primers 
contained restriction sites for EcoRI or BamHI (Table 2.1) and PCR products 
were ligated into pCDH-MCS1-EF1-Puro (System Biosciences, Mountain 
View, CA). Infectious lentiviral particles were prepared using ViraPower 
Lentiviral Packaging Mix (Invitrogen, Carlsbad, CA) per the manufacturers’ 
protocol. Viral titer was also calculated per the manufacturers’ protocol and 
cells were transduced with approximately 1 MOI. For stable transduction, 
transduced cells were cultured in 4 µg/ml puromycin until non-transduced cells 
were all killed. 
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*Underlined sequence represents EcoRI recognition site (forward primer) or 
BamHI recognition site (reverse primer). 
 
 
 
 
 
Table 2.1 miR-34b/c amplification primers for lentivirus construction. 
Gene Forward primer* Reverse primer* Product 
size 
miR-34b ATACTGAATTCGGGA
GCCTGAGGCACCTCT 
TGAATGGATCCGCCGG
TCTCCGAGGGTTA 
347 bp 
 
miR-34c TATCAGAATTCCAAGG
CAGCGACTAGAGTC 
GCAATGGATCCTCCCTA
TGGCTCTGTCCTCAC 
258 bp 
 
miR-34b/c ATACTGAATTCGGGA
GCCTGAGGCACCTCT 
GCAATGGATCCTCCCTA
TGGCTCTGTCCTCAC 
795 bp 
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Pre-miR transfection and proliferation assay. Cells seeded in either 24-
well plates or 8-well chamber slides were transfected with 33 nM or 66 nM pre- 
miR miRNA precursor molecules (Ambion, Austin, TX) using 
Lipofectamine2000 (Invitrogen, Carlsbad, CA), or transduced with lentivirus 
encoding miR-34b and/or miR-34c and assayed for proliferation status 48 
hours later. Proliferation was quantified by bromodeoxyuridine (BrdU) 
incorporation assay as described previously (Nikitin and Lee, 1996). For 
estimation of proliferative indices, three representative images were collected 
per well using a SPOT-RT digital camera (Diagnostic Instruments, Inc., 
Sterling Heights, MI).  
 
 Soft agar assay. Soft agar assay was performed essentially as 
described in (Reid, 1979). Briefly, 6 cm plates were covered in a Nobel agar 
base layer (0.5% agar, 10% FBS and 0.2% tryptone in DMEM). A top layer 
containing 5 x105 cells to be assayed were suspended in DMEM containing 
10% FBS, 0.2% tryptone and 0.4% Nobel agar and pipetted on top of the base 
layer. After 3 days, growth medium was added to prevent the gel from drying. 
 
 Statistical Analyses. For statistical testing, two-sided unpaired Student’s 
t-tests were performed using InStat 3.05 and Prism 4.03 software (GraphPad, 
Inc., San Diego, CA).  
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2.4 Results and discussion 
 
2.4.1 p53 inactivation results in miRNAome alteration  
 
To demonstrate that p53 either directly or indirectly regulates a subset of 
miRNAs, we performed miRNA microarray profiling of mouse ovarian surface 
epithelial cells subjected to the acute inactivation of p53 (Figure 2.1A). A total 
of 84 miRNAs were significantly over or under expressed (Figure 2.1B), while 
the majority of miRNAs were unchanged or not expressed in either wild type or 
mutant, in agreement with previous data demonstrating spatiotemporal-
specific expression of a high percentage of miRNAs (Liu et al., 2004). The 3 
most downregulated miRNAs were the miR-34 family which consists of miR-
34a, miR-34b and mir-34c. mir-34a is located at mouse chromosome 4qE2 
while mir-34b and mir-34c are located 435bp apart on chromosome 9qA5 and 
appear to be coordinately expressed as a miRNA cluster. In order to confirm 
the microarray data (Figure 2.1C) we performed quantitative RT-PCR. Using 
stem loop primers, we were able to specifically amplify mature miRNA 
molecules and confirm approximately 12-fold down regulation of both miR-34b 
and miR-34c (Figure 2.1D). 
 
2.4.2 Identification of a p53 responsive element upstream of the mir-
34b/c locus.  
 
In order to identify candidate p53-regulated miRNAs, we conducted an in silico 
screen for p53 responsive elements (p53REs). We focused our attention on 
downregulated miRNAs, since the p53 activation consensus sequence is well  
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Figure 2.1 miRNAome alterations after acute p53 inactivation in primary 
mouse OSE cells. A, Outline of experiments. miRNA expression profile was 
generated after AdCre-mediated p53 inactivation followed by computational 
miRNA promoter analysis for p53REs. Finally, the function of p53-dependent 
miRNAs was elucidated by experimental testing. B, Expression profile of top 
84 miRNAs differentially expressed after acute p53 inactivation in three 
independent experiments. miR-34b and miR-34c, two of the most 
downregulated miRNAs, are indicated by asterisks. C, Expression levels of 
miR-34b and miR-34c as judged by microarray analysis of 4 wild type and 5 
p53 deficient (mutant) OSE cultures (P= 0.055 and P= 0.046 for miR-34b and 
miR-34c, respectively). D, Expression levels of miR-34b and miR-34c relative 
to RNU6B as judged by quantitative RT-PCR of 5 wild type and 5 mutant OSE 
cultures (P<0.0001 and P= 0.0053 for miR-34b and miR-34c, respectively). C, 
D, R.U., relative units. 
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defined whereas in contrast the repression sequence is less so. In this 
respect, loss of p53-mediated transcriptional activation after p53 inactivation 
will lead to a decrease in expression of the target gene (Yugawa et al., 2007). 
Towards this we took advantage of the p53MH algorithm (Hoh et al., 2002),  
which has previously identified novel p53-responsive genes (Feng et al., 
2005), to search 5 kb up- and down-stream of each downregulated miRNA. 
Predicted p53 binding sites were identified upstream of 9 miRNAs.  
Given that p53 is evolutionarily conserved, noteworthy p53 binding may 
also be expected to be evolutionarily conserved. Therefore we also searched 
the corresponding human miRNA locus for predicted binding sites. Three 
binding sites were conserved between human and mouse: mir-129, mir-34b 
and mir-34c. We decided to direct our attention towards miR-34b and miR-34c 
(Figure 2.2A), given that we observed a far greater reduction in expression of 
these two genes compared to miR-129. In addition to the conserved p53RE 
upstream of the miRNA locus, both miR-34b and miR-34c are remarkably well 
conserved between species (Figure 2.2B), suggesting that these miRNAs 
have critical roles in animals. Finally, in order to demonstrate that expression 
of miR-34b/c is lost in p53-deficient human cancer cells, we performed 
quantitative RT-PCR on RNA isolated from briefly cultured wild type human 
OSE cells and the p53-null cell line SKOV-3, which was derived from 
adenocarcinoma of the ovary. In good agreement with miR-34b/c expression 
in our mouse model, both miRNAs were dramatically reduced in the p53-null 
cells (Figure 2.2C). 
 We next decided to establish if p53 activation induces expression of 
miR-34b/c. Doxorubicin leads to DNA strand breaks and a physiological 
increase in p53 protein, partly through its stabilization by posttranslational  
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Figure 2.2 miR-34b and miR-34c are direct targets of p53. A, Structure of the 
mouse and human mir-34b/c locus. Computational analysis identified a p53RE 
approximately 3 kb upstream of the miRNA coding sequence, which is 
conserved between mouse and human. B, In addition to conservation of a 
p53RE, miR-34b and miR-34c mature sequences are remarkably well 
conserved among species. C, miR-34b and miR-34c expression relative to 
RNU6B in p53-null SKOV-3 human OSE cell line is considerably lower than 
expression in wild type human OSE. D, Doxorubicin treatment (0.5 μg/ml) of 
wild type OSE cultures results in a rapid increase in expression of both miR-
34b and miR-34c (top, P= 0.0004). In contrast, no such induction is observed 
in identically treated p53 mutant OSE cultures (bottom). C, D, R.U., relative 
units. 
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modifications via the DNA damage pathway. We therefore treated cells with 
0.5 µg/ml doxorubicin. While a 4-fold increase in miR-34b/c expression was 
observed by 12 hours of doxorubicin exposure in wild type OSE cells, no such 
increase was observed in p53 mutant OSE cells (Figure 2.2D), consistent with  
computational analysis predicting that these miRNAs contain a p53RE and are 
therefore p53-responsive.  
 
2.4.3 miR-34b and miR-34c cooperate in reducing proliferation and 
adhesion-independent growth.  
 
In order to characterize the roles of these p53-dependent miRNAs, we 
transfected OSN1 or OSN2 cells with synthetic miRNAs for miR-34b. 48 hours 
post transfection, proliferation index was determined by BrdU incorporation. A 
visible reduction in proliferation was observed upon miR-34b transfection 
compared to a non-targeting negative control molecule in OSN1 cells (Figure 
2.3A), which was also somewhat dose-dependent (Figure 2.3B).  
 To generate cell lines with stable integrations of miR-34b and/or miR-
34c, we cloned the miRNA and surrounding genomic sequence into a 
lentivirus vector. Quantitative RT-PCR of miR-34b and miR-34c in cells after 
puromycin selection demonstrated an increase in miRNA expression (Figure 
2.4). Stably transduced OSN2 cells demonstrated a significant reduction in 
proliferation (Figure 2.3C). Interestingly, while transduction of either lenti-34b 
or lenti-34c individually reduced percent of proliferating cells (Mean ± SD, 48.4 
±1.8%, P= 0.0025 and 46.2 ± 3.6%, P= 0.0041, respectively, compared to 
62.4 ± 3.1% for blank virus), transduction of both miRNAs reduced 
proliferation to an even greater extent (36.3 ± 8.4%, P= 0.0074). Furthermore,  
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Figure 2.3 miR-34b and miR-34c cooperate in decreasing proliferation and 
anchorage-independent growth. A, GFP-expressing OSN2 cells were either 
untreated (upper left) or transfected with 33 nM siRNA directed against GFP 
(upper right), demonstrating efficient knockdown. Transfection of OSN2 cells 
with 33 nM non-targeting synthetic miRNA molecules (lower left) or synthetic 
miR-34b (lower right) followed by BrdU administration. A significant decrease 
in cell proliferation as determined by BrdU incorporation is observed 48 hours 
after miR-34b transfection. B, Quantitative assessment of cell proliferation 
after transfection with 33 nM or 66 nM synthetic miR-34b demonstrates 
significantly reduced percent of BrdU incorporating cells as compared to non-
targeting control molecule (33 nM: miR-34b versus control, P= 0.0042; 66 nM: 
miR-34b versus control, P= 0.0213). C, Quantitative assessment of OSN1 cell 
proliferation after transduction with either control (blank) lentivirus or lentivirus 
encoding for mir-34b and/or mir-34c. A significant reduction in proliferating 
cells was observed for each treatment compared to control lentivirus (Lenti-
control versus Lenti-34b, P= 0.0025; Lenti-34c, P= 0.0041; Lenti-34b/c, P= 
0.0074). D, Quantitative assessment of soft agar colony formation by OSN1 
cells transduced with Lenti-34b/c demonstrates a significant decrease in 
colony formation in soft agar (Lenti-control versus Lenti-34b/c, P= 0.0214). A, 
GFP fluorescence with DAPI counterstain (upper), BrdU, ABC Elite method, 
hematoxylin counterstaining (bottom). Bar, 50 μm (A).  
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Figure 2.4 miR-34b/c expression after lentivirus transduction. OSN1 cells (p53 
mutant) were transduced with blank lentivirus or lentivirus containing genomic 
sequence of miR-34b and/or miR-34c. After puromycin selection, total RNA 
was isolated and quantitative RT-PCR performed, demonstrating increased 
miRNA expression. Expression of miR-34b (A) and miR-34c (B) in wild type 
cells and in cells after acute p53 inactivation is shown for comparison. A, miR-
34b expression in mutant (Mean ± SD): 0.078 ± 0.059 versus Lenti-34b: 0.792 
± 0.062, P= 0.0001, n= 4; versus Lenti-34c: 0.143 ± 0.014, P= 0.1369, n= 4; 
versus Lenti-34b/c: 0.343 ± 0.03, P= 0.0023, n= 4. B, miR-34c expression in 
mutant (Mean ± SD): (0.079 ±0.059) versus Lenti-34b: 0.073 ± 0.005, P= 
0.8692, n= 4; Lenti-34c: 4.912 ± 0.11, P< 0.0001, n=4; Lenti-34b/c: 0.962 ± 
0.077, P<0.0001, n=4. A, B, R.U., relative units. 
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a cooperative relationship was also observed when transduced OSN1 cells 
were cultured in soft agar (Figure 2.3D). Transduction of lenti-34b and lenti-
34c reduced the number of colonies per 4x field of view from 5.3 ± 1.1 for cells 
transduced with blank virus to 3.2 ± 0.8 (P= 0.0534) and 3.6 ± 0.6 (P= 0.0835), 
respectively, whereas statistically significant reduction was observed in lenti-
34b/c- transduced cells (2.9 ± 0.6 colonies, P= 0.0214). These data suggest 
that while  
the sequences, and therefore predicted targets, of miR-34b/c are very similar, 
their differences have a significant consequence on biological activity and that 
maximal suppression of proliferation and anchorage-independent growth is 
achieved only when both miRNAs are expressed. In particular, Delta-like 1, 
Notch1, Met and Ezh2 are all predicted targets for both miR-34b and miR-34c. 
In contrast, Myc and Cdk6 are among predicted targets for miR-34b and E2f3, 
Bcl2 and Cyclin D1 for miR-34c (Griffiths-Jones et al., 2006).  
 
2.4.4 A model for p53-dependent miRNA-mediated gene silencing.  
 
Taken together, our data illustrate a novel mechanism for p53-mediated 
control of gene expression. As outlined in Figure 2.5, p53 is activated by DNA 
damage and directly induces expression miR-34b and miR-34c through a 
p53RE approximately 3 kb upstream of the coding sequence. This activation, 
in turn, leads to repression of target genes. Although these two miRNAs share 
significant sequence similarity, their predicted targets are not perfectly 
conserved, thereby explaining cooperative effects of miR-34b and miR-34c. It 
should be noted that different stimuli, such as inappropriate mitogenic 
signaling, hypoxia, and spindle damage, etc., may result in disparate  
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Figure 2.5 A model for p53-dependent miRNA-mediated repression of gene 
expression. p53 activation by DNA damage and possibly other stimuli, such as 
mitogenic signaling, lead to a rapid increase in expression of the p53-
dependent miRNAs miR-34b and miR-34c. These miRNAs are predicted to 
bind a large number of target mRNAs; a selection of these targets are shown. 
Predicted targets of each miRNA are both independent (top and bottom) and 
conserved (middle). 
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consequences as a result of p53 binding to different subsets of its target 
genes (Levine et al., 2006). Whether miR-34b and miR-34c may have different 
extent of p53-dependant activation by other stimuli remains to be determined. 
The discovery of inhibitory effects of these microRNAs on such critical 
components of neoplastic growth as cell proliferation and adhesion- 
independent colony formation opens an exciting opportunity for development 
of novel therapeutic approaches utilizing these small molecules. 
 
After submission of our paper, He et al. reported p53-dependent 
regulation of miR-34b/c in mouse embryonic fibroblasts and IMR90 fibroblasts 
and demonstrated reduction of cell growth and induction of senescence after 
ectopic expression of miR-34b/c in IMR90 fibroblasts (He et al., 2007). Taken 
together with our observations of miR-34b/c effects on cell proliferation and 
adhesion-independent growth of OSE, these results indicate that miR-34b/c 
play important roles in controlling carcinogenesis in various cell types, likely 
due to the diversity of their mRNA targets. 
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CHAPTER 3 
 
FREQUENT DOWNREGULATION OF MIR-34 FAMILY IN HUMAN OVARIAN 
CANCERS* 
 
3.1 Abstract 
 
Purpose: The miR-34 family is directly transactivated by tumor suppressor p53 
which is frequently mutated in human epithelial ovarian cancer (EOC). We 
hypothesized that miR-34 expression would be decreased in EOC and that 
reconstituted miR-34 expression might reduce cell proliferation and invasion of 
EOC cells. 
Experimental designs: miR-34 expression was determined by quantitative RT-
PCR and in situ hybridization in a panel of 83 human EOC samples. 
Functional characterization of miR-34 was accomplished by reconstitution of 
miR-34 expression in EOC cells with synthetic pre-miR molecules followed by 
determining changes in proliferation, apoptosis and invasion. 
Results: miR-34a expression is decreased in 100%, and miR-34b*/c in 72%, of 
EOC with p53 mutation, while miR-34a is also downregulated in 93% of 
tumors with wild-type p53. Furthermore, expression of miR-34b*/c is 
significantly reduced in stage IV tumors compared to stage III (p= 0.0171 and 
p= 0.0033, respectively). Additionally, we observed promoter methylation and 
copy number variations at mir-34 loci. In situ hybridization demonstrated that 
miR-34a expression is inversely correlated with MET immunohistochemical 
staining, consistent with translational inhibition by miR-34a. Finally, miR-34 
                                                 
*
 Previously published as Corney et al., (2010). Clinical Cancer Research. 16 (4): 1119-1128. 
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reconstitution experiments in p53 mutant EOC cancer cells resulted in reduced 
proliferation, motility and invasion, the latter of which was dependent on MET 
expression. 
Conclusions: Our work suggests that miR-34 family plays an important role in 
EOC pathogenesis and reduced expression of miR-34b*/c may be particularly 
important for progression to the most advanced stages. Part of miR-34 effects 
on motility and invasion may be explained by regulation of MET, which is 
frequently overexpressed in EOC.  
 
3.2 Translational relevance 
 
Diagnosis and treatment of EOC is particularly difficult due to poor 
understanding of disease pathogenesis. We show that miR-34 expression is 
frequently decreased in EOC due to several mechanisms, but mainly due to 
p53 mutation. Importantly, reconstitution of miR-34 in human ovarian cancer 
cells results in decreased proliferation and invasion, at least partially by 
inhibition of the MET oncogene. Taken together, these data suggest that miR-
34 family is important for EOC development and may be an attractive 
candidate for development of novel therapeutic approaches. 
 
3.3 Introduction 
 
Ovarian cancer is the most deadly malignancy and will lead to almost 15,000 
deaths in the USA in 2009 (Jemal et al., 2009). While survival has increased 
slightly over the past 25 years, 5-year survival remains below 50%. A major 
factor for low survival is our poor understanding of the initiating events that 
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lead to ovarian cancer and how the disease progresses. Due to asymptomatic 
development and few screening options, almost 70% of women present at late 
stages of carcinogenesis. At an advanced stage, treatment options are 
severely limited, with palliative treatment most often administered in the form 
of debulking surgery and paclitaxel and platinum based therapeutics. 
However, work over the past decade using human cancer samples and mouse 
models have revealed new insights into the molecular basis of ovarian cancer, 
particularly its most common form, epithelial ovarian cancer (EOC). For 
example, it is well established that over 50% of high-grade serous type EOC 
contain p53 mutations and alterations in the RB pathway (reviewed in Bast et 
al., 2009; Corney et al., 2008). Consistently, conditional inactivation of p53 and 
Rb in the mouse ovarian surface epithelium (OSE) leads to development of 
poorly differentiated serous ovarian adenocarcinomas (Flesken-Nikitin et al., 
2003), while K-Ras, Pten and Wnt/beta-catenin are implicated in 
carcinogenesis of the endometrioid EOC subtype (Dinulescu et al., 2005; Wu 
et al., 2007). 
 In recent years, the involvement of small non-coding RNAs called 
microRNAs (miRNAs) in cancers of many types has become unambiguous, 
including in ovarian cancer (Iorio et al., 2007; Zhang et al., 2008). Although the 
precise roles they play during carcinogenesis are still being dissected, it is 
clear that miRNAs can act as tumor suppressors and oncogenes by regulating 
processes such as proliferation and the cell cycle, apoptosis, invasion and 
metastasis (reviewed in Esquela-Kerscher and Slack, 2006). miRNAs have 
been found to be dysregulated in cancer by DNA copy number changes and 
epigenetic alterations, altered processing by the miRNA biogenesis machinery 
and through altered transcriptional activation. In particular, the transcription 
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factor and tumor suppressor p53 has been independently shown by several 
laboratories to directly transactivate genes of the miR-34 family, which is 
comprised of three members (Bommer et al., 2007; Chang et al., 2007; 
Corney et al., 2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 
2007). Gene encoding miR-34a is located on human chromosome 1p36, while 
miR-34b and miR-34c are co-transcribed from one transcription unit on 
chromosome 11q23. The miR-34 family downregulates numerous important 
regulatory proteins and thereby presumably mediates tumor suppression 
(reviewed in Hermeking, 2010). 
 Previously, we have demonstrated that conditional inactivation of p53 
results in miR-34 downregulation in mouse OSE (Corney et al., 2007). To 
evaluate the potential roles of miR-34 family in human EOC, we have 
determined their expression level in a panel of 83 cancer tissues and found 
that miR-34 expression is frequently decreased in EOC, is associated with 
metastatic clinical stage and increased expression of receptor protein tyrosine 
kinase MET. Furthermore, reconstitution of miR-34 expression in EOC cells 
leads to reduced proliferation and invasion, as well as decreased MET levels. 
 
3.4 Materials and methods 
 
Clinical samples. Informed consent was obtained from patients 
undergoing surgery for ovarian cancer at Fox Chase Cancer Center, 
Philadelphia, PA and M.D. Anderson Cancer Center, Houston, TX. Sample 
collection was performed after approval by an Institutional Review Board and a 
portion of tumor tissue not required for diagnostic purposes was snap frozen in 
liquid nitrogen and stored at -80°C. Surgical evaluation was used to determine 
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clinical stage and presence of metastases, while histopathological analysis by 
gynecologic pathologists was performed to assess cancer type and subtype. 
Only tumors found to contain over 70% tumor cells were used in the study and 
tissue sample and clinical data was available for 83 patients (Table 3.1). 
Additional formalin-fixed paraffin embedded specimens were obtained from 
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY. 
 
miR-34 nomenclature. miRNA nomenclature has recently been revised 
such that the miR-34b sequence has been renamed miR-34b* (i.e. the 
passenger strand) (Landgraf et al., 2007). Nevertheless, “star” or passenger 
strands of the miRNA duplex have previously been shown to be biologically 
important (e.g. miR-199a* and miR-10* (Migliore et al., 2008; Stark et al., 
2007). Although both miR-34b strands are likely to be functional, the miR-34b 
strand is not predicted to bind the 3’ UTR of MET and our studies have 
therefore focused on the miR-34b* strand. It is worth noting that our qRT-PCR 
data demonstrate that both strands are present at equal quantities and are 
highly correlated (Figure 3.1); they therefore might be renamed miR-34b-3p 
and miR-34b-5p, respectively, consistent with mouse miR-34b nomenclature.  
 
p53 mutation screening. The IARC protocol (http://www-p53.iarc.fr) was 
followed for p53 mutation screening. DNA was isolated by Qiagen DNeasy 
mini kit (Qiagen, Valencia, CA) and exons 4-11, including splice junctions, 
were amplified by PCR and sequenced with both forward and reverse primers 
(Table 3.2). In the case sequencing data was unclear, T-vector cloning was 
performed, and three clones sequenced by T7 and SP6 primers. 
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Table 3.1 Characteristics of 83 patients with epithelial ovarian cancer. 
 
 
 
 
 
 
 
 
 
 
 Characteristic Value 
Age (years) 
Mean 60.8 
Range 28-87 
Race (%) 
White 64 (77.1) 
African American 5 (6) 
Other non-white 6 (7.2) 
Unknown 2 (2.4) 
Tumor stage 
(%) 
I 2 (2.4) 
II 4 (4.8) 
III 46 (55.4) 
IV 18 (21.7) 
TX 13 (15.7) 
Histology 
Serous 62 (74.7) 
Mucinous 2 (2.4) 
Endometrioid 3 (3.6) 
Clear cell 1 (1.2) 
Adenocarcinoma, NOS/undifferentiated 4 (4.8) 
Mixed 11 (13.3) 
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Figure 3.1 miR-34b  and  miR-34b*  are  present  in  equal  amounts  and  are 
highly correlated. A. miR-34b* and miR-34b strands are present in equal 
quantities in RNA isolated from EOC specimens (n=30, p= 0.1764, 2-tailed 
paired t-test. B. miR-34b* and miR-34b show significant correlation in their 
expression (r2= 0.8497, p<0.0001). Error bars represent standard deviation. 
 
 
 
 
  
 
Table 3.2 List of primers used for p53 mutation analysis and mir-34a copy number and methylation analysis. 
Gene Forward primer Reverse primer Probe 
miR-34a AGTGTCTTAGCTGGTTGTTGTGA GCAGCACTTCTAGGGCAGTAT TTGCTGATTGCTTCCTTACTATTGC 
LINE1 GCTCCTGAATGACTACTGGGTACA GTGTCTTTGTTCTCGTTGGTTTCAA ACGAAATGAAGGCAGAAATAAA 
p53 
Exon 4 TGCTCTTTTCACCCATCTAC ATACGGCCAGGCATTGAAGT N/A 
Exon 5 TTCAACTCTGTCTCCTTCCT CAGCCCTGTCGTCTCTCCAG N/A 
Exon 6 GCCTCTGATTCCTCACTGAT TTAACCCCTCCTCCCAGAGA N/A 
Exon 7 AGGCGCACTGGCCTCATCTT TGTGCAGGGTGGCAAGTGGC N/A 
Exon 8/9 TTGGGAGTAGATGGAGCCT AGTGTTAGACTGGAAACTTT N/A 
Exon 10 CAATTGTAACTTGAACCATC GGATGAGAATGGAATCCTAT N/A 
Exon 11 AGACCCTCTCACTCATGTGA TGACGCACACCTATTGCAAG N/A 
miR-34a 
methylated 
GGTTTTGGGTAGGCGCGTTTC TCCTCATCCCCTTCACCGCCG N/A 
miR-34a 
unmethylated 
IIGGTTTTGGGTAGGTGTGTTTT AATCCTCATCCCCTTCACCACCA N/A 
miR-34b*/c 
methylated 
TTTAGTTACGCGTGTTGTGC ACTACAACTCCCGAACGATC N/A 
miR-34b*/c 
unmethylated 
TGGTTTAGTTATGTGTGTTGTGT CAACTACAACTCCCAAACAATCC   N/A 
 
7
1
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Quantitative RT-PCR. Total RNA was isolated using mirVana miRNA 
Isolation Kit (Ambion, Austin, TX) according to the manufacturer’s protocol and 
RNA concentration and purity determined by NanoDrop analysis. Stem-loop 
qRT-PCR for mature miR-34 and miR-199a* miRNAs was performed as  
previously described (Chen et al., 2005). For MET qRT-PCR, cDNA was 
prepared from 100 ng total RNA using SuperScript III (Invitrogen, Carlsbad, 
CA) and amplified with TaqMan primer/probes. All PCR reactions were 
performed in triplicate on an AB 7500 Real Time PCR system (Applied 
Biosystems Inc, Foster City, CA) and miRNA and mRNA expression 
normalized to RNU6B and GAPDH, respectively, using the 2-ΔΔCt method 
(Livak and Schmittgen, 2001).  
 
MET immunohistochemistry. Paraffin sections of formalin-fixed tissue 
were stained according to modified avidin-biotin-peroxidase technique (Nikitin 
and Lee, 1996). The antibody used for detection of MET was CVD13 from 
Zymed Laboratories (dilution 1:200). 
 
In situ hybridization. Detection of miR-34 in a panel of serous 
adenocarcinomas was performed by the protocol adapted from Nelson et al. 
(Nelson et al., 2006). In order to prevent the loss of miRNAs, we additionally 
applied 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) fixation as 
described in (Pena et al., 2009). In brief, 6 µm-thick sections of formalin-fixed 
paraffin-embedded material were deparaffinized, rehydrated, and fixed with 
EDC. After 1 hour prehybridization, a DIG-labeled LNA probe (Exiqon, 
Woburn, MA) was hybridized to Proteinase K-treated sections at 56°C for 16 
hours. Slides were then incubated with anti-DIG-AP antibody (Roche, 
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Indianapolis, IN), and microRNA expression was detected by NBT/BCIP 
method. Methyl green was used for nucleic counter staining. 
 
Quantitative PCR. For copy number variation analysis, DNA was 
isolated with a DNeasy DNA mini kit (Qiagen, Valencia, CA) and 60 ng DNA 
amplified with custom TaqMan real time primers and probes that were 
designed to amplify across the mir-34a locus (Table 3.2). Copy number was 
calculated by normalizing to LINE1 retrotransposon gene copy number, which 
is maintained at relatively constant levels in neoplastic and normal tissues 
(Kuo et al., 2009; Wang et al., 2002), using the 2- ΔΔCt method (Livak and 
Schmittgen, 2001). Primer sequences are given in Table 3.2. A total of 30 
serous, 1 mucinous and 2 tumors of undetermined histology with clinical 
characteristics similar to the entire cohort were analyzed. Pooled human 
placental DNA served as a wild type control (Bioline, Taunton, MA). 
 
Methylation-specific PCR analysis. Genomic DNA isolated as described 
above was treated with bisulfite using the EZ DNA methylation kit (Zymo 
Research, Orange, CA). A total of 27 serous, 1 mucinous and 2 undetermined 
EOC tumors with clinical characteristics similar to the entire cohort were 
analyzed. The modified DNA was eluted with a final volume of 16 µl, and 1 µl 
to 2 µl were used for the methylation specific polymerase chain reactions 
(MSP). In case of mir-34a, amplification conditions were 5 min at 95°C; 2 
cycles of 20 sec at 95°C, 30 sec at 68°C, and 30 sec at 72°C; followed by 2 
cycles with 66°C annealing temperature, then 34 cycles with 65°C annealing 
temperature and a 4 min final extension at 72°C. For mir-34b*/c, amplification 
conditions were 37 cycles of 20 sec at 95°C, 30 sec at 61°C and 30 sec at 
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72°C, 4 minutes final extension. Primers used were previously reported 
(Lodygin et al., 2008; Lujambio et al., 2008) and are listed in Table 3.2. PCR 
products were separated by electrophoresis on an 8% polyacrylamide gel and 
band intensities visually scored. 
 
Cell culture experiments. Human p53 mutant ovarian adenocarcinoma 
cell line SKOV-3 was obtained from the American Type Culture Collection and 
maintained according to the supplier’s directions. For proliferation and 
apoptosis analysis, cells were seeded in triplicate in 24-well plates and the 
next day transfected with Pre-miR synthetic miRNA molecules (Ambion, 
Austin, TX) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Proliferation 
was assessed by BrdU incorporation and apoptosis assessed by cleaved 
caspase-3 staining 48 hours post-transfection as previously described (Nikitin 
and Lee, 1996; Zhou et al., 2006). For the apoptosis assay, cells were treated 
with 5 µM camptothecin for 17 hours to induce apoptosis. Invasion assays 
were performed in a chamber containing an 8 µm pore-size PET membrane 
coated with a uniform layer of BD Matrigel™ Basement Membrane (BD 
Bioscience, San Jose, CA). For MET knock down experiments, 2 µmol/mL of 
MET siRNA (sc-29397, Santa Cruz, Santa Cruz, CA) was transfected. 24 
hours after transfection, 5 x 103 SKOV-3 cells per each well were seeded in a 
control insert or Matrigel insert in serum free media and translocated toward 
complete growth media containing 20 ng/µl hepatocyte growth factor (HGF). 
20 hours after additional culture, invading cells were stained by Multiple 
Staining Solution (Polysciences, Inc., Warrington, PA) and counted under the 
microscope. All experiments were performed in triplicate and three different 
fields of each well were counted.  
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Western blotting. Cells were lysed with RIPA buffer (25mM Tris, pH 8.2, 
50mM NaCl,  0.1% SDS, 0.5% Nonidet P-40, 0.5% deoxycholate) containing 
protease inhibitor cocktail (Roche, Indianapolis, IN). Lysates were resolved by 
8% SDS-PAGE, transferred to PVDF membrane, and probed with antibodies 
against MET (clone C-28, Santa Cruz, Santa Cruz, CA), CDK4 (clone C-22, 
Santa Cruz, Santa Cruz, CA) and GAPDH (clone 6C5, Advanced 
Immunochemical, Long Beach, CA). 
 
Statistical analysis. Statistical tests used were two-sided Student’s t 
tests, with Welch’s correction for unequal variance where appropriate, using 
InStat 3.05 and Prism 4.03 software (Graphpad, Inc., La Jolla, CA). 
 
3.5 Results 
 
3.5.1 miR-34 expression is reduced in EOC and is correlated with 
metastatic stage.  
 
To determine miR-34 family expression in EOC, we isolated total RNA from 83 
EOC samples and compared expression levels to that in six wild type OSE 
primary cell samples (Table 3.1). We observed significantly reduced 
expression for all three family members in EOC compared to wild type (Figure 
3.2A), with miR-34a most significantly reduced by 21.2-fold (p< 0.0001), while 
miR-34b* and miR-34c were reduced 2.3-fold (p= 0.0172) and 3.4-fold (p= 
0.0002), respectively. It has been recently reported that Drosha and Dicer  
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Figure 3.2 miR-34 is downregulated in EOC and is associated with metastatic 
clinical stage. A, qRT-PCR analysis reveals significantly reduced miR-34a, 
miR-34b*, and miR-34c expression in a panel of EOC samples (n=83; ○) 
relative to normal OSE samples (n=6; P < 0.0001, P= 0.0172, and P= 0.0022, 
respectively; Δ). B, ovarian cancer stage was determined by surgical 
evaluation during cryoreduction/debulking surgery. miR-34a, miR-34b*, and 
miR-34c expression is shown for stage III (n=46; Δ) and stage IV (n=18; ○) 
tumors. miR-34b* and miR-34c expression is significantly decreased in stage 
IV (distant metastasis) compared with stage III (localized to peritoneum; P= 
0.0171 and 0.0033, respectively). C, adenocarcinomas (serous type, n=26) 
and wild-type OSE samples (n=6) were analyzed for p53 mutational status by 
direct sequencing and correlated with miR-34 expression. Whereas both p53 
wild-type (WT; ○) and p53 mutant (Mut; □) EOC samples show significantly 
reduced miR-34a expression compared with wild-type OSE (N; Δ), EOC 
samples with mutant p53 show most downregulated expression for miR-34a, 
miR-34b*, and miR-34c (P= 0.0012, 0.0285, and 0.0216, respectively). Bars, 
SD. 
 
 
 
 
 
  
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
78 
 
expression is deregulated in EOC (Merritt et al., 2008; Zhang et al., 2008). To 
test whether alteration in miR-34 expression can be explained by 
Drosha/Dicer-mediated global changes in miRNA processing, we determined 
miR-199a* expression, which has been shown to be deregulated in EOC (Iorio 
et al., 2007; Yang et al., 2008). miR-199a* expression appears to be elevated, 
although this is not statistically significant (Figure 3.3). No significant 
differences in expression of miR-34 family members were detected among 
different histological types of EOC, with an exception of reduced miR-34a 
expression in endometrioid compared to serous adenocarcinoma (Figure 3.4). 
Tumor staging is linked to survival, with stage III tumors having tumor cell 
dissemination in the peritoneum, while stage IV tumors have distant 
metastasis, commonly to liver, and is indicative of poor prognosis. We 
compared gene expression in stage III and stage IV tumors, and observed 
significantly reduced miR-34b* and miR-34c expression in stage IV tumors (p= 
0.0171 and p= 0.0033, respectively) (Figure 3.2B), suggesting that miR-34b* 
and miR-34c may be involved in metastatic progression. Interestingly 
however, change in miR-34a expression was not statistically significant (p= 
0.2574). 
 
3.5.2 Decreased miR-34 expression is associated with p53 mutation.  
 
 Mutation of p53 is a common event in many human cancers but is 
particularly common in high-grade serous EOC (Corney et al., 2008). We 
therefore took a subset of our serous EOC samples (n= 26) and sequenced 
p53 exons 4-11, where over 99% of p53 mutations are located (Table 3.3). We 
have found that while miR-34a expression is reduced in both in samples with  
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Figure 3.3 miR-199a* is not significantly altered in EOC. qRT-PCR profiling 
demonstrates no significant alteration in miR-199a* expression between EOC 
samples (n= 50, open circles) and normal OSE (n= 6, open triangles) (p= 
0.1578). Error bars represent standard deviation. 
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Figure 3.4 miR-34 family expression in different EOC subtypes. qRT-PCR 
analysis reveals significantly reduced miR-34a expression in endometrioid 
compared to serous EOC  (p= 0.0144)  (A),  while  no  significant  alteration  in  
miR-34b*  (B) or  miR-34c  (C) expression  is observed. Adeno Ca, 
adenocarcinoma. Error bars represent standard deviation. 
 
 
 
 
 
  
 
 
   Table 3.3 p53 mutation status of human samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case no. 
Mutation 
type exon codon Change Wild-type Mutated 
Wild-type 
AA 
Mutated 
AA 
OvCa 1 Wild-type 
       OvCa 2 Wild-type 
       OvCa 6 Wild-type 
       OvCa 11 Wild-type 
       OvCa 12 Wild-type 
       OvCa 21 Wild-type 
       OvCa 24 Wild-type 
       OvCa 27 Wild-type 
       OvCa 28 Wild-type 
       OvCa 31 Wild-type 
       OvCa 4 Missense 7 237 G>A ATG ATA Met Ile 
OvCa 7 Missense 6/7 220/229 A>G / T>C TAT/TGT TGT/CGT Tyr/Cys Cys/Arg 
OvCa 8 Missense 5 176 G>T TGC TTC Cys Phe 
OvCa 10 Missense 11 375 A>G CAG CGG Gln Arg 
OvCa 14 Missense 7 244 G>A GGC GAC Gly Asp 
OvCa 15 Missense 7 237 G>T ATG ATT Met Ile 
OvCa 17 Missense 8 286 G>A GAA AAA Glu Lys 
OvCa 18 Missense 5 151 C>T CCC TCC Pro Ser 
OvCa 25 Missense 7 248 G>A CGG CAG Arg Glu 
OvCa 30 Missense 11 385 T>C TTC TCC Phe Ser 
OvCa 32 Missense 7 241 C>G TCC TGC Ser Cys 
OvCa 13 Nonsense 5 144 C>T CAG TAG Gln STOP 
OvCa 33 Nonsense 4 107 C>A TAC TAA Tyr STOP 
OvCa 16 Insertion 5 169 + T ATG    
OvCa 22 Insertion 4 99 + C TCC    
OvCa 34 Deletion 7 241 - T TCC    
8
1
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wild type or mutant p53, patients with mutant p53 demonstrate significantly 
lower expression of all miR-34 family members than patients with wild type 
p53 (p= 0.0012, p= 0.0285 and p= 0.0216 for miR-34a, miR-34b* and miR-
34c, respectively) (Figure 3.2C).  
 
3.5.3 Regulation of miR-34 by promoter methylation and copy number 
alterations.  
 
Promoters of both mir-34a and mir-34b*/c are located in CpG islands and 
methylation has been reported to regulate miR-34a expression in several 
cancer cell lines and primary prostate tumors and melanomas, while miR-
34b*/c expression in colorectal cancer is also epigenetically regulated 
(Lodygin et al., 2008; Toyota et al., 2008). Such methylation has not been 
reported in ovarian cancer, so we set out to determine the frequency of such 
methylation by methylation-specific PCR analysis. Methylation at the mir-34a 
and mir-34b*/c loci was observed in 27% (8/30) and 47% (14/30) EOC 
samples, respectively (Figure 3.4A). All samples (8/8) with mir-34a methylation 
demonstrate reduced miR-34a expression, while 57% (8/14) of samples with 
methylation at mir-34b*/c show reduced miR-34b*/c expression. Classification 
of samples based upon p53 mutation status revealed that 21% (3/14) and 
50% (7/14) mutant p53 samples show promoter methylation at mir-34a and 
mir-34b*/c, respectively, while for samples with wild type p53, 38% (5/13) and 
46% (6/13) show methylation, respectively.  
We next raised the question of whether loss of heterozygosity (LOH) or 
copy number alterations could be responsible for reduced miR-34a expression 
and designed custom TaqMan primer and probes to amplify the mir-34a locus  
  
83 
 
 
 
 
 
 
Figure 3.5 mir-34 promoter methylation and copy number variations are 
common in EOC. A and B, representative examples of mir-34a and mir-34b*/c 
promoter methylation determined by methylation-specific PCR with primers 
specific for methylated (m) and unmethylated (u) DNA (A) and copy number 
changes at the mir-34a locus determined by qPCR (B). Bars, SD. Panel A 
kindly provided by Dr. Heiko Hermeking and Markus Vogt. 
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in a qPCR assay. Reduced copy number at the mir-34a locus was observed in 
39% (13/33) of EOC samples (Figure 3.4B), of which 92% (12/13) had 
reduced miR-34a expression. Three of these 12 samples (25%) with reduced 
mir-34a copy number and expression show no p53 mutation or promoter 
methylation. Taken together, reduced miR-34a expression is associated with 
p53 mutation, mir-34a promoter methylation and/or copy number variation in 
82% (27/ 33) of EOC samples. 
 
3.5.4 miR-34 and MET expression in EOC paraffin sections.  
 
To explore miR-34 expression in EOC tissue, we performed miRNA in situ 
hybridization with paraffin-embedded tissue sections of human ovarian cancer. 
In the case of miR-34a probe, we observed positive signal in cytoplasm 
compared to control probe, whereas U6 snRNA was exclusively expressed in 
nucleus as expected (Figure 3.5). We tested a total of 21 cases of serous 
EOC with LNA-miR-34a probe. Consistent with qRT-PCR data, 85.7% (18/21) 
of cases have weak or undetectable miR-34a expression.  
One of the shared targets of miR-34 family is the receptor tyrosine 
kinase MET according to bioinformatic assessment and luciferase assays (He 
et al., 2007; Migliore et al., 2008). Furthermore, the majority of EOC express 
elevated levels of MET (Auersperg et al., 2001). Thus, we decided to compare 
MET and miR-34a expression level in parallel sections of 17 cases using 
semi-quantitative immunohistochemistry analysis. Staining intensity was 
scored from 0 (no staining) to 4 (strong staining). EOC cases expressing 
moderate to strong miR-34a had a relatively weak expression of MET. On the 
contrary, low miR-34a expressing EOC had strong expression of MET (Figure  
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Figure 3.6 miR-34a expression is inversely associated with MET expression in 
EOC. Sections of formalin-fixed, paraffin-embedded human EOC specimens 
were hybridized with DIG-labeled LNA control probe (A), U6 small nuclear 
RNA probe (B), and miR-34a probe (C and E) or immunostained with MET 
antibody (D and F). C and D, EOC with strong miR-34a expression shows 
relatively low level of MET expression. E and F, on the contrary, EOC with 
weak miR-34a expression has strong staining for MET. Insets show high 
magnification of areas indicated with arrows. Similar structures of parallel 
sections (A and B, C and D, and E and F) are indicated with arrowheads. 
Methyl green and hematoxylin were used for counterstaining of in situ 
hybridization and immunostaining, respectively. Scale bar, 100 μm. Kindly 
provided by Chang-il Hwang. 
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3.5). MET and miR-34a staining was found to be inversely correlated (r=-
0.5898, p= 0.0162), confirming that miR-34a might play a role in regulating 
MET expression in EOC.  
 
3.5.5 miR-34 reduces migration, invasion and proliferation in EOC cells.  
 
To determine the role of miR-34 in human ovarian cancer, we transfected 
synthetic miR-34 molecules either separately or in combination into SKOV-3, 
p53 null human ovarian adenocarcinoma cells (Figure 3.6). SKOV-3 cells 
express low endogenous levels of all three miR-34 family members (Corney et 
al., 2007; Zhang et al., 2008) and is therefore well suited to test functions of 
miR-34. We transfected SKOV-3 cells with 15 nM miR-34 individually or 5 nM 
combined and observed reduced amounts of MET protein and mRNA (Figure 
3.6). Even more significant reduction of MET levels was observed after 
transfection with 30 nM of miR-34 (Figure 3.6C).  
The miR-34 family has been shown to reduce cell invasion in gastric 
and hepatocellular carcinoma cells, at least partially through downregulation of 
MET (Li et al., 2009b; Migliore et al., 2008). To examine the role of miR-34 
family in invasion and motility in ovarian cancer, we performed transwell 
motility and Matrigel invasion assays with miR-34 family and/or MET siRNA 
transfected SKOV-3 cells. Notably, while MET knock down was observed after 
MET siRNA treatment, CDK4, which is another target of miR-34 family, was 
not affected by MET siRNA but only after miR-34 family transfection (Figure 
3.6C). As expected, individual miR-34 reconstitution by transfection caused 
significant reduction in motility and invasion in the presence of the MET ligand, 
HGF (Figure 3.7D, E and Figure 3.8). However, when miR-34 and MET siRNA  
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Figure 3.7 miR-34 reconstitution decreases migration, invasion, and 
proliferation in EOC cells. A and B, individual miR-34 family member (15 
nmol/L) or entire miR-34 family (5 nmol/L each) was transfected, and 
statistically significant reduction in mRNA was observed for each treatment 
(miR-34a, P= 0.028; miR-34b*, P= 0.0017; miR-34c, P= 0.0022; entire miR-34 
family, P= 0.0020), although reconstitution of entire miR-34 family does not 
further downregulate MET expression. C, MET siRNA and/or indicated miR-34 
precursor molecule (30 nmol/L) was transfected in SKOV-3 cell line. 
Transfected cell lysates were probed against MET, CDK4, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in Western blot 
analysis. MET siRNA induced strong knockdown of MET protein with no effect 
on CDK4, whereas miR-34 downregulated CDK4 as well as MET. D and E, 
MET siRNA and/or miR-34 transfection induced significant reduction of cell 
migration (MET siRNA, P= 0.0005; miR-34a, P= 0.0003; miR-34c, P= 0.0003; 
MET siRNA and miR-34a, P= 0.0008; MET siRNA and miR-34c, P= 0.0003) 
and invasion (MET siRNA, P= 0.0013; miR-34a, P= 0.0009; miR-34c, P= 
0.0011; MET siRNA and miR-34a, P= 0.0009; MET siRNA and miR-34c, P= 
0.0009). F, quantitative assessment of proliferation by bromodeoxyuridine 
incorporation 48 h after transfection of SKOV-3 cells with either 15 nmol/L 
synthetic miR-34a, miR-34b*, or miR-34c pre-miR individually or 5 nmol/L of 
each pre-miR concurrently (miR-34a, P= 0.0044; miR-34b*, P= 0.0042; miR-
34c, P= 0.0106; miR-34 in combination, P= 0.0021). Bars, SD. Parts A-E 
kindly provided by Chang-il Hwang. 
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Figure 3.8 miR-34 family reduces invasion. Individual miR-34 family member 
(30 nM) or entire miR-34 family (10 nM each) were transfected in SKOV-3 cell 
line. miR-34 family transfection induced significant reduction of invasion (miR-
34a, p<0.0001; miR-34b*, p<0.0001; miR-34c, p<0.0001; all three family 
members, p<0.0001). Error bars represent standard deviation. Kindly provided 
by Chang-il Hwang. 
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were transfected together no further reduction was observed, demonstrating  
that MET downregulation by miR-34 is largely responsible for the reduced 
invasion. 
 Next, we asked whether miR-34 family reconstitution reduces cell 
proliferation, since miR-34 family also can target cell cycle related genes such 
as CDK4 (Figure 3.6C). Transfection of SKOV-3 cells with either 15 nM miR-
34a, miR-34b* or miR-34c reduced proliferation by approximately 30% 
compared to control transfected cells (p= 0.0044, p= 0.0042 and p= 0.0106, 
respectively) (Figure 3.6F). We next treated cells with a combination of 5 nM 
of each miR-34 family member to determine whether additional suppression 
could be achieved due to sequence, and presumably target, differences of 
miR-34 family members. Although the percentage of proliferative cells was 
reduced to 20.7% (p= 0.0021 compared to control), the difference in reduction 
compared to miR-34c transfection individually was not statistically significant 
(p= 0.0876). Additionally, we assessed the amount of apoptosis in miR-34 
transfected cells by determination of cleaved caspase 3 staining (Figure 3.8). 
No significant change in number of apoptotic cells was observed in p53 mutant 
SKOV-3 cells, consistent with miR-34-induced apoptosis being p53-
depenedent (Yamakuchi et al., 2008). 
 
3.6 Discussion 
 
Previously we showed that miR-34b-5p and miR-34c expression is reduced in 
a p53-dependent manner in a mouse model of EOC, while others also 
reported reduced miR-34 expression in a variety of cell lines and mouse 
models (Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et 
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Figure 3.9 Apoptosis is unaffected by miR-34 reconstitution. SKOV-3 cells 
were transfected with either 15 nM miR-34a, miR-34b* or miR-34c Pre-miR 
individually, or 5 nM of  each  concurrently.  Number  of  apoptotic  cells  was  
determined  by  cleaved  caspase  3 immunostaining   48   hours   after   
transfection   and   17   hours   after   treatment   with   5   µM camptothecin  to  
induce  apoptosis.  Compared  to  cells  transfected  with  15  nM  non-
targeting control Pre-miR, no significant alteration in number of cells 
undergoing apoptosis was observed (miR-34a,  p= 0.4066;  miR-34b*,  p= 
0.4513;  miR-34c,  p= 0.1209;  all  three  family  members, p= 0.6554). Error 
bars represent standard deviation. 
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al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 2007) These results led 
us to question the involvement of miR-34 in human EOC and we show here 
that miR-34 family expression is also significantly reduced in human EOC, 
particularly in patients with p53 mutations.  
Recently, the involvement of Drosha and Dicer in EOC has been 
reported, linking reduced expression of these proteins to poor outcome (Merritt 
et al., 2008). Yet while reduced Drosha/Dicer processing might be expected to 
lead to globally decreased miRNA expression, this does not appear to account 
for all miRNA expression defects, given that miR-199a* expression is modestly 
increased (Figure 3.3). Moreover, unlike miR-34a, miR-34b*/c expression is 
not reduced in tumors with wild type p53. This discrepancy between miR-34a 
and miR-34b*/c expression suggests that, in addition to shared p53-
dependent transactivation, control mechanisms unique to miR-34a are altered 
in tumors with wild type p53. Underlining differences between the two mir-34 
loci is our observation that miR-34b*/c, but not miR-34a, is significantly 
associated with stage IV distant metastatic disease (Figure 3.2B). To 
understand the cause of these differences we investigated the role of promoter 
methylation and copy number variations of mir-34. mir-34 promoter 
methylation has been reported in several tumor types (Lodygin et al., 2008; 
Toyota et al., 2008), while megabase pair deletions at chromosome 1p36 
containing the mir-34a locus have been identified in 7 low-grade serous 
carcinomas (Kuo et al., 2009) and in neuroblastoma (Welch et al., 2007). 
Indeed, promoter methylation was observed at mir-34a and mir-34b*/c in 27% 
and 47% of EOC samples, respectively. Furthermore, reduced mir-34a copy 
number was observed in 39% of samples. However, there was no direct 
correlation between methylation or copy number and miR-34 expression 
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levels. There are several possible explanations that may account for these 
data. Firstly, although our p53 sequencing data identified p53 mutations with 
high confidence, mutation in genes that regulate p53 may be involved, such as 
MDM2 which post-translationally silences p53 through ubiquitinylation (Haupt 
et al., 1997; Kubbutat et al., 1997), while p53 may itself be epigenetically 
silenced (Kang et al., 2001). Secondly, many miRNAs, including miR-34a, 
have been shown by Chang et al. to be suppressed by c-Myc (Chang et al., 
2008), an oncogene frequently overexpressed in multiple tumor types, 
including in EOC. Additionally, it is likely that additional transcription factors 
regulate miR-34 expression. Very recently, Christoffersen et al. studied human 
primary hTERT-immortalized TIG3 fibroblasts and observed p53-independent 
transcription of miR-34a (Christoffersen et al., 2010). Oncogene-induced 
senescence (OIS) mediated through B-RAF activation induces miR-34a 
expression in cells treated with a p53 siRNA or a p53 dominant negative 
variant. Through chromatin immunoprecipitation experiments, the authors 
demonstrate that the ETS oncogene family member and transcription factor 
ELK1 binds a conserved region in the mir-34a promoter.  
Clearly, future studies are required to obtain a more complete 
understanding of the regulation of miR-34 expression in both normal 
development and in disease. However, the observation of B-RAF induced 
miR-34a expression through OIS raises an important question regarding the 
etiology of EOC. It has been hypothesized that low-grade and high-grade 
serous tumors have distinct precursor lesions (Corney et al., 2008; Singer et 
al., 2005), with p53 mutations rarely found in low-grade tumors but common in 
high-grade. Interestingly, and further emphasizing the differing molecular 
defects between the two tumor types, activating B-RAF mutations are found 
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exclusively in low-grade serous EOC (Shih Ie and Kurman, 2004; Singer et al., 
2003a). Together, this suggests that activation of miR-34a transcription by B-
RAF/ELK1 and p53 in low-grade serous EOC induces senescence and 
prevents progression to high-grade disease. In contrast, a lack of B-RAF 
mutations combined with frequent p53 mutation in high-grade serous EOC 
would appear to largely eliminate miR-34 expression and subsequently tumor 
suppression capability is lost. Additionally, while p53 mutation has no impact 
on mir-34b*/c methylation, mir-34a methylation is more common in samples 
with wild type p53, consistent with a requirement for diminished p53-miR-34 
activity in order to progress to carcinoma. Together, these observations 
suggest that high-grade tumors arise from a population of cells with mutated 
p53 but wild type B-RAF.  
These data demonstrating correlation of miR-34b*/c expression with 
metastatic disease suggests that these two miRNAs will be useful as a 
prognostic marker. This observation is in a good agreement with recent report 
that low miR-34a levels are correlated with increased probability of relapse in 
non-small cell lung carcinoma (Gallardo et al., 2002) and reinforces the 
importance of decreased miR-34 expression. Future studies based on 
complete follow-up data will determine if miR-34 expression correlates with 
survival of EOC patients. 
The functional studies of miR-34 reconstitution suggest therapeutic 
applications too. miRNAs represent attractive candidates for gene therapy 
approaches for several reasons. Computationally, individual miRNAs have 
been predicted to target tens or hundreds of mRNAs for translational 
repression. Indeed, one miRNA may regulate many targets. For example, in 
the case of miR-223 in neutrophils, hundreds of proteins are directly repressed 
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which has a significant impact on phenotype, despite protein repression being 
relatively modest (Baek et al., 2008; Johnnidis et al., 2008). It is noteworthy 
that microarray experiments performed after miR-34 reconstitution in cancer 
cell lines revealed highly significant alterations that are clustered to important 
biological pathways, for example cell cycle pathway genes (Bommer et al., 
2007; He et al., 2007). These data suggest that reconstituted expression of a 
downregulated miR-34 might reset or otherwise induce normal function of 
these gene networks. 
Due to its large number of transcriptional targets p53 has also been an 
attractive candidate for gene therapy. It was therefore disappointing that p53 
gene therapy in EOC failed in phase II/III clinical trials (Zeimet and Marth, 
2003). Yet while p53 therapy may have failed due to p53 degradation through 
MDM2 and dominant negative tetramer formation, gene therapy with a p53-
independent miR-34 transgene under control of a strong promoter would not 
be expected to face either of these problems. Furthermore, miR-34 may be 
more attractive than p53 due to its small size, making it more amenable to 
packaging in viral and non-viral technologies. No less of importance, a number 
of EOCs do not harbor p53 mutations but express low levels of miR-34 which 
could be corrected. Thus, it would be interesting to study the consequence of 
miR-34 delivery to EOC cells with wild type p53. However, currently 
characterized EOC cell lines carrying wild type p53, such as the serous 
adenocarcinoma cell line A2780 and clear cell carcinoma cell line TOV-21G 
(He et al., 2007; Migliore et al., 2008), demonstrate high levels of expression 
of endogenous miR-34.  
MET is one of few common targets for all three miR-34 family 
members. Taking into account that the majority of EOC express elevated 
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levels of MET (Auersperg et al., 2001) we have tested the role of all miR-34 
family members in repression of MET in EOC cells by using Western blotting, 
invasion and motility assays, finding that all three members inhibit MET. Small-
molecule MET inhibitors are now under clinical trials for several cancers 
(Comoglio et al., 2008), and Sawada et al. showed that MET siRNA could 
reduce adhesion, invasion, metastasis and tumor burden in intraperitoneal 
ovarian cancer xenograft model, but did not affect proliferation (Sawada et al., 
2007). On the contrary, miR-34 therapeutics may have advantages compared 
to siRNA approach, since miR-34 is capable of regulating cell proliferation as 
well as invasion through targeting several target genes in addition to MET, 
such as MYC, E2F3 and others. This is underscored by our experiment 
demonstrating reduced CDK4 protein after miR-34 treatment, but not MET 
siRNA (Figure 3.7C). 
 Taken together, our data demonstrates the frequent reduction of miR-
34 family expression in EOC and its functional properties as an inhibitor of 
proliferation and invasion. This miRNA family is therefore an attractive 
candidate gene for further studies aimed at better understanding of disease 
pathogenesis and development of novel therapeutic approaches. 
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CHAPTER 4 
 
GENERATION OF MIR-34B/C CONDITIONAL KNOCKOUT MICE 
 
4.1 Abstract 
 
It was recently shown that the transcription factor p53 directly transactivates 
the miR-34 family of microRNAs. By down regulating mRNA targets such as 
Cyclin D1, Cdk4/6, Bcl-2, Sirt1 and Met, which are involved in diverse cellular 
processes such as proliferation, apoptosis, senescence and invasion, miR-34 
appear to fulfill at least part of the p53 response. Whether the miR-34 family 
functions as tumor suppressors in a similar manner to p53 has not been 
characterized. However, reduced proliferation and invasion following 
reconstitution of miR-34 expression, and our observations of decreased miR-
34 expression in human epithelial ovarian cancer patients, are consistent with 
such a hypothesis. To address this question, ES cells and mice carrying 
conditional alleles of mir-34b/c were prepared. Expression profiling revealed 
that miR-34 is differentially expressed during ES cell differentiation and that 
miR-34 is most strongly expressed during G0/1 phase of the cell cycle. 
Although no obvious phenotype was observed following mir-34b/c inactivation 
in pluripotent ES cells, mutant embryoid bodies demonstrated a plastic 
adherence defect and dissociated embryoid body cells underwent greater 
population doublings compared to wild type cells. Future studies will take 
advantage of mir-34b/cloxP/loxP mice to study the role of these miRNAs during 
cancer initiation and progression.  
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4.2 Introduction 
 
The miR-34 family of microRNAs (miRNA), comprising miR-34a, miR-34b and 
miR-34c, were shown independently by several groups to be direct targets of 
the transcription factor and tumor suppressor p53 (Bommer et al., 2007; 
Chang et al., 2007; Corney et al., 2007; He et al., 2007; Raver-Shapira et al., 
2007; Tarasov et al., 2007). Studies in cell cultures have revealed that the 
miR-34 family is involved in control of many of the processes that are 
dysregulated in cancer, including apoptosis, proliferation, senescence, motility, 
invasion and adhesion-independent growth in soft agar (Bommer et al., 2007; 
Chang et al., 2007; Christoffersen et al., 2010; Cole et al., 2008; Corney et al., 
2007; Corney et al., 2010; He et al., 2007; Hermeking, 2010; Kumamoto et al., 
2008; Li et al., 2009b; Migliore et al., 2008; Raver-Shapira et al., 2007; Rokhlin 
et al., 2008; Sun et al., 2008; Tarasov et al., 2007; Tazawa et al., 2007; Wei et 
al., 2008; Yamakuchi et al., 2008). Our understanding of the role of miR-34 in 
control of these processes is aided by the research describing validated 
mRNA targets of this miRNA family. Validated targets include Bcl-2, Cyclin D1 
and E2, Cdk4/6, c-Myc, E2f3, Notch1/2 and Met (reviewed by Hermeking, 
2010). Interestingly, the majority of miR-34 anti-invasion and migratory effect 
can be accounted for by downregulation of the Met oncogene (Corney et al., 
2010; Migliore et al., 2008), despite the fact that in addition to the genes listed 
above, hundreds of targets have been predicted computationally to be 
targeted by miR-34 (John et al., 2004). These data suggest that the miR-34 
family act as tumor suppressors and consistent with this hypothesis, miR-34 
expression is reduced in a variety of human cancers via multiple mechanisms. 
Mutation of p53 has strong correlation with reduced miR-34 expression in 
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serous epithelial ovarian cancer (EOC) (Corney et al., 2010) and chronic 
lymphocytic leukemia (CLL) (Mraz et al., 2009; Zenz et al., 2009), while copy 
number variation at the mir-34a genomic locus has been identified in serous 
EOC (Corney et al., 2010; Kuo et al., 2009; Zhang et al., 2008), CLL (Calin et 
al., 2004) and neuroblastoma (Wei et al., 2008; Welch et al., 2007). The three 
members of the miR-34 family are transcribed as two transcripts; mir-34a is 
located on chromosome 1 (mouse chromosome 4) and is transcribed by itself, 
while mir-34b and mir-34c, located 417 bp apart (435 bp in mice) on 
chromosome 11 (mouse chromosome 9), are co-transcribed and processed 
from a single transcript. Both mir-34a and mir-34b/c promoters are enclosed in 
CpG islands that are heavily methylated in various cancers including lung, 
breast, colon, pancreatic and EOC (Corney et al., 2010; Lodygin et al., 2008; 
Toyota et al., 2008). Finally, miRNA biogenesis machinery components 
Drosha and Dicer are frequently dysregulated in cancer, resulting in altered 
miRNA expression (Karube et al., 2005; Merritt et al., 2008; Zhang et al., 
2006), while Dicer inactivation also drives tumorigenesis (Kumar et al., 2007; 
Kumar et al., 2009).  
The miR-34 family is extremely well conserved among metazoans. One 
copy of the miR-34 gene is found in most animals, with up to five copies in 
higher vertebrates (Table 4.1). While miRNA sequence is evolutionarily well 
conserved, expression pattern might not necessarily be the same between 
species. One such example is miR-9 which, despite 100% sequence 
conservation, is differentially expressed in fruit fly, zebrafish, rats and humans 
(Delaloy et al., 2010; Leucht et al., 2008; Li et al., 2006). In Caenorhabditis 
elegans, a mir-34:gfp fusion transgene is expressed in most somatic tissues, 
such as head neurons, intestine and excretory canal, in addition to mature  
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Table 4.1 mir-34 gene copy number in metazoans. 
 
1 copy 2 copies 3 copies 
Anopheles gambiae Branchiostoma floridae Bos taurus 
Apis mellifera Xenopus tropicalis* Canis familiaris 
Ateles geoffroyi  Danio rerio 
Bombyx mori  Gallus gallus 
Caenorhabditis briggsae  Homo sapiens 
Caenorhabditis elegans  Macaca mulatta 
Capitella sp.  Mus musculus 
Ciona intestinalis  Pan troglodytes 
Ciona savignyi  Rattus norvegicus 
Daphnia pulex   
Drosophila sp.   
Equus caballus   
Lagothrix lagotricha   
Lottia gigantea   
Macaca nemestrina   
Monodelphis domestica   
Ornithorhynchus anatinus   
Pan paniscus   
Pongo pygmaeus   
Saguinus labiatus   
Strongylocentrotus purpuratus   
Sus scrofa   
Tribolium castaneum   
* X. tropicalis genome contains two unique mir-34 genes with 5 copies in total 
(1 mir-34a locus and 4 mir-34b loci). Table is current to miRBase release 14.  
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vulva cells (Kato et al., 2009). As determined by in situ hybridization, miR-34 is 
also expressed in neural tissue, such as hindbrain, but not forebrain or 
midbrain, of larval and adult Danio rerio, while miR-34b is expressed in 
habenular nuclei of the thalamus (Kapsimali et al., 2007). Neural miR-34a 
expression is conserved in Gallus gallus embryos, while localization is 
additionally observed in the atria (Darnell et al., 2006). miR-34b and miR-34c 
localization has not been reported in either D. rerio or G. gallus. Localization of 
miR-34a, but not miR-34b or miR-34c, has been observed in neural tissue and 
gastro-intestinal tract of mouse embryos  (Lodygin et al., 2008). In the adult 
mouse, intense miR-34c staining was observed specifically in pachytene 
spermatocytes and round spermatids but not in interstitial tissues (Bouhallier 
et al., 2010). 
 Despite observations which strongly suggest that the miR-34 family 
acts as tumor suppressors, no controlled in vivo studies have been performed 
to directly test this hypothesis. The gold standard to test such a hypothesis is 
to knockout the gene in a model organism, most frequently in the mouse, 
followed by detailed phenotypic characterization focusing on observation of 
tumor incidence. Therefore, we have prepared embryonic stem (ES) cells and 
mice carrying conditional alleles of mir-34a and mir-34b/c gene. 
Characterization of mir-34a conditional mice will be reported elsewhere 
(Chang-Il Hwang and Alexander Nikitin, personal communication). Here, the 
generation of mir-34b/cloxP/loxP mice is described. 
 
4.3 Methods 
 
MicroRNA in situ hybridization. In situ hybridization was performed as 
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previously described (Corney et al., 2010; Nelson et al., 2006). Briefly, 6 µm-
thick paraffin sections of 13.5-day old FVB/N mouse embryos were 
deparaffinized and dehydrated, followed by 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) fixation (Pena et al., 2009). Following pre-hybridization 
blocking, sections were incubated overnight at 55-56°C with digoxigenin-
labeled locked nucleic acid- (LNA) modified miR-34a or miR-34b oligo probe 
(Eqixon, Woburn, MA). After stringency washes, sections were incubated with 
anti-digoxigenin alkaline phosphatase-labeled secondary antibody (Roche, 
Indianapolis, IN) overnight at 4°C followed by development of stain with 
NBT/BCIP (Promega, Fitchburg, WI). Finally, sections were hydrated, cleared 
in xylene, mounted and coverslipped and digital images prepared using 
ScanScope CS slide scanner (Aperio, Vista, CA).  
 
Embryonic stem cell culture. The v6.5 mouse embryonic stem cell line 
(derived from F1 blastocysts from C57BL/6 x 129/sv cross (Eggan et al., 
2001)) was chosen due to the advantages of allowing for targeting with 
isogenic DNA and providing hybrid vigor (Eggan et al., 2001). Cells were 
cultured in undifferentiating conditions on mitotically inactivated feeder cells 
and in the presence of LIF at 37°C in 5% CO2. Briefly, medium used was 
Dulbecco’s Modified Eagle Medium (high glucose) containing 15% heat-
inactivated ES cell qualified fetal bovine serum, 6 mM L-glutamine, 1 mM 
sodium pyruvate, 1x Dulbecco’s non-essential amino acids (all purchased from 
Invitrogen, Carlsbad, CA) plus 10-4 M 2-mercaptoethanol (Sigma, St. Louis, 
MO), and 103 units/ml LIF (Millipore, Billerica, MA). For positive neomycin 
selection, cells were cultured in medium containing 200 µg/ml G418. Mouse 
embryonic fibroblast (MEF) cells were prepared from 13.5-15.5-day old 
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C57Bl/6 embryos carrying neomycin cassette under control of PGK promoter 
(C57BL/6J-Tg(pPGKneobpA)3Ems/J, The Jackson Laboratory, Bar Harbor, 
ME; stock number 002356) and prior to use as feeder cells mitotically 
inactivated by exposure to 10 µg/ml mitomycin C for one hour at 37°C followed 
by three washes with phosphate-buffered saline (PBS). ES cells were routinely 
passaged using 0.25% trypsin/EDTA prior to reaching confluence. Feeder 
cells were separated from ES cells by differential attachment to gelatinized 
plates for one hour at 37°C. 
 
Embryonic stem cell differentiation. Recently thawed undifferentiated 
ES cells were trypsinized, depleted of feeder cells and counted. Embryoid 
bodies were initially formed using the hanging drop method (McKinney-
Freeman and Daley, 2007). Briefly, cells were resuspended at a concentration 
of 1.5x104 cells per ml in ES medium without LIF and, using a multichannel 
pipette, rows of 20 µl drops prepared on the lids of culture dishes. Lids were 
carefully inverted, placed on to culture dish bottoms containing 5 ml PBS and 
incubated undisturbed for two days at 37°C, 5% CO2. Embryoid bodies were 
subsequently transferred to bacterial-grade plastic petri dishes and maintained 
in suspension culture. After four days of suspension culture, medium was 
changed to fresh ES medium without LIF either with or without 1.5 µg/ml 
retinoic acid and cultured for a further four days.  
 
DNA content analysis. One day prior to FACS, cells were passed such 
that they were 50% confluent the following day. Following trypsinization and 
feeder cell depletion, cells were resuspended to a concentration of 2x106 cells 
per ml in pre-warmed ES cell medium, 100 µl 1 mM Hoechst 33342 added to 2 
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ml of cell suspension and incubated at 37°C for 30 minutes followed by 
filtration through a 70 µm nylon mesh. Cells were maintained in Hoeschst 
33342-containing medium on ice until analyzed by FACS Aria machine (BD 
Biosciences, San Jose, CA). Unstained cells were used for setting of gates. 
Following sorting of cells into G0/1, S and G2/M phases, total RNA was 
isolated using mirVana total RNA Isolation Kit (Ambion, Austin, TX) according 
to the manufacturer’s instructions.  
 
Quantitative reverse transcription PCR. qRT-PCR was performed as 
previously described (Corney et al., 2007; Corney et al., 2010) using Rnu6b 
amplification as housekeeping control. 
 
4.4 Results 
 
4.4.1 miR-34a and miR-34b are widely expressed in the mouse embryo 
 
While miR-34a in situ hybridization staining is observed in neural tissue and 
the gastro-intestinal tract of the mouse embryo, poor resolution and clarity did 
not permit a thorough assessment of miR-34a localization at the cellular level 
(Lodygin et al., 2008). Therefore, we performed in situ hybridization 
experiments in the mouse embryo to localize miR-34a and miR-34b/c 
expression to both increase our understanding of miR-34 biology and provide 
a basis for tissue-specific inactivation in later experiments.  
 Thirteen point five day old mouse embryo sections incubated with a 
non-targeting oligo resulted in undetectable staining and the U6 positive 
control was expressed in all cells as expected, while miR-34a staining was 
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also observed, albeit at levels far lower than that observed for U6 (Figure 4.1). 
miR-34a staining was most prominently observed in lung and gastro-intestinal 
epithelium, ventricle and atrium of heart, and cartilage of developing ribcage 
and spine and dorsal root ganglion (DRG) and trigeminal ganglion (Figure 
4.2). While miR-34a was mostly expressed in the epithelial cells of lung and 
intestine, fainter staining was also observed in surrounding stroma (Figure 
4.2A, E). miR-34b had a similar expression pattern, with strong staining in lung 
epithelium, ventricle of heart, cartilage and DRG but additionally staining was 
observed in pancreas and male gonads (Figure 4.3). While miR-34a and miR-
34b expression is observed in DRG of the developing mouse embryo, staining 
in the brain was not observed. Given data from other model organisms 
showing expression in the brain, we hypothesized that in addition to spatial 
restriction, expression is also temporally restricted and we therefore 
determined whether either miRNA is expressed in the adult mouse brain. 
Towards this, sagittal sections of adult mouse brain were hybridized with miR-
34a or miR-34b probes. miR-34a is strongly expressed in layers II and III of 
the cerebral cortex which are mostly stellate, Martinotti and pyramidal cells 
(Figure 4.2 F). Staining is notably absent in the horizontal cell-containing layer 
I of the cortex. Strong staining is also observed in dentate gyrus of 
hippocampus (Figure 4.2 G) and Purkinje cells of cerebellum (Figure 4.2 H). 
Similarly, miR-34b is expressed in Purkinje cells although less pronounced. 
Rather, miR-34b is more widely expressed throughout the molecular layer of 
cerebellum, and the cerebral cortex (Figure 4.3 G, H). Expression of miR-34 in 
embryonic and adult ovary is currently being determined.  
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Figure 4.1 miR-34 in situ hybridization in the mouse embryo. Mouse embryo 
paraffin sections were incubated with miR-34a probe (A), U6 probe as positive 
control (B) or a non-targeting control probe (C). Dark blue/purple, Digoxigenin 
staining; light green, methyl green counterstain. Calibration bar is 500 µm. 
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Figure 4.2 miR-34a expression in mouse embryo and adult brain. miR-34a 
localization was interrogated by in situ hybridization in mouse embryo and 
revealed strong staining in lung epithelium (A; arrow), ventricle (arrow) and 
atrium (arrowhead) of heart (B), trigeminal ganglion (C; arrow), dorsal root 
ganglion (arrow) and cartilage of developing ribcage (arrowheads) (D) and 
intestinal epithelium (E; arrow). In the adult brain, miR-34a is expressed in 
layers II/III of the cortex, but not layer I (F), dentate gyrus of hippocampus (G; 
arrow). Particularly strong staining is observed in Purkinje cells (H; arrow). 
Dark blue/purple, Digoxigenin staining; light green, methyl green counterstain. 
Calibration bar is 50 µm (A, D, E and H), 95 µm (C, F and G) and 165 µm (B). 
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Figure 4.3 miR-34b expression in mouse embryo and adult brain. miR-34b 
localization was interrogated by in situ hybridization in mouse embryo and 
revealed strong staining in lung epithelium (A; arrow), ventricle of heart (B; 
arrow), cartilage (C), cartilage of spine (arrow) and dorsal root ganglion (D; 
arrowhead), testis (E; arrow) and pancreas (F; arrow). In the adult brain, miR-
34b is expressed throughout the cortex but most prominently in the Purkinje 
layer (PL) and molecular layer (ML) of the cerebellum (G, H). Dark blue/purple, 
Digoxigenin staining; pink, nuclear fast red counterstain. GL, granular layer; M, 
medulla. Calibration bar is 50 µm (A, D, E, and F), 55 µm (G), 70 µm (H) and 
95 µm (B). 
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4.4.2 Use of BAC recombineering to prepare mir-34b/cloxP/loxP targeting 
construct 
 
Bacterial artificial chromosome (BAC) recombineering relies on the controlled 
expression of lambda Red proteins resulting in recombination between short 
(approximately 500 bp) regions of homology between donor and recipient 
pieces of DNA in modified Escherichia coli cells (reviewed in Copeland et al., 
2001). Advances in utilizing phage-based recombination systems, however, 
have reduced the length of homologies ten-fold to 40-50 bp (Zhang et al., 
1998). The main significance of this development is the ability to PCR-amplify 
any genetic material to be inserted into a BAC using primers containing the 
required 40-50 bp homologies, which greatly simplifies recombineering 
experiments. The most recent generation of BAC recombineering has utilized 
dual negative and positive selection through the galK gene (Warming et al., 
2005). This modification allows precise control of location of genetic 
modification through PCR-based amplification but with the significant 
advantage of allowing introduction of point mutations and loxP sites and an 
unlimited number of targeting steps, opposed to previous 2-3 steps.  
 To generate a mir-34b/c targeting construct, the galK recombineering 
method was used to flank the mir-34b/c primary transcript with loxP sites and 
insert a FRT-flanked neomycin/kanamycin cassette for prokaryotic and 
eukaryotic selection (Figure 4.4). The bacteriophage P1 protein Cre 
recombinase recognizes the 34 bp loxP sequence and causes deletion or 
inversion of flanked sequence, depending on orientation of the pair of loxP 
sites (reviewed by Nagy, 2000), while FRT sites function in a similar manner 
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Figure 4.4 mir-34b/c targeting strategy. The mir-34b/c allele was conditionally 
targeted by homologous recombination to introduce loxP sites flanking the 
primary transcript. In the first step (A), a neomycin cassette flanked by FRT 
sites (green triangles) and one loxP site (black triangle) was PCR-amplified 
using primers with areas homologous to a region 3’ of the mir-34b/c primary 
transcript (red and blue boxes) and homologously recombined. The neomycin 
cassette was inserted in an opposite orientation to mir-34b/c to allow potential 
generation of hypomorphic allele. The neomycin cassette also contains its own 
em7 promoter for prokaryotic expression of kanamycin. Following a similar 
strategy, a PCR-amplified galK cassette was inserted 5’ of the mir-34b/c 
primary transcript (yellow and green boxes indicate homologous DNA) (B). 
Following this, the galK cassette was substituted for a single loxP site (black 
triangle) flanked by homologous DNA sequences (yellow and green boxes). 
The final targeting construct is shown in (C). FRT- and loxP-mediated 
recombination events are depicted by dotted lines. PCR primer binding sites 
are indicated by arrows, with the following abbreviations: A, mirn34bcA; B, 
mirn34bcB; C, mirn34bcC; D, mirn34bcD; E, mirn34bcE. Expected PCR 
product sizes are given in Table 4.4. 
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after recognition by the Flpe protein. First, BAC RP23-318E9 (C57Bl/6 
genomic DNA; BACPAC Resource Center at Children’s Hospital Oakland 
Research Institute, California) containing the complete mir-34b/c locus was 
electroporated into SW102 E. coli cells (Warming et al., 2005) and BAC 
identity confirmed by PCR and RFLP analysis. Subsequently, a 
neomycin/kanamycin cassette, flanked by two FRT sites and one loxP site, 
was PCR amplified from plasmid pL451 with primers “Neo_F” and “Neo_R” 
(primer sequences are given in Table 4.2), each containing 66-70 bp of 
homology to a region 5’ of mir-34c, using Herculase II Fusion Polymerase 
(Stratagene, La Jolla, CA) with conditions 95°C 2 minutes followed by 10 
cycles of 95°C, 20 seconds; 55°C +1°C per cycle, 20 seconds; 72°C, 1 
minute, followed by 20 additional cycles of 95°C, 20 seconds; 65°C, 20 
seconds; 72°C, 1 minute and a final 3 minute extension at 72°C. Before 
electroporation into SW102 cells, the PCR reaction was digested with DnpI, 
which cleaves its recognition site only when dam-methylated, and PvuI and 
ScaI which cut outside the PCR product, to digest pL451 template present in 
PCR reaction. Subsequently, the digested PCR reaction was run on 1% 
agarose gel and the 1.95 kb product excised under long wave UV radiation 
and purified using Qiaex II Gel Extraction Kit (Qiagen, Valencia, CA). Purified 
neomycin cassette was electroporated in to heat shocked SW102 bacteria 
containing RP23-318E9 BAC and plated out on to 23.5 µg/ml chloramphenicol 
and 25 µg/ml kanamycin LB plates at 32°C as previously described (Warming 
et al., 2005). 36 hours later, 23 colonies from electroporated heat shocked 
SW102 cells were picked for colony-PCR to screen for correct insert of Neo 
cassette. Fifteen of twenty three (65%) picked colonies had a correctly 
inserted neomycin cassette as evidenced by diagnostic 251 bp PCR product 
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Table 4.2 Primers used during generation of mir-34b/c conditional knockout 
mice. 
Primer name Primer sequence (5’ – 3’) 
mirn34bcA ctgcgcttctttcttcgatgtagc 
mirn34bcB tggctttaggatctccatttcagc 
mirn34bcC gactagagcttgcggaacccttc 
mirn34bcD acctggttaagtgggctgagttcc 
mirn34bcE acaacttcttcacggcttccagac 
Neo_F ttaaatggttagttgctatacagacaaaatctccagggaaacgtctcacacatg
attgtgacctggcggccgctctagaactagtgga* 
Neo_R aatatacctggttaagtgggctgagttcccttgccccatggaaaattatgaaaa
catttaacgttcccttccctcgaggtcgacggtatc* 
galK+5’loxP_F gatggatgtaggtctctgcgcttctttcttcgatgtagcagtaactacactgtgaa
gataaacttccctgttgacaattaatcatcggca** 
galK+5’loxP_R aggggcaatgggagggctcctgcagagcctcctgggaaggggccgggga
gatggagagacagattcttgatcagcactgtcctgctcctt** 
BAC1_F gacgatttccggcagtttctacac 
BAC1_R attaagcattctgccgacatggaa 
BAC2_F taatgcagccatctgctcatcatc 
BAC2_R gaccaggagctgcttactgaggac 
BAC3_F cgtctctcatattacacgccatga 
BAC3_R tttccagctgtcgattgagttgtc 
* Underlined sequence is homologous to 3’ of mir-34b/c primary transcript. 
** Underlined sequence is homologous to 5’ of mir-34b/c primary transcript. 
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with primers “mirn34bcB” and “mirn34bcC” in addition to wild type BAC as 
evidenced by 249 bp product from amplification with primers “mirn34bcB” and 
“mirn34bcD” (Table 4.3 and Figure 4.5), suggesting multiple copies of BAC. 
Therefore, BAC DNA was isolated from neomycin-inserted colony number 3 
and re-electroporated into wild type SW102 cells and selection on 23.5 µg/ml 
chloramphenicol and 25 µg/ml kanamycin LB plates. Since electroporation is 
expected to result in uptake of a single BAC molecule by each E. coli cell, this 
re-electroporation step eliminates mosaicism since the unmodified BAC 
provides no kanamycin resistance. Colony-PCR of 10 randomly picked 
colonies demonstrated amplification of neomycin cassette but no amplification 
of wild type BAC. Colony number 6 was used for subsequent manipulations. In 
the targeting second step, a Herculase II Fusion Polymerase PCR-amplified 
galK cassette was amplified from pGalK (Warming et al., 2005) with primers 
“galK+5’loxP_F” and “galK+5’loxP_R” containing 66-70 bp homology to a 
region 5’ of the mir-34b primary transcript, with same conditions as used for 
neomycin amplification. PCR reaction was digested with DnpI, ScaI and PvuII 
and then run on a 1% agarose gel followed by purification with Qiaex II Gel 
Extraction Kit. GalK PCR product was electroporated into SW102 colony 6 and 
grown on M63 minimal plates supplemented with 0.2% galactose, 0.1 mg/ml 
L-leucine, 40 ng/ml d-biotin, 23.5 µg/ml chloramphenicol and 25 µg/ml 
kanamycin at 32°C for 3 days as previously described (Warming et al., 2005). 
BAC DNA was isolated from colonies appearing after 3 days growth on 
minimal plates and electroporated into wild type SW102 cells to eliminate any 
contaminating galK- BAC molecules in SW102 cells. Culture on MacConkey 
agar plates confirmed insertion of the galK cassette. In the final step, the galK 
cassette was replaced with a single loxP site. Two complementary 134 bp 
  
124 
 
 
 
 
 
Table 4.3 Expected PCR genotyping product sizes. PCR product sizes for 
genotyping of knockout targeting construct, ES cells and of animals prior to 
Flpe-mediated neomycin excision are shown. Primer sequences are given in 
Table 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 mirn34bcC mirn34bcD mirn34bcE 
mirn34bcA 
Wild type: N/A 
N/A 
Wild type: 
289 bp 
loxP 
recombined 
(null allele): 
160 bp 
Floxed:  
323 bp 
mirn34bcB Floxed: 251 bp 
Wild type: 
177 bp 
N/A FRT 
recombined: 
335 bp 
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Figure 4.5 Identification of correctly inserted neomycin cassette in mir-34b/c 
locus. Colony PCR was performed on SW102 E. coli electroporated with 
neomycin cassette using primers mirn34bcB and mirn34bcC to amplify 
correctly inserted neomycin cassette and primers mirn34bcB and mirn34bcD 
to amplify the wild type locus. 
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Table 4.4 Ultramer oligos used during generation of mir-34b/c conditional 
knockout mice. 
Ultramer name Ultramer sequence (5’ – 3’) 
loxP_ultramer_F tgcgcttctttcttcgatgtagcagtaactacactgtgaagataaacttcataactt
cgtatagcatacattatacgaagttattcaagaatctgtctctccatctccccggc
cccttcccaggaggctctgca* 
loxP_ultramer_R tgcagagcctcctgggaaggggccggggagatggagagacagattcttgaa
taacttcgtataatgtatgctatacgaagttatgaagtttatcttcacagtgtagtta
ctgctacatcgaagaaagaagcgca* 
* Underlined sequence is homologous to 5’ of mir-34b/c primary transcript. 
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Ultramer Oligos (Integrated DNA Technologies, Inc., Coralville, IA) containing 
loxP site flanked by 50 bp regions of homology were synthesized (Table 4.4) 
and annealed by heating to 95°C in heating block for 4 minutes followed by 
turning off heating block and letting cool to room temperature over 
approximately 3 hours. Annealed loxP Ultramer duplex was electroporated into 
galK+ SW102 cells and cultured for 3 days at 32°C on M63 plates 
supplemented with 0.2% 2-deoxy-galactose (DOG), 0.1 mg/ml L-leucine, 0.2% 
glycerol, 40 ng/ml d-biotin, 23.5 µg/ml chloramphenicol and 25 µg/ml 
kanamycin. Finally, colonies were picked and screened by colony-PCR for 
correct insertion of the 5’ loxP site followed by direct sequencing of the regions 
of BAC that were modified.  
 
4.4.3 A novel quantitative PCR assay to identify targeted ES cells 
 
Towards generation of mir-34b/c conditional mice, v6.5 ES cells were targeted 
with the mir-34b/c targeting BAC. Our initial targeting experiments with an 11.2 
kb fragment of BAC (with 5 kb and 3 kb arms of homology at 5’ and 3’, 
respectively) were unsuccessful with no homologous recombination events 
identified (data not shown). We therefore sought an alternative approach and 
utilized the full-length BAC construct to considerably increase the arms of 
homology to 114 kb and 83 kb at 5’ and 3’, respectively. 1x107 v6.5 cells were 
electroporated with 25 µg PI-SceI-linearized modified BAC using Gene Pulser 
II (Bio-Rad, Hercules, CA) at settings of 320 V and 250 µF and, after a 20 
minute incubation on ice, divided equally between 8-10 10 cm dishes 
containing mitotically inactivated G418-resistant MEF feeder cells. 24 hours 
later, 200 µg/ml G418 was added to ES culture medium and thereafter 
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medium changed daily. 10 days post electroporation, 333 distinct ES cell 
colonies were manually picked and transferred to individual wells of 96-well 
plates with mitotically inactive MEF feeder cells and expanded in triplicate with 
two plates for storage at -80°C and one plate without feeder cells for DNA 
isolation. 
DNA was isolated in 96-well plate format as described (Ramirez-Solis 
et al., 1992). Briefly, 50 µl lysis buffer (10 mM Tris (pH7.5), 10 mM EDTA (pH 
8), 10 mM NaCl, 0.5% (w/v) sarcosyl and 1 mg/ml Proteinase K) was added to 
each well, incubated at 60°C overnight followed by adding 100 µl of ice cold 
slurry of 75 mM NaCl in 100% ethanol to precipitate DNA. Plates were 
carefully inverted to discard NaCl/ethanol and washed twice with 70% ethanol, 
air dried and resuspended in 50 µl 10 mM Tris (pH 8.5).  
Use of extremely long arms of homology necessitated a screening 
approach other than Southern blotting or long-range PCR. Therefore, to 
distinguish between homologous and non-homologous recombination events, 
two screening steps were performed. In the first step, endpoint PCR was used 
to amplify the BAC backbone with three primer sets BAC1 (product size 288 
bp), BAC2 (product size 207 bp) and BAC3 (product size 286 bp) (Table 4.2 
and Figure 4.6). PCR conditions were 95°C for 2 minutes followed by 30 
cycles of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 minute 
followed by a final 72°C extension for 3 minutes on the final cycle. Forty-six 
percent (107/230) of colonies had no evidence of any BAC backbone 
amplification and were screened in a second step; colonies with amplification 
were discarded. To identify homologous recombination during generation of 
conventional knockout ES cells, Valenzuela et al. described a loss of native 
allele assay, wherein a neomycin reporter replaces one allele of an 
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Figure 4.6 First round of screening for homologous recombination in ES cells. 
A, Schematic of conventional endpoint PCR amplification for BAC backbone 
DNA (black rectangle) with primer sets BAC1, BAC2 and BAC3. B, 
Representative screening results for 11 ES cell colonies amplified with BAC2 
primers with diagnostic 207 bp PCR product. Colonies in lanes 1, 3, 5, 9 and 
11 were discarded due to BAC2 amplification, while negative lanes were 
subsequently screened for BAC1 and BAC3 amplification. Schematic is not to 
scale. 
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endogenous gene (Valenzuela et al., 2003). In our conditional knockout 
approach, however, no endogenous material is lost. Therefore, an assay, 
termed here a “loss of homozygosity assay”, was designed so that carefully 
designed custom TaqMan probes amplify the endogenous region precisely 
where the FRT-flanked neomycin cassette is inserted: PCR amplification at 
“Targ” region of wild type DNA will give an expected product size of 73 bp, 
while the locus with the neomycin insert will not be amplified due to the 2 kb 
product size (Figure 4.7). Clones having undergone homologous 
recombination (and are consequently heterozygous at the mir-34b/c locus) 
have 50% reduction in “Targ” copy number at this locus relative to both β actin 
control on chromosome 5 and “Norm” located at an unmodified region of the 
BAC. In contrast, clones having undergone non-homologous recombination 
have increased “Norm” copy number and wild type “Targ” copy number. Rare 
cases of both homologous and non-homologous recombination occurring in 
the same cell can be identified by 50% reduction in “Targ” copy number 
concomitant with increased “Norm” copy number. In total, 5 clones with 
homologous recombination were identified (5/230 (2.2%) of all picked clones 
analyzed; 5/68 (7.4%) of analyzed BAC backbone-negative clones) and 
expanded from frozen 96-well plates. Two clones, 9F6 and 9G5, were chosen 
for further expansion, karyotyping and mycoplasma testing, the results of 
which showed normal euploid karyotype and no mycoplasma contamination. 
Based upon colony morphology, clone 9F6 was chosen for microinjection into 
C57BL/6 blastocysts which were subsequently transferred to pseudopregnant 
females. Seven high ES cell-derived (80-100%) chimeras were identified 
based upon agouti coat color and, at sexual maturity, were mated with 
Rosa26-Flpe transgenic mice (Farley et al., 2000), resulting in simultaneous 
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Figure 4.7 Loss of homozygosity assay identifies homologous recombination. 
A, Schematic outlining mir-34b/c locus and location of TaqMan qPCR primers 
(arrows) and probes (green lines). Amplification at three unique loci allows one 
to distinguish between wild type, homologous and non-homologous 
recombination. First, β actin copy number should be constant across all 
samples, while “Norm” and “Targ” loci are contained on both wild type 
genomic DNA and modified BAC DNA. Importantly, while “Norm” amplification 
occurs efficiently in both wild type and BAC-derived DNA, “Targ” amplification 
can only occur in wild type DNA due to insertion of a neomycin cassette at the 
“Targ” locus in BAC DNA. As shown in B, wild type colonies have equivalent 
copy number at all three loci, while colonies that have undergone homozygous 
recombination have equal β actin and “Norm” but reduced “Targ” copy 
number. Increased “Norm” copy number is diagnostic of a non-homologous 
recombination event, which might occur with or without concomitant 
homologous recombination event. C, Compared to wild type parental v6.5 
genomic DNA (WT), the majority of colonies demonstrated evidence of a 
single non-homologous recombination (e.g. 23A7), while rare colonies had 
undergone multiple non-homologous recombination events (e.g. 24A5). A total 
of 5 colonies that had undergone homologous recombination were identified 
(arrows) which was validated by replicating qPCR with a new preparation of 
genomic DNA (D). 
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germline transmission and FRT-mediated deletion of neomycin cassette. 
 
4.4.4 Inactivation of mir-34b/c in cell culture 
 
To assess the role of miR-34b/c in ES cells and their differentiated progeny, 
conventional null ES cells were prepared. Firstly, cells homozygous for the 
conditional, floxed, allele were prepared by culturing cells in high 
concentrations of G418 as previously described (Mortensen et al., 1992). After 
10 days culture in ES cell medium containing 4.38-5.25 µg/ml G418, individual 
colonies were picked and expanded in 96-well plates of mitotically inactivated 
feeder cells. Genomic DNA was isolated as described earlier and PCR 
genotyping performed. Two of eighty one (2.5%) colonies had become 
homozygous for the conditional allele (Figure 4.8 A). Importantly, homozygous 
floxed/null ES cells demonstrate no wild type locus by PCR amplification, 
confirming generation of true homologous recombinants and not a transgenic 
insert. One of these colonies, 9F6C1, was expanded and 4.5x106 cells 
electroporated with 40 µg circular pPGK-Cre-bpA plasmid (kindly provided by 
Dr. Klaus Rajewsky; Addgene plasmid 11543). Electroporated cells were 
grown on mitotically inactivated feeder cells for 48 hours, after which time cells 
were trypsinized and re-plated at low density prior to picking of individual 
colonies. The re-plating step allows Cre expression and avoids mixed colonies 
should Cre/loxP-mediated recombination occur after the cell divides. Thirty 
three percent (32/96) of picked ES cell colonies had undergone Cre/loxP-
mediated recombination as demonstrated by PCR (Figure 4.8 B).  
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Figure 4.8 Cre/loxP-mediated mir-34b/c inactivation in homozygous ES cells. 
A, 9F6 mir-34b/cloxP/+ ES cells were cultured in high concentrations of G418 
and rare instances of gene conversion to homozygosity was identified. PCR 
genotyping with PCR primers mirn34bcA and mirn34bcE was performed with 
289 bp diagnostic for wild type allele and 323 bp diagnostic for floxed allele. 
Lane 5, homozygous colony 9F6C1; lane 4, no template control. B, 9F6C1 
mir34bcloxP/loxP ES cells were electroporated with pPGK-Cre-bpA plasmid as 
described in the text. Recombination between loxP sites was identified by 
PCR with primers mirn34bcA, mirn34bcC and mirn34bcE, with 323 bp 
amplicon diagnostic of floxed allele and 160 bp diagnostic of mir-34b/c null 
allele. 100% recombination was observed in approximately 30% of colonies 
(e.g. lanes 2, 4 and 12), while less efficient recombination was not as frequent 
(e.g. lanes 9 and 11). Lane 16, no template control. 
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No obvious changes in morphology or growth characteristics were 
observed in mir-34b/c-null ES cells in undifferentiated growth conditions, 
although whether proliferation defects are present in long-term culture is 
currently being determined by cell doubling time and BrdU incorporation. 
However, during the generation of embryoid bodies, overt changes in 
adhesion characteristics were observed. When embryoid bodies were 
transferred from hanging drops to suspension culture on bacterial-grade 
plastic petri dishes almost all mir-34b/cloxP/+ 9F6 embryoid bodies attached to 
the plate and flattened out, while few mir-34b/c-/- embryoid bodies attached 
and instead remained in suspension (Figure 4.9). These observations, 
together with reduced soft agar colony formation in neoplastic OSE cells after 
miR-34b/c reconstitution (Corney et al., 2007), indicate a role for miR-34b/c in 
cell adhesion and/or epithelial-to-mesenchymal transition (EMT). When 
embryoid bodies are dissociated and single cells cultured in adherent culture 
conditions, mir-34b/c-/- cells have significantly increased population doubling 
(Figure 4.9) and are consistent with decreased proliferation following miR-34 
reconstitution.  
 
4.4.5 miR-34 expression in ES cells 
 
Cell proliferation and differentiation are tightly controlled processes. p53 has 
well-known roles in controlling proliferation, in part through transactivation of 
its targets p21 and mir-34 family. Interestingly, p53 has also been implicated in 
control of cell differentiation through repression of Nanog, which results in loss 
of pluripotency in mouse ES cells (Lin et al., 2005). Consistent with this, 
multiple groups recently demonstrated an important role for p53 in induced  
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Figure 4.9 mir-34b/c inactivation in embryoid bodies results in plastic 
adherence defect and increased population doubling. A, mir-34b/c-/- embryoid 
bodies have plastic adherence defect Following formation in hanging drop 
culture, embryoid bodies were transferred to suspension culture on bacterial-
grade plastic petri dishes. While 73.67% mir-34b/c heterozygous floxed 
embryoid bodies attached, the majority of mir-34b/c-null embryoid bodies 
derived from two independent null colonies remained in suspension and 
unattached to the plastic (p= 0.0276 and 0.0339, for mir-34b/c-null colonies 
9F6C1D6 and 9F6C1-G8. B, mir-34b/c-null dissociated embryoid body-derived 
differentiated ES cells show continued and increased population doubling 
compared to mir-34b/cloxP/- cells. Error bars represent standard deviation. 
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pluripotent stem (iPS) cell reprogramming to an ES cell-like state (Hong et al., 
2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 
2009), although this may be a function of p53 role in proliferation rather than  
differentiation (Hanna et al., 2009). We performed miR-34 expression analysis 
in wild type ES cells undergoing controlled differentiation in embryoid bodies 
(Figure 4.10). Compared to pluripotent ES cells, miR-34b and miR-34c 
expression is significantly reduced (p < 0.05) at every stage of embryoid body 
formation. The picture for miR-34a expression, however, is less clear. An initial 
reduction in miR-34a expression is observed in 2-day old embryoid bodies (p= 
0.0162) but is followed by an increase in expression in older embryoid bodies 
to levels not significantly different to that in ES cells. One explanation for this 
observation is that mir-34a and mir-34b/c loci are differentially regulated at the 
transcriptional level during the differentiation process, for example to 
suppress, but not eliminate, miR-34-mediated inhibition of proliferation. 
Consistent with this, multiple members of the Notch signaling pathway, such 
as receptors Notch 1 and Notch 2 and their ligands Delta-like 1 and Jagged 1, 
are validated miR-34 targets (Bommer et al., 2007; Ji et al., 2009; Lewis et al., 
2003; Pang et al., 2010). In addition to a role in proliferation, Notch signaling 
plays a role in differentiation and cell fate decisions. While its function may be 
cell-type dependent, tight control over Notch signaling is important in 
mammary gland stem cells and keratinocytes for controlled differentiation 
(Bouras et al., 2008; Rangarajan et al., 2001).   
Reconstitution or overexpression of miR-34 has been shown to result in 
cell cycle arrest at G1 phase (He et al., 2007; Ji et al., 2009; Lodygin et al., 
2008; Tarasov et al., 2007). Interestingly, ES cells have considerably different 
cell cycle structure compared to differentiated cells with a short G1 phase;  
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Figure 4.10 The miR-34 family is differentially expressed during ES cell 
differentiation. ES cells were induced to undergo differentiation in embryoid 
bodies (A): 2-day old EB (inset A); 6-day old EB (inset B); 10-day old EB 
incubated with retinoic acid (inset C) or without retinoic acid (inset D); 
myocardiocytes (arrow) observed spontaneously beating 5 days after 
enzymatic digestion of 10-day EBs and plating onto gelatinized cell culture 
dishes (inset E); F, Neuronal cells (arrow) observed 5 days after enzymatic 
digestion of 10-day EBs (inset F). Bar= 112.5 µm (A, B), 500 µm (C, D) and 
100 µm (E, F). B, Total RNA isolated from EBs at various stages of 
differentiation was used in qRT-PCR reactions for miR-34a (red), miR-34b 
(blue) and miR-34c (green). Error bars represent standard error of the mean. 
*, p< 0.05. 
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cells spend most of their time in S phase (Stead et al., 2002; reviewed in 
White and Dalton, 2005). This has been shown to be due to a lack of 
Cdk4/Cdk6-cyclin D1 activity at G1 phase and precocious cell cycle- 
independent Cdk2 and cyclin A/E activity (Savatier et al., 1996; Stead et al., 
2002). In light of the fact that miR-34 targets Cdk4/Cdk6 and cyclin D1 
(Bommer et al., 2007; Corney et al., 2010; Fujita et al., 2008; He et al., 2007; 
Lodygin et al., 2008; Sun et al., 2008) and that miR-34 is differentially 
expressed during HeLa cell cycle (Zhou et al., 2009), we investigated the 
expression of miR-34 in each phase of the cell cycle of wild type ES cells. ES 
cells were incubated with the cell membrane-permeable fluorophore Hoechst 
33342, fluorescence-activated cell sorted (FACS) based upon DNA content 
using FACS Aria (BD Biosciences, San Jose, CA) and total RNA isolated was 
used in qRT-PCR reactions. While only 8% of cells were in G0/1 phase, miR-
34 expression was highest in this population and expression during S and 
G2/M phase was 38-fold to 167-fold lower than during G0/1 (Figure 4.11). We 
next sorted primary cultured wild type MEF cells and a similar trend was 
observed, albeit with overall 4- to 8-fold reduced expression, consistent with 
data presented in Figure 4.10. These data support the hypothesis that miR-34 
has a function in controlling Cdk4/Cdk6-cyclin D1 activity and proliferation in 
ES cells. 
 
4.5 Discussion 
 
As shown in Table 4.1, one copy of the mir-34 gene is found in most animals, 
with more copies in higher vertebrates. Branchiostoma floridae, the Florida 
lancet, has two identified copies of mir-34 in its genome and sits between the  
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Figure 4.11 miR-34 is preferentially expressed during G0/1 phase of the cell 
cycle. ES cells (ESC) or MEF cells were sorted based upon DNA content and 
total RNA isolated. qRT-PCR expression analysis reveals 38-fold, 48-fold and 
53-fold reduced expression in S phase compared to G0/1 phase for miR-34a, 
miR-34b and miR-34c, respectively. During G2/M phase, expression is 
reduced 38-fold and 167-fold for miR-34a and miR-34b/c, respectively. A 
similar relationship, although less pronounced, is observed for MEF cells.   
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invertebrates, with one copy, and most vertebrates that have three. 
Interestingly, B. floridae might be considered a proto-vertebrate and is widely 
regarded to be a close relative to the chordate ancestor that eventually gave 
rise to higher vertebrates 500 million years ago (Putnam et al., 2008). It 
therefore appears that the progression from one to three mir-34 copies has 
been selected during evolution.  
Mechanisms of tumor suppression have become more complex 
simultaneously with the increasing complexity of multicellular organisms. For 
example, the ancestral p53 gene, nvp-63, found in the sea anemone 
Nematostella vectensis functions in protecting the germline, but not somatic 
cells, from UV irradiation-induced DNA damage (Pankow and Bamberger, 
2007). Over hundreds of millions of years, nvp-63 has evolved into a three-
member family, comprising p53, p63 and p73, which protect both germ and 
somatic cell lineages from a diverse range of oncogenic stimuli (Belyi and 
Levine, 2009). Given our current understanding of the role of miR-34 in tumor 
suppression, an increase in number of mir-34 genes is consistent with an 
important role in evolutionary fitness. 
 Our in situ hybridization experiments reveal that miR-34a is expressed 
in the adult, but not embryonic, mouse brain consistent with expression in C. 
elegans, D. rerio and G. gallus (Darnell et al., 2006; Kapsimali et al., 2007; 
Kato et al., 2009). Additionally, however, expression is observed in cardiac 
muscle, epithelial tissues of lung and intestine and cartilage and peripheral 
nervous tissue. miR-34b, and by extension miR-34c due to sharing of 
promoter, is expressed in the same tissues as miR-34a with the exception of 
loss of staining in intestine and gain in pancreas and testis. The strong miR-
34b expression and overlap in expression with miR-34a is surprising given 
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qRT-PCR data suggesting little co-expression (Bommer et al., 2007). 
However, there is an important caveat that might explain these differences. 
Bommer et al. determined miR-34 expression in the adult mouse and, as 
observed in brain, miR-34a and miR-34b expression appears to be 
developmentally regulated in this tissue. Evaluation of miR-34a and miR-34b 
expression by in situ hybridization at later stages of embryonic development 
will be required to fully understand expression pattern. However, the possibility 
remains that, due to high sequence similarity, miR-34a and miR-34b probes 
are not completely specific. This can be best addressed by in situ hybridization 
experiments using miR-34a and miR-34b probes in mir-34b/c-null embryos.  
To study the role of miR-34b/c in the mouse, conditional knockout mice 
were prepared. To facilitate this, a recombineering approach was used, which 
takes advantage of the high efficiency of homologous recombination between 
short regions of homology in an E. coli system. The targeting construct, with a 
total of 8 kb arms of homology, was electroporated into E14.1 ES cells, but no 
homologous recombination events were identified after screening over 300 
colonies. We therefore used BAC targeting in ES cells, taking advantage of 
the large arms of homology that this approach affords. Using a novel qPCR 
screening approach, 2.2% (5/230) clones were identified as having undergone 
homologous recombination. Valenzuela et al. prepared 200 conventional 
knockout ES cells using BAC electroporation and calculated an average 
targeting frequency of 3.8% using a related qPCR assay (Valenzuela et al., 
2003). Since cells are grown and screened in 96-well plates, rather than 24-
well plates used for traditional Southern blotting approaches, BAC 
recombineering combined with a BAC qPCR assay results in a relatively high 
throughput method well suited to rapid creation of conditional knockout ES 
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cells ready for blastocyst injections.  
 mir-34b/c-/- embryoid bodies appear to have reduced propensity to 
attach to bacterial plastic compared to wild type embryoid bodies. This 
observation suggests that miR-34b/c functions in cell adhesion. EMT is a 
process whereby epithelial cells lose their characteristic apical-basal polarity, 
reorganize their cytoskeleton and acquire migratory and invasiveness 
properties typical of mesenchymal cells (Acloque et al., 2009). This process is 
critical for normal development, for example neuroepithelial cells of the neural 
tube undergo EMT resulting in migratory neural crest cells that navigate away 
from the neural tube to generate peripheral ganglia (Acloque et al., 2009). Yet 
it is becoming increasingly accepted that an EMT-like process may play a role 
in carcinogenesis, since metastatic cells share similar traits to normal cells that 
have undergone EMT, such as the ability to migrate and invade (Gregory et 
al., 2008; Mani et al., 2008; Morel et al., 2008; Polyak and Weinberg, 2009; 
Thiery, 2002). Given these observations, it is noteworthy that multiple 
members of the Notch pathway are predicted or validated targets of miR-34, 
including receptors Notch 1, Notch 2, Notch 3, and their ligands  Delta-like 1, 
Jagged 1 (Hermeking, 2010; Ji et al., 2008; Li et al., 2009c; Pang et al., 2010; 
Tsang et al., 2010). Notch is critical for EMT to proceed correctly in the 
developing zebrafish, in part through activation of Snail signaling (Timmerman 
et al., 2004). In addition to regulating EMT, differentiation and cell fate 
decisions (reviewed by Bolos et al., 2007), Notch signaling is frequently 
altered in cancer and is most well understood to be oncogenic, although 
depending on cell type and mutation type can be tumor suppressive (reviewed 
by Radtke and Raj, 2003). Notch has also been shown to play a potential role 
in EMT during carcinogenesis and its overexpression is correlated with EMT-
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like characteristics in cells grown in culture, such as increased E-cadherin 
expression (Sahlgren et al., 2008; Timmerman et al., 2004), while inhibition of 
Notch signaling increases E-cadherin expression in vivo (Leong et al., 2007). 
Additionally, the hepatocyte growth factor receptor, c-Met, has pro-migratory 
and EMT function and is a critical target in miR-34-dependent inhibition of 
invasion and motility (Corney et al., 2010; He et al., 2007; Migliore et al., 
2008). Together, these observations suggest that miR-34b/c may control EMT 
processes during embryonic development and cancer progression. Clearly it 
should be stressed, however, that given the preliminary nature of these results 
detailed follow up and experimental interrogation is required. 
 In addition to targeting of numerous members of the Notch signaling 
pathway, miR-34 family has been shown to regulate expression of multiple 
proteins involved in cell cycle progression such as Cdk4, Cdk6 and Cyclin D1 
(Bommer et al., 2007; Corney et al., 2010; Fujita et al., 2008; He et al., 2007; 
Lodygin et al., 2008; Sun et al., 2008). The Cdk4/Cdk6/Cyclin D complexes 
are important for progression through the G1/S phase transition and their 
inactivation results in reduced proliferation, although only of certain cell 
lineages (Malumbres and Barbacid, 2005). While these proteins are active at 
G1/S transition, ES cells have a short G1 phase due to low Cdk4/Cdk6-Cyclin 
D1 activity. We therefore hypothesized that miR-34 expression would be 
highest at G0/1 in ES cells and our observations support this (Figure 4.10). On 
the other hand, Cdk4/Cdk6-Cyclin D1 is active in differentiated cells and 
consistent with this miR-34 levels are reduced 4- to 8-fold during G0/1 phase 
compared to ES cells.  
In conclusion, there is evidence to support a role for miR-34 family in 
both normal development and in carcinogenesis, potentially though control of 
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Notch signaling and cell cycle progression. The mir-34b/cloxP/loxP conditional 
knockout ES cells, and mice, that have been generated will allow for a more 
complete understanding of miR-34b/c function in normal development and 
disease. 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary 
 
Given that mutation of the transcription factor p53 is one of the most common 
genetic alterations observed in EOC, particularly in high-grade serous tumors 
(Chapter 1 and reviewed in Corney et al., 2008), a study was initiated to 
determine whether inactivation of p53 would result in miRNAome alterations 
(Chapter 2 and Corney et al., 2007). Towards this aim we took advantage of 
mice carrying conditional alleles of p53, such that p53 is inactivated by 
Cre/loxP-mediated recombination. Previously, we demonstrated that 
adenovirus mediated delivery of Cre (AdCre) to the OSE of mice carrying 
conditional alleles of both p53 and Rb results in frequent serous 
adenocarcinomas (Flesken-Nikitin et al., 2003). However, to identify 
alterations in miRNA expression immediately after acute p53 inactivation, we 
decided to use a cell culture approach, whereby the ovary from p53loxP/loxP 
mice is enzymatically digested to release the OSE which is briefly cultured 
prior to AdCre treatment. Compared to non-floxed wild type OSE, 84 miRNAs 
were significantly up/downregulated after p53 inactivation, demonstrating that 
p53 does indeed control miRNA expression, at least indirectly. We observed 
that miR-34b and miR-34c, which are encoded by genes located 417 bp apart 
on human chromosome 11q23 and together form the miR-34b/c cluster, were 
two of the most down regulated miRNAs, with a 12-fold reduction in their 
expression as determined by qRT-PCR. Through a bioinformatics approach, a 
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conserved p53 responsive element (p53RE) was identified 2.4 kb upstream of 
mouse mir-34b/c and 3.8 kb upstream of human mir-34b/c. We observed that 
expression of both miRNAs after treatment with the DNA damaging agent 
doxorubicin was p53-dependent and, taken together with ChIP-PET data (Wei 
et al., 2006) and ChIP-PCR performed by other research groups (Bommer et 
al., 2007; He et al., 2007), demonstrates that p53 directly transactivates miR-
34b and miR-34c. In addition, several other groups concomitantly identified 
another miR-34 family member, miR-34a, as being directly regulated by p53 
through the presence of a p53RE 30 kb upstream of the miRNA mature 
sequence (Bommer et al., 2007; Chang et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007). 
 The data shown here, as well as those of others, demonstrates that 
members of the miR-34 family control important processes that are altered in 
cancer, including proliferation, apoptosis and senescence in various cell types 
(Chang et al., 2007; Corney et al., 2007; He et al., 2007; Raver-Shapira et al., 
2007; Tarasov et al., 2007). Importantly, however, we have demonstrated that 
miR-34b and miR-34c cooperate in the suppression of proliferation and 
adhesion-independent growth in soft agar, and that maximal suppression is 
achieved when both miRNAs are expressed (Chapter 2 and Corney et al., 
2007). This observation may be due to the fact that each miRNA is predicted 
to target a separate pool of mRNAs in addition to a conserved pool. Predicted 
targets include Cdk4, Met, Ezh2, Cyclin D1, Myc and Bcl-2, Notch 2, Jagged 1 
and Sirt1 and a number of these have been validated as genuine targets 
(Hermeking, 2010; Tsang et al., 2010).  
 Given the strong evidence that members of the miR-34 family are 
directly transactivated by p53 and function in several pathways controlled by 
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p53 (i.e. proliferation, apoptosis and senescence), we decided to initiate a 
follow-on study to elucidate the role of miR-34 in human EOC (Chapter 3 and 
Corney et al., 2010). First, expression profiling of a panel of human EOC 
specimens revealed that expression of all three miR-34 family members are 
frequently reduced compared to wild type OSE cells. Reduced miR-34a and 
miR-34b/c expression was strongly correlated with presence of mutant p53, 
yet interestingly, miR-34a was reduced in patients with wild type p53 too. We 
interrogated two potential p53-independent mechanisms of miR-34a 
regulation: promoter methylation and gene copy number variation. 
Methylation-specific PCR analysis shows that promoter region of mir-34a, as 
well as mir-34b/c, are methylated in 27% (8/30) and 47% (14/30) of EOC, in 
agreement with methylation observed in other neoplastic tissues (Lodygin et 
al., 2008; Lujambio et al., 2008; Toyota et al., 2008). Additionally, reduced mir-
34a gene copy number was observed in 39% (13/33) of EOC specimens 
analyzed, consistent with deletion in neuroblastoma and low grade serous 
EOC tumors (Cole et al., 2008; Kuo et al., 2009; Welch et al., 2007). These 
observations strongly suggest that loss of miR-34 expression can occur via a 
p53-independent mechanism in some cases. Recently, Christoffersen et al. 
presented data suggesting that an ETS family transcription factor, ELK1, is 
capable of inducing transcription of miR-34a (Christoffersen et al., 2010). 
Whether this is also the case for miR-34b/c remains to be determined.  
  To enable comprehensive analysis of miR-34b/c in a natural context, a 
conditional mir-34b/c knockout mouse strain was prepared (Chapter 4). While 
gene reconstitution, overexpression and knockdown studies performed by us 
and others have given noteworthy insight to the role of these miRNAs in 
disease, such approaches may result in non-physiological levels of 
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expression, off-site effects and nonspecific alterations due to random 
transgene integration site. To the contrary, targeted mutation approaches, 
such as gene knockout or knockdown, do not suffer from these limitations and 
are considered the gold standard for evaluation of gene function in 
physiological context.  
 
5.2 Future directions  
 
5.2.1 Control of mir-34 transcription 
 
The p53 protein has been shown to bind promoter regions of both mir-34 loci 
resulting in their transactivation, while reduced miR-34 expression is strongly 
correlated with p53 mutation in human cancers (Corney et al., 2010; Mraz et 
al., 2009; Zenz et al., 2009). Recently, alternative mechanisms of mir-34 
regulation have been studied, with a focus on promoter methylation and copy 
number variation (Cole et al., 2008; Corney et al., 2010; Kuo et al., 2009; 
Lodygin et al., 2008; Lujambio et al., 2008; Toyota et al., 2008; Welch et al., 
2007). However, a complete understanding of transcriptional control over mir-
34 loci has not been achieved. miR-34c expression in testis has been shown 
to be p53-independent (Bouhallier et al., 2010), demonstrating that 
transcription factors other than p53 are also involved in mir-34b/c regulation. 
Two transcription factors have recently been proposed to regulate miR-34a 
expression with strong evidence of directly binding the mir-34a promoter from 
chromatin-immunoprecipitation experiments. First, ELK1 directly binds mir-34a 
in response to B-RAF-mediated oncogene-induced senescence (OIS) in 
primary human fibroblasts (Christoffersen et al., 2010). Meanwhile, mir-34a is 
  
158 
 
transactivated by AP-1 in the chronic myelogenous leukemia (CML) cell line 
K562 following phorbol ester-directed differentiation (Ichimura et al., 2010). 
The AP-1 transcription factor complex, comprised of c-Fos and c-Jun family 
proteins, is activated by external stimuli via MAPK signaling and is strongly 
implicated in oncogenic signaling, although some tumor suppressive role has 
also been reported (reviewed by Eferl and Wagner, 2003). While phorbol ester 
appears to induce highest transcriptional activity, other stimuli include UV 
irradiation, TNF α, TGF β, interleukin-1 and mitomycin C (reviewed by Angel 
and Karin, 1991). Perhaps AP-1-mediated mir-34a transcription in response to 
mitogenic stimuli, and ELK1-mediated mir-34a transcription following OIS, 
functions as a fail-safe mechanism to halt neoplastic growth. In theory, this 
makes a great deal of sense given that p53 mutation is a potentially early 
event in carcinogenesis and without p53-independent transactivation miR-34 
function would be completely ablated. Such mitogen-stimulated expression of 
an antimitogenic gene results in an incoherent feed-forward loop and is typical 
of the general role of miRNAs in dampening signaling pathways (Hornstein 
and Shomron, 2006; O'Donnell et al., 2005; Sylvestre et al., 2007). 
Certainly, similar currently unidentified pathways might be expected to 
control miR-34b/c following mitogenic stimulation. Indeed, MAPK signaling 
was recently implicated in control over miR-34b/c expression following DNA 
damage (Cannell et al., 2010). Taken together, knowledge of these 
transcription pathways might go some way to explaining our observations of 
frequent promoter methylation and copy number variation in human EOC, 
since both methylation and reduced copy number would be expected to largely 
eradicate both p53-dependent and independent transcription in response to 
oncogenic stimuli and might be a critical step in carcinogenesis (Figure 5.1).   
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Figure 5.1 A model of known transcriptional regulation of miR-34 and their 
function. Among other stimuli, DNA damage posttranslational activates p53, 
resulting in increased transcriptional activity of mir-34a, mir-34b/c and other 
p53 targets. However, p53 mutation is thought to be an early event during 
carcinogenesis. Yet, through an incoherent feed-forward loop, potentially 
oncogenic signaling transcriptionally activates miR-34 and dampens the 
oncogenic signal. Inactivation of the mir-34 loci, by either methylation or 
reduced copy number, would largely eliminate miR-34 control over 
carcinogenesis. Potentially oncogenic genes and processes are indicated in 
red, while green text indicates tumor suppressive genes/processes. 
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5.2.2 miR-34 role in carcinogenesis 
 
Experiments to understand the role of miR-34 during cancer initiation will rely 
heavily on availability of mir-34b/c knockout mice. A first aim will be to cross 
mir-34b/c mice with mir-34a conditional knockout mice and EIIA-Cre 
transgenic mice (Lakso et al., 1996), to generate mir-34a, mir-34b/c and mir-
34a; mir-34b/c compound conventional knockout mice to determine phenotype 
in regards to embryonic and adult development and cancer susceptibility. 
Characterizing the effect of mir-34 inactivation in mouse embryonic fibroblasts 
(MEFs) and ovarian surface epithelial cells (OSE) will give a rapid indication of 
p53-independent miR-34 control of proliferation, apoptosis, senescence, 
colony formation and transformation potential.  
Towards cancer susceptibility in vivo, wild type and knockout mice 
exposed to mutagenic treatments, such as whole body gamma irradiation, 
topical administration with 7,12-dimethylbenz[a]anthracene (DMBA)/phorbol 
12-myristate 13-acetate (TPA) or intraperitoneal administration of N-nitroso-N-
methylurea (MNU) will allow analysis of DNA damage response in the 
absence of miR-34, while spontaneous tumor formation can be assessed in 
untreated knockout mice. p53-null mice have increased tumor susceptibility, 
especially when challenged with genotoxic stimuli (Donehower et al., 1992; 
Jacks et al., 1994; Kemp et al., 1993; Kemp et al., 1994); a similar or slightly 
less severe phenotype after mir-34 inactivation is anticipated. 
To build upon characterization of conventional mir-34 knockout mice, in 
particular in the event of embryonic lethality, mir-34a and/or mir-34b/cloxP/loxP 
mice can be crossed with tissue-specific Cre transgenic mice, such as PB4-
Cre to induce gene inactivation in prostate epithelium (Wu et al., 2001), 
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MMTV-Cre to induce gene inactivation in mammary epithelium (Cheng et al., 
submitted) and Stra8-Cre to inactivate mir-34 in spermatocytes (Sadate-
Ngatchou et al., 2008). Characterization of phenotype following inactivation in 
testis will be of particular interest given strong expression in this tissue 
(Bouhallier et al., 2010 and chapter 4).  
Our initial identification of miR-34b/c was in OSE cells and, given our 
findings of frequent loss of miR-34 expression in human ovarian cancers, mir-
34 conditional mice will be useful to identify what role these genes play in 
ovarian cancer pathogenesis. Unfortunately, however, no suitable Cre-
expressing transgenic line exists due to an absence of OSE-specific promoter 
(Corney et al., 2008; Nikitin and Hamilton, 2005). To circumvent this quandary, 
the enclosed anatomical location of the mouse ovary within the ovarian bursa 
can be used to selectively expose the OSE to AdCre (Flesken-Nikitin et al., 
2003). This approach has a number of advantages over other methods to 
model EOC in the mouse. Firstly, intrabursal administration of AdCre removes 
the requirement for an OSE-specific promoter, while gene inactivation is 
accomplished in adult immunocompetent mice. The approach also allows 
conditional and temporal control of the initiating events, which is particularly 
useful for modeling the early stages of EOC initiation (Corney et al., 2008; 
Nikitin and Hamilton, 2005). Secondly, a low dose of Cre mimics random low 
frequency somatic mutation which can result in a more accurate model of 
tumor initiation (Jackson et al., 2001). Given that inactivation of p53 in the 
OSE results in tumor formation in only 6% of mice treated with AdCre 
(Flesken-Nikitin et al., 2003), one might anticipate a similar low frequency of 
tumor formation after mir-34 inactivation. However, this might not be the case, 
particularly in mir-34a; mir-34b/c compound conditional knockout mice, since 
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targets of miR-34 are vast, numbering in the hundreds, and function in multiple 
signaling pathways and cellular processes. 
Our analysis of miR-34 expression in human EOC specimens revealed 
that miR-34b and miR-34c, but not miR-34a, is downregulated to a greater 
extent in stage IV tumors than stage III tumors. While the possibility remains 
that reduced miR-34b/c is a passenger alteration, reconstitution of miR-34b or 
miR-34c reduces cell motility and invasion (Chapter 3 and Corney et al., 2010; 
Migliore et al., 2008) and suggests their direct involvement in EOC 
progression. Our preliminary experiments have shown that miR-34 
reconstitution in neoplastic EOC cells reduces tumor formation in a mouse 
model of peritoneal spreading (David Corney and Alexander Nikitin, 
unpublished observations), while tail-vein injection experiments of miR-34b/c 
transfected head and neck cancer cell line SIHN-011B show reduced lung 
metastasis formation (Lujambio et al., 2008).  
 These observations suggest that miR-34b/c is involved in metastatic 
progression. It has been shown that when p53 is ectopically expressed in p53-
deficient tumors in vivo, tumors rapidly regress through induction of apoptosis 
or senescence depending on cell type  (Martins et al., 2006; Ventura et al., 
2007; Xue et al., 2007). Based upon the diverse range of miR-34 targets, one 
might expect that inducing miR-34 in neoplastic cells deficient in the p53 
pathway will have therapeutic benefit. Such a hypothesis might be tested by 
intraperitoneal injection of p53-null and/or mir-34-null neoplastic cell lines 
carrying into mice followed by activation of miR-34 expression from a tet-on 
based lentiviral system (Shin et al., 2006).  
One of the signaling pathways known to play a critical role in invasion 
and metastasis is the hepatocyte growth factor (HGF)/MET pathway (Mazzone 
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and Comoglio, 2006). HGF is a pleiotropic factor capable of controlling the 
proliferation, survival, motility and morphology of a wide spectrum of tissues 
including epithelial cells through activation of Met tyrosine kinase activity 
(Bottaro et al., 1991);(Naldini et al., 1991). MET expression has been shown to 
be a poor prognostic indicator of patients with cancer and knock down of MET 
by siRNA decreased tumor growth of SKOV-3 ovarian cancer cells injected 
intraperitoneally into mice (Sawada et al., 2007). Since Met is a well 
established miR-34 target that has been shown to be required for miR-34 anti-
invasion and motility activity in cell culture, it will be interesting to see whether 
Met is also required for metastatic progression after mir-34 inactivation in vivo. 
Currently, strand-specific function of miR-34 (i.e. miR-34a versus miR-
34a*) is unaddressed, and the targeting strategy currently reported results in 
inactivation of both strands of miR-34b and miR-34c. Until recently, only 
concurrent inactivation or overexpression of both miRNAs was possible, since 
insertion of a loxP site in the hairpin region of a pre-miRNA would likely result 
in little or no processing by Dicer, while targeted mutation of the seed region of 
one strand may result in loss of secondary hairpin structure and consequently 
reduced processing. Work in the Hannon lab has identified processing of a 
miR-451, an endogenous non-canonical Dicer-independent miRNA containing 
a single, mature, miRNA localized to the loop of the hairpin with no passenger 
strand (Cheloufi et al., 2010). As a result, one could envision designing a 
lentivirus containing an artificial Dicer-independent miRNA to allow expression 
of one miRNA per hairpin without production of any passenger strand. 
Furthermore, such a system could be optimized for conditional strand 
inactivation in vivo, as outlined in Figure 5.2. 
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Figure 5.2 A strategy for strand-specific miRNA inactivation. A, Schematic of 
canonical, Dicer-dependent miRNA hairpin (left) and non-canonical, miR-451-
based Dicer-independent miRNA hairpin (right). Guide strand shown in red 
and passenger strand shown in blue. B, A strategy for guide strand-specific 
inactivation of miR-34b and miR-34c. pri-mir-34b/c, under control of its 
endogenous promoter, is flanked by loxP sites (black triangles). An 
endogenous poly[A] site prevents polymerase II read-through to a Dicer-
independent miR-34b* and miR-34c* cassette that has been inserted 3’ of pri-
mir-34b/c. Following Cre-loxP-mediated inactivation of pri-mir-34b/c and 
subsequent loss of poly[A] site, non-canonical miR-34b* and miR-34c* are 
transcribed under control of the endogenous promoter. A neomycin cassette 
flanked by FRT sites (green triangles) allows for positive selection in ES cells. 
Recombination between loxP and FRT sites indicated by dotted lines. 
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5.2.3 Role of miR-34 in cell reprogramming and normal development 
 
Cell fusion and nuclear transfer approaches have been successful in 
reprogramming somatic cells to a pluripotent state, although the mechanism of 
this reprogramming process is unclear (Cowan et al., 2005; Wakayama et al., 
1998; Wilmut et al., 1997). In 2006, however, Takahashi and Yamanaka 
reported that ectopic expression of just 4 genes, Oct3/4, Sox2, c-Myc and Klf4, 
followed by selection for Fbx15 expression, is sufficient to reprogram adult and 
embryonic mouse somatic cells into a pluripotent state (Takahashi and 
Yamanaka, 2006). With the exception of being able to generate adult 
chimaeric mice, such cells, termed induced pluripotent stem (iPS) cells, are 
analogous to ES cells by all functional assays. However, at the molecular 
level, such iPS cells are not comparable to ES cells, having different mRNA 
gene expression and methylation profiles, suggesting that reprogramming is 
not complete. The same group and others went on to show that using the 
same four factors followed by selection for Nanog expression, instead of 
Fbx15, results in iPS cells with an almost identical DNA methylation pattern of 
ES-cell specific genes, greater identity to ES cells by microarray analysis 
compared to Fbx15 iPS cells and, most importantly, generation of germline 
transmitting chimeras (Okita et al., 2007; Wernig et al., 2007).  
The most recent studies show that expression of the four 
reprogramming factors is only required for 10-12 days, after which iPS cells 
enter a self-sustaining pluripotent state and the ectopic genes are silenced 
(Brambrink et al., 2008; Stadtfeld et al., 2008a) can be completely removed 
(Kaji et al., 2009; Stadtfeld et al., 2008b; Woltjen et al., 2009). Lack of viral 
insertion and excision of transgene is important to reduce risk of tumor 
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formation, since tumors have been observed after c-Myc reactivation (Okita et 
al., 2007). Although the precise mechanism is yet to be clearly defined, 
reprogramming appears to be a stochastic process that can be accelerated by 
elimination of the p53 pathway (Hanna et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 
2009). Whether this effect is due to increased proliferation following p53 
pathway inactivation or a role of p53 in promoting differentiation, i.e. through 
inhibition of Nanog (Lin et al., 2005), remains to be determined, although 
Hanna et al. suggested the former. However, I hypothesize that miR-34 also 
plays a role in inhibiting reprogramming and that this inhibition is not 
necessarily dependent on its anti-proliferative function. Among the known 
targets of miR-34 are two of the original reprogramming factors, Myc and Klf4 
(Christoffersen et al., 2010; Kong et al., 2008; Lujambio et al., 2008; Tazawa 
et al., 2007; Klf4 validation by our unpublished observations, David Corney, 
Chang-il Hwang, Kirsten Elzer and Alexander Nikitin). Therefore, miR-34 
inactivation should relieve c-Myc and Klf4 repression and result in increased 
reprogramming efficiency. Given recent data showing p53-independent miR-
34a transcription (Christoffersen et al., 2010), this outcome might be 
independent of p53 and so it would be interesting to observe reprogramming 
efficiency 1) in p53 wild type, mir-34-null cells and 2) p53-null cells with miR-
34 reconstitution via p53-independent lentiviral transgene expression, such as 
the lentivirus used in Chapter 2. These experiments would determine whether 
the observed involvement of p53 in inhibiting reprogramming is dependent on 
intact miR-34 function. 
 A role for miR-34 family in cell reprogramming leads one to question 
their potential function normal stem cells and during differentiation. One well-
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characterized model of stem cell differentiation is that of the hematopoietic 
system, where multipotent hematopoietic stem cells (HSC) give rise to all 
blood cells (reviewed by Orkin and Zon, 2008). As previously mentioned, miR-
34a expression is induced following phorbol ester-directed differentiation of 
K562 cell line towards megakaryocytic lineage (Ichimura et al., 2010; Navarro 
et al., 2009). miR-34a reconstitution in the absence of phorbol ester reduced 
proliferation as expected, but also induced differentiation as measured by 
CD41 expression. The mechanism appears to involve direct repression of 
MEK1 and Myb, although Navarro et al. report that Myb expression is reduced 
prior to miR-34a expression, leading the authors to suggest that miR-34a is 
required to maintain, but not establish, Myb repression prior to differentiation. 
Further supporting a role in stem cell differentiation, miR-34c is reported to be 
expressed most strongly in more differentiated late pachytene spermatocytes 
and round spermatids than early pachytene spermatocytes (Bouhallier et al., 
2010). It is worth noting, however, that miR-34 function may be cell-type 
specific, for example miR-34 expression is decreased during early ES cell 
differentiation (Chapter 4).  
 In conclusion, the mouse studies presented here identified p53-
dependent regulation miR-34b/c in OSE and provided evidence to suggest a 
role in tumor suppression through inhibition of proliferation and adhesion-
independent growth. Our follow-up study in human EOC further supports a 
role in tumor suppression, firstly by providing evidence that miR-34 expression 
is reduced in EOC via multiple mechanisms and secondly showing that 
parameters of advanced disease, such as invasion and motility, are also 
controlled by miR-34 family. To provide the gold standard evidence to support 
a hypothesis that miR-34 family represent tumor suppressors, gene targeting 
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experiments must be performed. Therefore our most recent work has focused 
on the generation of mir-34b/c conditional knockout mice. Characterization of 
these mir-34b/c, and mir-34a, knockout mice will allow for a more complete 
understanding of their role in vivo and their potential therapeutic use in 
humans. 
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